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Abstract 
For in vivo imaging of molecular processes via positron emission tomography (PET) radiotracers of 
high specific activity are demanded. In case of the most commonly used positron emitter fluorine-18, 
this is only achievable with no-carrier-added [18F]fluoride, which implies nucleophilic methods of 
18F-substitution. Whereas electron deficient aromatic groups can be labelled in one step using no-
carrier-added [18F]fluoride, electron rich 18F-labelled aromatic molecules are only available by multi-
step radiosyntheses or carrier-added electrophilic reactions. Here, diaryliodonium salts represent an 
alternative, since they have been proven as potent precursor for a direct nucleophilic 18F-introduction 
into aromatic molecules. Furthermore, as known from non-radioactive studies, the highly electron rich 
2-thienyliodonium leaving group leads to a high regioselectivity in nucleophilic substitution reactions. 
Consequently, a direct nucleophilic no-carrier-added 18F-labelling of electron rich arenes via aryl-
(2-thienyl)iodonium precursors was developed in this work. The applicability of direct nucleophilic 
18F-labelling was examined in a systematic study on eighteen aryl(2-thienyl)iodonium salts. As 
electron rich precursors the ortho-, meta- and para-methoxyphenyl(2-thienyl)iodonium bromides, 
iodides, tosylates and triflates were synthesised. In addition, para-substituted (R = BnO, CH3, H, Cl, 
Br, I) aryl(2-thienyl)iodonium bromides were prepared as precursors with a systematically varying 
electron density. 
As first approach, the general reaction conditions of the nucleophilic 18F-substitution procedure were 
optimised. The best conditions for direct nucleophilic no-carrier-added 18F-labelling via aryl(2-thien-
yl)iodonium salts were found with dimethylformamide as solvent, a reaction temperature of 130 + 3 °C 
and 25 mmol/l as concentration of the precursor. For the effect of bromide, iodide, tosylate and triflate 
as counter anion on the radiochemical yield (RCY) the following order was obtained: tosylate < iodide 
< triflate < bromide. However, based on the kinetics a different order was observed for the initial 
reaction rates with: tosylate < bromide < iodide < triflate. The influence of the substitution pattern in 
ortho-, meta- and para-methoxyphenyl(2-thienyl)iodonium bromide showed an expected strong ortho-
effect, which led with 60 % of 2-[18F]fluoroanisole to the highest RCY. Also under no-carrier-added 
conditions, the 2-thienyl group directed to a regiospecific radiofluorination, thus in all 18F-substitutions 
no 2-[18F]fluorothiophene, but only the desired [18F]fluoroarenes were formed. 
With the intention of a systematic examination of electronic factors, the kinetics of the 18F-substitution 
on substituted aryl(2-thienyl)iodonium bromides were investigated and the determined relative 
reactivities were compared with the Hammett constants of the corresponding substituents. As result a 
good linear Hammett correlation and a reaction parameter of ρ = + 1.16 + 0.2 were obtained. This 
confirms the SNAr-mechanism and a consistent mechanism over the whole range of investigated 
substituents. 
In order to demonstrate the applicability of this method, the 18F-labelling of two pharmacological 
relevant molecules was carried out. First, n.c.a. 4-[18F]fluorophenol was synthesised via 4-benzyl-
oxyphenyl(2-thienyl)iodonium bromide within 40 min and an overall RCY of 34 to 36 %. Second, a 
complex AMPA receptor antagonist was 18F-labelled via iodonium precursors; however only with low 
RCY of 1.2 to 3.6 %. For comparison, the radioiodine analogue was labelled via a trimethyltin 
precursor and [131I]iodide with a very high RCY of 97 + 2 % within 2 min, thus it was available for 
preliminary pharmacological evaluation studies. 
In conclusion, the 2-thienyliodonium leaving group proved as highly effective for direct nucleophilic 
no-carrier-added 18F-labelling even of nucleophilically non-activated arenes. Concerning the 18F-label-
ling of complex molecules, further optimisation, however, is necessary for this method. 
 
Kurzzusammenfassung 
Zur in vivo Bildgebung molekularer Prozesse mittels Positronen-Emissions-Tomographie (PET) 
besteht eine große Nachfrage nach Radiotracern mit hohen spezifischen Aktivitäten. Im Fall des dafür 
meistgenutzten Positronenstrahlers Fluor-18 sind diese nur mittels trägerarmen [18F]Fluorids erreich-
bar, so dass nukleophile 18F-Markierungsmethoden erforderlich sind. Elektronenarme aromatische 
Gruppen können leicht mit trägerarmen [18F]Fluorid direkt markiert werden, wohingegen elektronen-
reiche [18F]Fluoraromaten nur über mehrstufige Radiosynthesen oder geträgerte elektrophile 
Methoden zugänglich sind. Hier stellen Diaryliodoniumsalze eine Alternative dar, seit sie sich als 
Vorläufer für die direkte nukleophile 18F-Markierung von aromatischen Verbindungen als vorteilhaft 
erwiesen haben. Weiterhin ist von nicht-radioaktiven Untersuchungen bekannt, dass die 2-Thie-
nyliodonium Abgangsgruppe in nukleophilen Substitutionen zu einer hohen Regioselektivität führt. 
Daher wurde die direkte nukleophile, trägerarme 18F-Markierung von elektronenreichen Arenen 
mittels Aryl(2-thienyl)iodoniumsalzen in dieser Arbeit entwickelt. In einer systematischen Studie wurde 
ihre Anwendbarkeit auf direkte nukleophile 18F-Substitutionsreaktionen an achtzehn Aryl(2-thienyl)-
iodoniumsalzen untersucht. Als elektronenreiche Vorläufer wurden die ortho-, meta- und para-
Methoxyphenyl(2-thienyl)iodonium Bromide, Iodide, Tosylate und Triflate synthetisiert. Zusätzlich 
wurde eine Gruppe von para-substituierten (R = BnO, CH3, H, Cl, Br, I) Aryl(2-thienyl)iodonium 
Bromiden als Vorläufer mit systematisch variierender Elektronendichte hergestellt. 
Zunächst wurden die allgemeinen Reaktionsparameter der nukleophilen 18F-Substitutionsreaktion 
optimiert. Als beste Bedingungen für den direkten trägerarmen 18F-Austausch mittels Aryl(2-thien-
yl)iodoniumsalzen ergaben sich Dimethylformamid als Lösungsmittel, eine Reaktionstemperatur von 
130 + 3 °C und eine Vorläuferkonzentration von 25 mmol/l. Für den Einfluss von Bromid, Iodid, 
Tosylat und Triflat als Gegenion auf die radiochemische Ausbeute (RCA) wurde die folgende 
Abstufung erhalten: Tosylat < Iodid < Triflat < Bromid. Basierend auf den Reaktionskinetiken ergab 
sich jedoch aus den initialen Reaktionsgeschwindigkeiten eine andere Reihenfolge mit: Tosylat < 
Bromid < Iodid < Triflat. Der Einfluss des Substitutionsmusters in ortho-, meta- and para-Methoxy-
phenyl(2-thienyl)iodonium Bromid äußerte sich wie erwartet als starker ortho-Effekt, der bei 
2-[18F]Fluoranisol zur höchsten RCA von 60 % führte. Die 2-Thienyl Gruppe führte auch im träger-
armen Fall zu regiospezifischen Radiofluorierungen, so dass in allen 18F-Substitutionen kein 
2-[18F]Fluorthiophen, sondern nur die gewünschten [18F]Fluorarene gebildet wurden. 
Für eine systematische Untersuchung des elektronischen Einflusses wurden die Kinetiken der 
18F-Substitution an substituierten Aryl(2-thienyl)iodonium Bromiden untersucht und die erhaltene 
relative Reaktivität mit den Hammett Konstanten der jeweiligen Substituenten verglichen. Es ergab 
sich eine gute lineare Hammett-Korrelation mit einem Reaktionsparameter von ρ = + 1,16 + 0,2. Dies 
bestätigt den SNAr-Mechanismus und eine hohe Reaktivität der Aryl(2-thienyl)iodoniumsalze. 
Um die Anwendbarkeit als Markierungsmethode zu demonstrieren, wurden die 18F-Radiosynthesen 
zweier pharmakologisch relevanter Moleküle durchgeführt. Zunächst wurde trägerarmes 4-[18F]Fluor-
phenol mittels 4-Benzyloxyphenyl(2-thienyl)iodonium Bromid dargestellt, für das nach 40 min eine 
radiochemische Gesamtausbeute von 34 - 36 % erhalten wurde. Weiterhin wurde ein komplexer 
AMPA Rezeptor Antagonist über Iodoniumvorläufer 18F-markiert; allerdings nur mit einer geringen 
RCA von 1,2 – 3,6 %. Zum Vergleich wurde das Radioiodanalog mittels eines Trimethylzinnvorläufers 
und [131I]Iodid innerhalb von 2 min mit sehr hoher RCA von 97 + 2 % hergestellt, womit es für erste 
pharmakologische Evaluierungsstudien zur Verfügung stand.  
Insgesamt erwies sich die 2-Thienyliodonium Abgangsgruppe als sehr effektiv, auch nukleophil nicht-
aktivierte Aromaten direkt trägerarm zu radiofluorieren. Bezüglich der 18F-Markierung komplexer 
Moleküle sind jedoch weitere Optimierungen der Methode notwendig. 
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 Introduction 
1.1 Radionuclides in Nuclear Medicine 
In 1896 Antoine Henri Becquerel noticed the blackening of photographic films by uranium ore 
whereby he discovered the radioactivity. This was the basis for a new branch of natural sciences 
and Becquerel received the physics Nobel price in 1903. Consequently, the sub-field of nuclear 
chemistry was established in 1898 by the researcher couple Marie and Pierre Curie, who isolated 
the radioactive elements polonium and radium from pitchblende by radiochemical procedures [1]. 
With the first in vivo examinations of biological processes using radionuclides by Georg de 
Hevesy in 1920, the way of radionuclides into life sciences was opened [2]. Hevesy and Adolf 
Paneth developed the radiotracer principle which is based on the identical chemical and 
biochemical behaviour of stable elements and their radioactive isotopes. Since that time Hevesy 
is known as the “Grandfather of Nuclear Medicine” and he received the medicine Nobel price in 
1943 for his life’s work. 
As far as 1930, the radionuclides were limited to the natural occurring nuclides and only very few 
were suitable as radiotracers in life sciences. By the development of the first cyclotron (Ernest 
Orlando Lawrence, 1930), the discovery of the induced nuclear fission (Otto Hahn and Fritz 
Strassmann, 1938/39, chemistry Nobel price 1944) and the construction of the first nuclear 
reactor (Enrico Fermi and Leo Szilard, 1942), the production of artificial radionuclides in large 
scale became possible [3]. Since then their applications in life science have increased rapidly [4]. 
Today only a selected minority of more than 2400 available radionuclides are employed in life 
sciences. Their number is strictly limited by special requirements in half-life, achievable chemical 
and radiochemical purity and radiation type and energy. Especially the field of nuclear medicine 
calls for high standards in these aspects, more than other domains in life sciences. 
Application in Nuclear Medicine classifies radionuclides generally in diagnostic and therapeutic 
nuclides. For in vivo diagnostic investigations only short-lived single photon and positron emitters 
are used to guarantee as small as possible radiation exposure for the patient, but well detectable 
signals  to get the important information [5, 6]. In contrast, for the in vivo therapeutic use (e.g. for 
brachytherapy and endoradiotherapy) longer-lived corpuscular emitting radioisotopes with high 
LET-values (Linear-Energy-Transfer) are in demand, with the intention that the α- and β--particles 
accomplish a local degeneration of the pathogen tissues. In addition, Auger electron emitting 
nuclides are of therapeutic interest, they cause degeneration in a very small radius of the emitting 
nuclide. Thus they are able to induce apoptosis, when they are brought into the cell nucleus and 
cause radiation damage of DNA [5, 7, 8]. 
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The application of radiolabelled biomolecules or pharmaceuticals with in vivo examinations 
enables the visualisation of physiological or pathophysiological processes on a molecular level. 
Besides in vivo techniques, many in vitro procedures (e.g. radioimmunoassay (RIA) and 
autoradiography) have been developed and became important tools in biochemistry, physiology 
and pharmacology. 
The radiotracer method now extends over widespread fields of physiology and pharmacology 
and has played a key role e.g. in investigations on metabolic principles, on the function and 
dysfunction of physiological processes and in the development of pharmaceuticals. 
 
1.2 Emission tomography 
In general, the non-invasive imaging techniques magnetic resonance tomography (MRT) and 
x-ray computed tomography (CT) give information about tissue structure. Hereby the MRT inclu-
des the sub-fields of magnetic resonance spectroscopy and imaging (MRS and MRI). An en-
hancement of MRI, the functional MRI (fMRI), is a step to observe specific physiological 
functions, particularly for brain imaging. fMRI is based on the so-called Bold-effect, an increase in 
blood flow of a local vasculature that accompanies neural activity in the brain. fMRI is versatile 
tool for mapping the brain and supports the clinical management in neurosurgery [9]. 
In contrast to the above mentioned methods, the emission tomography technology shows special 
advantage of visualising pathophysiological, physiological and metabolic processes. The use of 
compounds, which are involved in this biochemistry and labelled with suitable radionuclides, 
helps to understand the mechanisms and the processes of e.g. degenerative brain diseases such 
as Alzheimer’s, Parkinson’s and Huntington’s disease. Furthermore, in oncology radiotracers are 
widely employed for diagnoses as well as for controlling and monitoring endoradiotherapy. 
Additionally, the very sensitive traceability of radioactivity and radiotracers with high specific 
activities allow the use of substrate quantities in subnanomolar scales. In consideration of this 
fact, the implementation of highly potent or even toxic compounds is possible without any 
pharmacodynamic effects and a physiological or pathophysiological system can be studied 
without disturbance. [10-13] 
Emission tomography is possible as single photon emission tomography (SPET) and positron-
emission tomography (PET). Both are routinely used in nuclear medicine and pharmacological 
research. 
SPECT is the more popular technique, by reason that here the focus is on the artificial radio-
nuclide 99mTc. 99mTc has favourable properties: a monoenergetic 140 keV single photon emission 
and an opportune half life of 6 h. However, the major advantage is the availability of 99mTc 
generator systems, thus its application is independent of nearby cyclotrons or reactors. 
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Moreover, one-step-labelling systems (so-called kits) containing precursors and all necessary 
reagents were developed by the pharmaceutical industry and make practical application very 
convenient. More single photon emitting radionuclides such as 111In, 123I and 201Tl are also in 
routine use for SPECT, but not to the extension of 99mTc. 
Although SPECT became more developed in recent years and even attempts for quantitative 
analyses were made, PET is still the advanced technology. PET shows a higher sensitivity (more 
than 100-fold of SPECT) and its quantitation methods are well-elaborated. The characteristics of 
the positron decay itself establish the basic for a quantitative measurement of radioactivity. 
Nonetheless, an exact independent transmission measurement and attenuation correction is 
necessary. Consequently, radiotracer concentrations and their kinetics in organs and the regions 
of interest can be measured quantitatively and used with appropriate bio-mathematical models to 
evaluate (patho)physiological processes [14]. 
For labelling PET radiotracers, short-lived, neutron deficient positron emitters are of primary 
interest. From the decaying nucleus a positron (β+) and a neutrino (ν) are emitted synchronously 
by the conversion of a proton into a neutron. Neutrinos show practically no interaction with matter 
and PET cameras are not able to detect them [15]. The positron loses its kinetic energy by 
collisions and interactions with matter along a short distance. The range depends on the β+-ener-
gy, which is specific for the employed isotope (Table 1.1 shows the β+max-energies of important 
positron emitters used for PET) and reaches from less than 1 mm to several millimetres. When 
the positron is nearly at rest, it is able to interact with an electron, its anti-particle. Positron and 
electron compose an intermediary positronium, an exotic atom showing similarities to hydrogen. 
In the positronium the proton in the hydrogen’s nucleus is replaced by a positron. Positronium 
atoms exist as para-positronium in a singlet state (antiparallel spins, angular moment: 0, mean 
life: 1.25 · 10-10 s) or as ortho-positronium in a triplet state (parallel spins, angular moment: h = 
h/2π, mean life: 1.39 · 10-7 s). In the positronium the particles “spiral” closer to each other until 
they are terminated by annihilation. By annihilation, γ-rays are released with a total energy of 
1.022 MeV, the sum of the masses of positron and electron, 511 keV each. As a result of the 
conservation of energy, parity and angular momentum the singlet state emits two γ-rays and the 
triplet state emits three γ-rays. The two γ-rays from the singlet state show a nearly 180° 
distribution and each carries a characteristic energy of 511 keV. Due to different numbers of 
quantum states of ortho- and para-positronium their probability of creation is 3:1. However, in 
matter the ortho-positronium merge into para-positronium by the so-called pick-off process, 
where it interacts with electrons of its environment. In matter, the high efficiency of the pick-off 
process leads to a strong depression of the triplet state, thus only the two γ-rays annihilation is 
relevant here and the three γ-rays annihilation is negligible [16]. 
 
4  Introduction 
 
Figure 1.1: Principles of positron electron annihilation with coincidence measurement (left) 
and brain imaging with PET including ring of detectors (right) 
 
The annihilation of the para-positronium and the resulting two body-penetrating photons provide 
the basis for PET (Figure 1.1). The PET device (PET camera) consists of circular arranged 
scintillation detectors. In these rings of detectors every pair of opposite detectors are connected 
for coincidence measurement. As a result, the two γ-rays of the annihilation process will be 
detected, if they hit both opposite detectors within a time window of a few nanoseconds 
(generally ~12 ns). Assuming that both detected photons result from one event, the positron 
emitter must be located on or nearby the connection line of the detector pair. Hereby, the spatial 
resolution depends on both the distance between origin and annihilation of the positron and the 
size of the detector crystals. As the distance of the positron from emission to annihilation is 
dependent on its β+-energy, which is again specific for the decaying isotope, PET nuclides should 
emit positrons with an energy as low as possible to increase the spatial resolution and also to 
reduce the radiation dose. Besides, other uncertainties based on individual attenuation can be 
avoided by an attenuation factor, which is developed by an accurate independent transmission 
measurement. For this purpose a 68Ge source is generally used to correct adsorption and 
scattering effects before the real tracer will be injected. Finally, the distribution of radioactivity 
quantity in the object tissues can be measured precisely [14]. 
Computer-aided image reconstruction of the data of several transversal measurement planes 
allows the output of 3D-images of regions of interest. These can be obtained with spatial 
resolutions down to 3-5 mm and accuracy in quantity down to nano- and picomolar 
Introduction  5 
concentrations. Further on, physiological and pharmacological processes can be acquired in 
combination with a bio-mathematical model by dynamic studies with a longer span of time. With 
such methods and an accurate quantification, information about transport processes, metabolic 
rates and concentrations become accessible depending on the specific radiotracer used. Modern 
scanners combine PET and MRT/CT in one device, which leads to 3D-images with exact 
morphologic information as well as a physiological and biochemical representation. Those 
procedures are highly relevant in e.g. the clinical management of oncologic therapy [17]. 
Due to the fact that PET is a powerful tool in pharmacological and physiological research, special 
small animal PET scanners were developed in recent years [18]. Animal PET cameras make 
repeatable drug trials in one animal possible, without the need for vivisection and therefore costs 
and expenses for (radio)pharmaceutical development can be reduced [19, 20]. One of the latest 
innovations in this field is the so-called RatCAP, a small, head-mounted PET system, the main 
item of which is a 4 cm diameter ring consisting of 12 crystal detectors. Those systems allow 
PET measurements of the brain of an awake rat without the need of anesthesia, which actually 
make studies of behaviour or severely depressed brain functions impossible [21]. 
 
1.3 Radionuclides and -tracers for positron emission tomography 
As mentioned before, PET presents an excellent imaging technique with its advantages in very 
high sensitivity, good spatial resolution and the ability to acquire (patho)physiological processes 
and functions and to quantify them accurately. Enhancements of the devices and combined 
scanner systems made strong contributions to the understanding of metabolic functions and 
processes of the brain and of brain diseases. But not only the progress of the technical 
equipment had achieved these acquisitions, also steady improvement and advanced 
development of suitable and high specific radiotracers were needed. 
To find the right tracer molecule a close look into the designated processes and the related bio-
chemistry is necessary, the following gives a short overview: 
 
- metabolism and general biochemical function 
- receptor-ligand biochemistry 
- enzyme function and inhibition 
- immune reaction and response 
- pharmaceutical effects 
- toxicology (carcinogen and mutagenic substances) 
 
6  Introduction 
In terms of radiotracer development the choice of a biochemical or physiological concept is only 
the first step and more considerations are compulsory. One is the choice of the radionuclide with 
the suitable half-life (cf. Table 1.1), which is affected by the radiosynthesis as well as the 
characteristic of the finally studied biochemistry. Furthermore, a comprehensive pharmacological 
evaluation of the radiotracer including in vitro, ex vivo and in vivo metabolic investigations, 
dosimetry and toxicology studies is required. An inclusive quality management with automation 
and up-scaling (GBq range) of the radiosynthesis as well as validation of the bio-mathematical 
modelling for quantitation should be completed before the radiotracer is taken into routine 
practice. 
 
Table 1.1: Important positron emitters used for PET and their nuclear data [from 6, 12] 
Nuclide Half-life Decay mode (%) Eβ+,max [keV] 
organic    
11C 20.4 min β+ (99.8) EC (0.2) 960 
13N 9.96 min β+ (100) 1190 
15O 2.03 min β+ (99.9) EC (0.1) 1720 
30P 2.5 min β+ (99.8) EC (0.2) 3250 
    
analogue    
18F 109.6 min β+ (97) EC (3) 635 
75Br 98 min β+ (75.5) EC (24.5) 1740 
76Br 16.1 h β+ (57) EC (43) 3900 
73Se 7.1 h β+ (65) EC (35) 1320 
120I 1.35 h β+ (64) EC (36) 4100 
124I 4.18 d β+ (25) EC (75) 2140 
    
metallic    
38K 7.6 min β+ (100) 2680 
62Cu 9.7 min β+ (98) EC (2) 2930 
64Cu 12.7 h β+ (18) β-   (37) EC (45) 655 
68Ga 68.3 min β+ (90) EC (10) 1900 
82Rb 1.3 min β+ (96) EC (4) 3350 
86Y 14.7 h β+ (34) EC (66) 1300 
94mTc 52 min β+ (72) EC (28) 2470 
72As 26 h β+ (88) EC (12) 2515 
 
Biomolecules (e.g. glucose, amino acids, fatty acids, enzymes, etc.) and pharmaceuticals mainly 
consist of carbon, hydrogen, oxygen, nitrogen, sulfur and phosphorous. Due to that fact positron 
emitting, short-lived isotopes of these elements are in order to achieve the so-called authentic 
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labelling. The so-called “organic” PET nuclides 11C, 15O, 13N and 30P allow the authentic labelling 
without any changes in (bio)chemical and physiological behaviour or properties of the labelled 
compounds. However, extremely short half-lives of those isotopes from two to twenty minutes 
strongly limit their applicability. In case of 15O (T½ = 2 min) and 13N (T½ = 10 min) only fast 
accessible, simple compounds, such as [15O]H2O, [15O]C4H9OH and [13N]NH3 as tracers for blood 
flow, [15O]O2 as indicator for oxygen metabolism and [15O]glucose as indicator for glucose 
uptake, can be synthesised [22]. Only the half-life of 11C (T½ = 20.4 min) provides the possibility 
of multi-step radiosyntheses and allows PET measurements of slower physiological processes. 
From the production of carbon-11 the primary labelling precursor [11C]CO2 is available, which 
unfortunately is rarely useful for direct labelling reaction of organic molecules. Nonetheless, 
[11C]carbondioxide can be easily transferred to many precursors, which offer versatile 11C-label-
ling pathways [23]. The most important secondary 11C-precursor is [11C]CH3I, which enables 11C-
methylations of organic compounds in high specific activity [24]. For those radiotracers rapid, 
automatised radiosyntheses were developed and the 11C-labelled products, such as the amino 
acid L-[methyl-11C]methionine [25] or the dopamine D2 receptor ligand [11C]raclopride [26] are 
routinely prepared as PET radiopharmaceuticals for nuclear medicine diagnosis. 
With time-consuming radiosyntheses and in cases of slow physiological processes, the very 
short-lived organic isotopes do not meet the demands. Alternatively, the introduction of longer-
lived radionuclides into the tracer molecules should avoid these problems. The so-called 
“analogue” radiotracers are commonly labelled with 18F, 75,76Br, 73Se and 120,124I. Their longer half-
lives range from 1.35 h to 4.15 d and allow more extensive radiosyntheses as well as PET 
studies of slower biochemical processes. In general, analogue tracers make use of similarities in 
steric demand and/or in electronic character of the substituted atom or function. As a result, 
75,76Br and 120,124I can be regarded as structural analogues for methyl groups [27, 28]. Due to the 
fact that 73Se is the next homologue to sulfur, they have very similar steric and chemical 
properties. 73Se is therefore used in the same manner as sulfur, e.g. in the labelling of 
L-[73Se]selenomethionine [29] and L-homocysteine[73,75Se]selenolactone [30]. 
In the majority of cases the foreign isotopes evoke only small insignificant structural differences, 
but the arising electronic changes and those of chemical reactivity can be important. 
Substitutions with radioisotopes of higher halogens often result in an increased lipophilicity, what 
again is related to a higher non-specific binding. In particular radioiodine labelled molecules show 
frequently strong deviations in specificity, and even end sometimes as completely unspecific 
compounds. The biochemical behaviour of analogous labelled molecules has to be tested for 
changes in characteristics in each individual case. In the recent years the number of new 
developed pharmaceuticals has increased rapidly, thus more and more compounds can be found 
originally carrying fluorine, bromine and iodine. Consequently, the advantages of authentic 
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labelling and longer half-life accrue and simplify the evaluation of the corresponding radio-
pharmaceuticals (e.g. [18F]altanserin [31]). 
The most common analogue isotope is 18F, which is sterically replacing a hydrogen atom. While 
the Van der Waals radii of fluorine (1.35 Å) and hydrogen (1.20 Å) are almost the same, the 
differences in electronic character of both elements are so much bigger. Nevertheless, most of 
the 18F-labelled compounds are based on the analogy in steric demands of fluorine and 
hydrogen. In case of L-2-[18F]fluorotyrosine as analogue tracer for the amino acid tyrosine, the 
18F-radiotracer shows metabolic acceptance and is bound to tRNA and into proteins while the 
3-isomer does not and is very toxic. L-2-[18F]fluorotyrosine can be employed for quantitation of 
the local protein synthesis rate in brain [32]. A recent developed radiotracer for tumour imaging is 
O-(2-[18F]fluoroethyl)-L-tyrosine [33]. Although this amino acid is not incorporated into proteins, 
uptake by tumour cells is stereospecific and mediated by amino acid transporters [17, 34, 35]. 
Another example is 2-[18F]fluorodeoxyglucose ([18F]FDG), which is the most widely used PET 
radiopharmaceutical. For the first metabolic steps FDG is accepted as glucose analogue and 
taken up into cells by the glucose transporters. In cells it is metabolised by the enzyme hexo-
kinase to 2-[18F]fluorodeoxyglucose-6-phosphate, but the 18F-for-H substitution of the original 
glucose leads to a interruption of the metabolism and leaves the phosphorylated FDG in the cell 
unaltered. This effect is known as metabolic trapping and PET images of the regional glucose 
uptake can be obtained. Furthermore, with the help of a bio-mathematical three-compartment-
model the glucose metabolism can be quantified [36]. Besides, FDG helps to study brain and 
myocardial metabolism and function, it is also a powerful tracer for detection of tumours and 
metastases, whose cells exhibit an increased glucose uptake and metabolism [37, 38]. 
The success of fluorine-18 as routine PET nuclide and in diagnosis and pharmacological 
research is moreover based in its almost perfect chemical and nuclear properties. Fluorine-18 
can be produced in good yields, even with low-energy cyclotrons. As mentioned above, the half-
life of 109.7 min allows both time-consuming multi-step radiosyntheses up to a limit of 6 h and 
extended PET studies of slower biochemical processes. In addition, the half-life makes shipment 
within a range of at least 200 km possible, thus in a so-called satellite concept the supply of 
clinics without an on-site cyclotron can be ensured [39]. 18F has a low β+-energy of 635 keV, 
besides 64Cu the minimum of the PET nuclides, that promises a very high resolution for the PET 
images and guarantees minor radiation doses to the patients. In terms of chemistry several facile 
labelling reactions and methods are known for 18F-introduction in organic molecules. 
A third group of suitable positron emitters for PET is represented by the metallic isotopes (cf. 
Table 1.1). In contrast to the “organic” and “analogue” PET nuclides, a few metallic isotopes are 
achievable by generator systems (e.g. 82Rb, 62Cu and 68Ga) which make them available in places 
without an on-site cyclotron [40]. For in vivo studies they are applied as free cationic tracers or in 
a complexed form. For example, rubidium-82 has been evaluated as a myocardial perfusion 
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tracer because of its similarities to the potassium cation and it is routinely employed as its free 
cation [41]. Otherwise the cyclotron-produced positron emitters 86Y and 94mTc are of interest. 
94mTc offers the possibility to use PET for quantifying the uptake kinetics of γ-emitting 99mTc-label-
led SPECT radiopharmaceuticals. In the same sense 86Y is the quantitative access to the 
pharmacokinetics of therapeutic 90Y-agents for palliative treatment [28]. 
 
Production pathways of important positron emitting radionuclides 
PET requires neutron deficient nuclides, which are generally produced by bombardment of stable 
isotopes by small charged particles in accelerators. Here protons, deuterons and alphas are 
predominantly employed. For optimal results of production exact knowledge about the nuclear 
data, such as cross sections and excitation functions are required. The final chemical form of the 
product depends on the type of nuclear reaction and even more on the target, the aggregate 
state (e.g. gas, liquid, solid) and the chemical form of the target material. 
For fluorine-18 more than twenty nuclear reactions are known as production pathways. The most 
common nuclear reactions for 18F-production are listed in Table 1.2. The use of the 18O(p,n)18F 
(Ep = 16 → 3 MeV) reaction on 18O-enriched water is the most effective method for the 
production of [18F]fluoride of high specific radioactivity. Thus, under optimised conditions high 
activities of [18F]fluoride can be easily achieved from cyclotrons, even with low energy machines, 
within less than one hour irradiation time. In case of electrophilic radiolabelling reactions [18F]F2 is 
required. Accordingly, 20Ne and 18O gas targets are the first choice. The major problem of these 
latter methods is the deposition of the produced fluorine-18 on the target walls. An addition of 
elemental fluorine to the target gas is needed for isotopic exchange of the adsorbed fluorine-18. 
For electrophilic fluorine-18 the 20Ne(d,α)18F reaction is well-established and the most common 
process [42, 43]. 
 
Table 1.2: Most common nuclear reactions for production of fluorine-18 [from 6, 42, 43, 44] 
Reaction 18O(p,n)18F 16O(3He,p)18F 20Ne(d,α)18F 18O(p,n)18F c 
Target H218O a H2O Ne (0.1-0.2 % F2) b 18O2, Kr (1 % F2) b 
Particle energy [MeV] 16 → 3 36 → 0 14 → 0 10 → 0 
Main product form 18F-aq 18F-aq [18F]F2 [18F]F2 
Yield [GBq/µAh] 2.22 0.26 0.37 – 0.44 ∼0.37 
Specific activity 
[Bq/mmol] < 3.7 ⋅ 1015 < 3.7 ⋅ 1015 3.7 ⋅ 1010-11 3.7 - 185 ⋅ 1010 
a Ti-target with Ti-window b passivated Ni-target  c two step process 
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As a general production method for carbon-11 the 14N(p,α)11C nuclear reaction is applied. The 
reaction is carried out with 14N gas targets in the energy range of 15 → 7 MeV, which is feasible 
for low energy cyclotrons. Small portions of oxygen added to the target gas cause [11C]CO2 
formation and in case of hydrogen addition, [11C]CH4 is the product form [45]. Routinely produced 
13N results from the 16O(p,α)13N reaction on a natural water target [46]. 15O is regularly achieved 
from a natural nitrogen target via the 14N(d,n)15O reaction [47]. 
Further analogue isotopes are iodine-124 and iodine-120. An advantageous reaction for the 
former is 124Te(p,n)124I on a TeO2 (enriched tellurium) target. The formation of undesired long-
lived side products such as 125,126I is here reduced in contrast to alternative methods with natural 
antimony (natSb(3He,xn)124I or natSb(α,xn)124I), 124Te(d,2n)124I or reactions with other tellurium 
isotopes (126Te(p,3n)124I). The 124Te(p,n)124I reaction requires only a range of 13 → 9 MeV proton 
energy and is practicable with small cyclotrons [48, 49]. A recent developed production route is 
the 125Te(p,2n)124I reaction, which gives 124I yields about four times higher than the 
aforementioned 124Te(p,n)124I reaction. However, the energy range is too high for small cyclotrons 
but large quantities of 124I can be produced with medium-sized machines [50]. In all cases the 
radioiodine is extracted from the target by dry distillation. For the production of iodine-120 either 
122Te(p,3n)120I or 120Te(p,n)120I are available as appropriate nuclear reaction. Both require the 
adoption of enriched target material. In case of 122Te the required energies are higher than 
30 MeV, thus only high energy accelerators are applicable. The 120Te(p,n)120I reaction runs under 
better conditions, viz. energies of less than 15 MeV. Furthermore, the 120Te based reaction leads 
to reduced isotopic impurities [49, 51]. However, the costs for highly enriched 120Te targets are 
vast. Again, the radioiodine is obtained by dry distillation. 
Several production methods for the bromine isotopes 75Br and 76Br are known. Besides the 
75As(3He,3n)75Br nuclear reaction with a particle energy range of 36 → 25 MeV, the most suitable 
production route for Bromine-75 is the 76Se(p,2n)75Br reaction (E = 34 → 18 MeV). The target 
materials consist normally of alloys such as Cu3As, [76Se]Ag2Se, or [76Se]Cu2Se. However, the 
enriched material for selenium-76 targets is relatively expensive and the 75As(3He,3n)75Br 
reaction using natural arsenic target material is therefore the preferred route [42]. The 75Br 
activity is usually extracted from the solid target by dry distillation. 75Br, however, can not be 
generated without impurities of 76Br. In case of 76Br, three direct methods are available: 
76Se(p,n)76Br (E = 16 → 10 MeV), 77Se(p,2n)76Br (E = 25 → 16 MeV) and 75As(3He,2n)76Br 
(E = 18 → 10 MeV). Both reactions using selenium targets give the highest yields, but with the 
drawback of enriched target material. Thus the 75As(3He,2n)76Br process is the most suitable 
procedure. Bromine-76 is again recovered by dry distillation [52]. 
In case of Selenium-73 there are two major production pathways. The first production route uses 
natural or enriched germanium targets and 3He- and α-particles in medium-sized cyclotrons, i.e. 
natGe(3He,xn)73Se (E = 36 → 13 MeV) [ 53 ] and 70Ge(α,n)73Se (E = 28 → 13 MeV) [ 54 ]. The 
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second process, 75As(p,3n)73Se (E = 40 → 30 MeV) [55], is presently the method of choice for 
73Se. Although this reaction requires higher energies than the routes via germanium, the obvious 
advantage is a very high production rate of the arsenic reaction. Radioselenium can be isolated 
from the target by e.g. anion-exchange chromatography [55] or thermochromatography [56]. 
Within the group of metallic positron emitting radionuclides the before mentioned generator 
systems for 62Cu, 68Ga and 82Rb are very convenient sources. Of course, the appropriate mother 
nuclides which are fixed on the generator material still have to be produced. The remaining 
metallic nuclides are generally produced at cyclotrons. A short overview of the present methods 
of choice for metallic nuclides are given in Table 1.3 [data from 6, 28]. 
 
Table 1.3: Common production pathways of important metallic positron emitter [from 6, 28] 
Nuclide Production route particle energy [MeV] Generator system 
38K 35Cl(α,n)38K 27 → 12  
62Zn (62Cu) 63Cu(p,n)62Zn 27.5 62Zn → 62Cu (T½ = 9.26 h) 
64Cu 64Ni(p,n)64Cu 12 → 9  
68Ge (68Ga) RbBr(p,spall.) 800, 500 68Ge → 68Ga (T½ = 271 d) 
82Sr (82Rb) Mo(p,spall.) 800 82Sr → 82Rb (T½ = 25.6 d) 
86Y 86Sr(p,n)86Y 14 → 10  
94mTc 94Mo(p,n)94mTc < 17  
72As 72Ge(p,n)72As 14  
 
1.4 Basic aspects of reactions under no-carrier-added conditions 
One of the greatest advantages of short-lived radionuclides is their extremely high sensitivity of 
detection. Consequently, they are produced and employed in quantities at a subnanomolar 
range. What is a benefit for applications in nuclear medicine, because physiological, toxic or 
immunologic response can be excluded, causes big problems for the chemical handling and 
work. 
The quantity of the material is only determinable by the number of decays, thus the activity of 55 
GBq (average production at a small cyclotron) 18F equals 8.8 · 10-10 mol fluorine. Owing to the 
desired insignificant quantities, a fundamental criterion of the quality of a radiotracer is its specific 
activity (As), which depends on the amount of stable isotopes present (carrier). Carrier can be 
divided into isotopic carrier, isotopes of the same element as the radionuclide, and non-isotopic 
carrier, isotopes of other elements mostly with very similar properties to the radionuclide. On this 
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account, the mass related activity, the specific activity is chemically more relevant than the 
activity itself [57]: 


=
g
Bq  
m
A As  
where A is the activity and m is the mass of radioactive material including all impurities and 
carrier, respectively. The specification related to the mass is inconvenient in chemistry; more 
informative and practicable is the use of molar activity, thus As is usually expressed on the molar 
basis: 


=
mol
Bq  
n
A As  
here the mass m is replaced by n for the amount of substance in moles. In the absence of 
impurities or isotopic carrier, the theoretically attainable maximum molar activity As,max equals to: 


=
mol
Bq  
T
2 ln N A
2
1
Amax s,  
where NA is Avogadro’s number and T½ the half-life of the radionuclide. Most of the applications 
in molecular imaging call for high molar activities. Therefore it is useful to know the maximum 
achievable molar activities. For the most prevalently used PET nuclides 18F and 11C they amount 
to 6.3 · 1010 GBq/mol and 3.4 · 1011 GBq/mol, respectively. Due to the natural occurrence of 
stable isotopes of these radionuclides only a 103 – 105-fold smaller As is attainable in practise. 
However, the quantity of material becomes higher by the natural isotopic carrier, but it is still in 
nano- to picomolar scale. 
The ubiquity of stable elements reduce the molar activities, but in some cases, principally for 
increasing the yields or in case of electrophilic 18F production it is unavoidable, to add carrier on 
purpose. Otherwise, PET investigations using labelled biomolecules with very low concentrations 
in the destined tissue (e.g. substrates of enzymes, receptor ligands and reuptake inhibitors) 
demand for radionuclides of very high specific activity. In general, for radiochemical practise the 
radiosyntheses can be classified as: 
 
- carrier-free (c.f.) 
- no-carrier-added (n.c.a.) 
- carrier-added (c.a.) 
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Ideally carrier-free systems are only achieved when artificial radioelements (e.g. astatine) are 
used and the presence of longer-lived radioisotopes of the element can be excluded. Earlier, 
99mTc was also mentioned as an example for almost carrier-free radiosyntheses providing 
nuclide, but in recent years the extensive use and consequently the production of this SPECT 
nuclide increased rapidly. Due to this fact its very long-lived isomer 99Tc (T½ = 2.1 · 105 a) 
become more and more the status of a “natural-occurring” isotope, which scales down the 
radiochemistry of 99mTc almost to n.c.a. level. However, the dimension of 99mTc abundance is 
much lower than those of stable isotopes of other radionuclides. 
Nevertheless, in radiosyntheses with cyclotron-produced radionuclides of natural-occurring 
elements, traces of stable isotopes of these elements are omnipresent and act as isotopic carrier. 
Even the most accurate operation methods can not circumvent this effect. Sources of natural 
isotopic carrier are the air, target and reaction vessel materials, chemicals and solvents. Such 
contaminations in solvents and chemicals are below the normal chemical purification limits, but 
they are still in the quantity or even in excess of the radionuclides. As mentioned above, 
radiosyntheses under those conditions are referred to as no-carrier-added (n.c.a.) and corres-
pond to a state of practically highest As attainable. In contrast, some circumstances require 
addition of weighable quantities of stable isotopes. Predominantly carrier addition is employed to 
increase radiochemical yields or to make certain labelling reactions possible, but also for other 
reasons such as for electrophilic 18F, when n.c.a. [18F]F2 is too reactive to remove it from the 
walls of targets and tublines. These methods are termed as carrier-added (c.a.). 
Labelling reactions and radiosyntheses on the n.c.a. scale mean to work at a subnanomolar 
level. Hence, the course of the reaction may differ strongly from that of a classical reaction at 
equimolar stoichiometric ratios. Such reactions under non-equilibrium conditions generally 
proceed according to pseudo-first-order kinetics, since the concentration of the precursor to be 
labelled is in very high excess to the n.c.a. radionuclide and can approximately be set as 
constant. For a reaction in form of A + B → C, where A is precursor, B the radionuclide and C the 
labelled product and the starting concentration of B is [B]0, the concentration of C after the 
reaction time t can be presented as: 
[ ] [ ] ( ) = lmol  e - 1 B  C t'-t k0  
where k’ is the rate coefficient of pseudo-first-order type and contains [A] as constant factor [58]. 
The decay-corrected yield, i.e. the radiochemical yield (RCY), is related to the starting activity. So 
the RCY increases with proceeding reaction time t and increasing precursor concentration [A] 
and shows a hyperbolic character in a plot versus time. The final saturation yield ideally equals 
[B]0 and is often achieved within a few minutes, due to the high excess of the precursor. 
Furthermore, the radionuclide and the labelled product both exist on the n.c.a. scale, thus a 
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consecutive labelling reaction or other interactions of the two radioactive species can statistically 
be excluded. 
In contrast to classic equimolar chemistry, radiochemistry requires some special points to be 
considered. Firstly, slightest impurities in solvents or chemicals can easily reach the 
concentration level of the n.c.a. radionuclide; to that reason highest purity grade of solvents and 
substrates is obliged. Secondly, the introduction of the radionuclide into the designated molecule 
should occur in the latest possible step (so-called last-step labelling) to avoid multi-step 
syntheses with radioactive intermediates which will minimise the final yield of activity and 
increase the radiation burden. Finally, the whole preparation of a radiopharmaceutical including 
labelling reaction, purification, isolation and quality control should be finished within three half-
lives of the radionuclide. 
 
1.5 Radiolabelling with fluorine-18 and radioiodine 
1.5.1 18F-Labelling methods 
In principle general pathways for the fluorination of organic molecules are transferable from 
macroscopic organic chemistry to n.c.a. radiochemistry. The preparative organic chemistry 
usually uses the Wallach reaction [ 59 ] and the Balz-Schiemann reaction [ 60 ] for fluorine 
introduction into aromatic organic compounds. These are dediazoniation reactions, where the 
fluoride replaces a decomposing diazonium function. In case of the Wallach reaction diazonium 
piperidines of arenes are decomposed by treatment with hydrofluoric acid and heating, what 
leads to the corresponding fluoroarenes. Balz-Schiemann used diazonium tetrafluoroborates of 
the appropriate arenes which are decomposed by heating and give the fluoroarenes, but in much 
better purity and higher yields than the Wallach procedure. However, in n.c.a. labelling syntheses 
these reaction types only result in low radiochemical yields [61, 62]. For the Balz-Schiemann 
reaction this is an effect of the type of the counter ion to the diazonium cation, which is a 
tetrafluoroborate anion and leads axiomatically to a maximum RCY of only 25 %. In addition, the 
tetrafluoroborate ion causes in isotopic carrier and thus reduces the specific activity. Further on, 
both reactions’ mechanisms are principally of the SN1-type, thus reactive cations evoke and 
interact with any nucleophilic species close by. The statistical probability of the reactive 
intermediates to encounter a [18F]fluoride ion under n.c.a. conditions is marginal and only carrier 
addition leads to satisfying results and RCY, respectively [63]. 
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Depending on the production procedure of fluorine-18 (cf. above), its chemical form is given for 
the labelling reaction. Generally, the 18F-labelling methods can be divided into: 
 
- electrophilic substitutions    
- nucleophilic substitutions    
- 18F-fluorination via prosthetic groups  
- 18F-fluorination via built-up procedures  
 
where the former procedures represent direct methods and the latter indirect methods. In 
general, the indirect procedures are based on the direct methods for 18F-labelling of the required 
prosthetic group or synthon. 
 
Electrophilic substitution 
For electrophilic 18F-labelling reactions c.a. [18F]F2 is directly available directly from the target (cf. 
above), but only with specific activities of about 37 GBq/mmol [64]. In some cases [18F]F2 is 
transferred into somewhat less reactive and more selective fluorination agents such as 
acetylhypofluorite [18F]CH3COOF and xenon difluoride [18F]XeF2 [65, 66, 67]. These are options 
for the 18F-fluorination of electron rich compounds (e.g. alkenes, aromatic molecules, carbanions, 
etc.), which are actually unavailable with nucleophilic 18F-labelling methods. Due to the fact of 
necessary carrier-addition in the [18F]F2 production and the fact that every [18F]F2 molecule 
carries only one 18F atom, the theoretical achievable maximum RCY in electrophilic 18F-labelling 
is limited to 50 %. More recent attempts were made to reduce the amount of fluorine-19 carrier in 
the synthesis of the electrophilic 18F-species in order to get higher specific activities of about 
18 TBq/mmol, however, with the drawback of lower radiochemical yields [68]. As a result, the 
electrophilic 18F-labelling routes are restricted to radiopharmaceuticals, where high specific 
activities are not compulsory. These particular cases occur when physiological processes are 
examined with endogenous tracers, which are naturally present in the investigated tissue area 
and the body. On the basis of the high reactivity of the electrophilic 18F-labelling agents the 
selectivity is rather low and undesired radical side reactions and reactions with solvents take 
place. Therefore, electrophilic methods call for extensive purification procedures to meet the 
requirements of very high purity of radiopharmaceuticals. To increase the regioselectivity in 
arenes, demetallation reactions of organometallic precursors can be used (cf. Scheme 1.1). 
Suitable organometallic precursors are aryltrimethyltin, aryltrimethylgermanium and aryltrimethyl-
silicium compounds, whereas the organotin moiety shows the best results [ 69 , 70 ]. The 
substituent X deactivates the arene, but for the 18F-fluorodemetallation reaction the effect is less 
direct methods 
indirect methods 
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strong than in direct electrophilic 18F-labelling reactions. Thus, side reactions and consecutive 
fluorination are decreased and simplify the purification. 
 
Scheme 1.1: Regioselective 18F-labelling via electrophilic demetallation reactions (M = Sn, Ge, 
Si; X = OCH3, CH3, H, F, CF3, NO2) [from 70] 
 
However, for complex molecules including sensitive functions, which have to be protected, 
further radiosynthesis steps become necessary for the deprotection. In case of 4-[18F]fluoro-L-
phenylalanine for example the 18F-labelling via an organotin precursor leads to 25 % RCY [71]. 
One more relevant PET radiopharmaceutical produced via electrophilic substitution is 
6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine (6-[18F]fluoro-L-DOPA). 6-[18F]fluoro-L-DOPA is a 
radiotracer for the dopamine anabolism in the brain and is employed for the diagnosis of patients 
with neurodegenerative diseases (Parkinson’s disease) and recently also in oncology due to its 
high tumour uptake. In clinical routine 6-[18F]fluoro-L-DOPA is produced via 18F-
fluorodestannylation, although the maximum RCY is only 30 % and the specific activities are low 
[72, 73]. The lack of an efficient and simple automate nucleophilic access to 6-[18F]fluoro-L-
DOPA requires the electrophilic pathway. The so far best nucleophilic method still encloses a 
multi-step radiosynthesis including chiral auxiliaries, and therefore complicates the automation 
and reduces the RCY [74]. 
 
Nucleophilic substitution 
The most important route to get 18F-labelled compounds is the nucleophilic 18F-fluorination based 
on n.c.a. [18F]fluoride, which is directly available from the target without any carrier addition. This 
is the only method to obtain n.c.a. 18F-radiopharmaceuticals with high specific activity. This is 
required for investigations of e.g. binding-sites of neural receptor systems, which can then be 
studied without perturbation of the physiological equilibrium. The n.c.a. [18F]fluoride is obtained in 
a water solution and due to its high electronegativity it is strongly hydrated (∆hydrate = 506 kJ/mol) 
and inactivated for nucleophilic reactions. In the presence of proton donors, the fluoride anion is 
very easily protonated and forms [18F]hydrogen fluoride (EB = 565 kJ/mol), thus it is unavailable 
for further reactions. Therefore the n.c.a. [18F]fluoride must be activated and water removed 
M(CH3)3
X
18F
X
[18F]CH3COOF
[18F]F2
CFCl3, -78 °C
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before radiolabelling. For this purpose water is replaced ideally by dipolar aprotic solvents such 
as acetonitrile (ACN), dimethyl sulphoxide (DMSO), N,N-dimethylformamide (DMF) and 
dimethylacetamide (DMAA) and anion activation phase transfer catalysts (PTC) like 
tetraakylammonium carbonates, hydroxides or mainly aminopolyethers such as Kryptofix© 2.2.2 
in combination with potassium carbonate or oxalate as base are employed [63, 75, 76]. While the 
aminopolyether complexes the potassium ion and composes a [K⊂2.2.2]2CO3 cryptate system, 
the [18F]fluoride ion is non-hydrated and available with a high nucleophilicity. If the solubility 
product of the cryptate system is not exceeded in this procedure, the losses by wall-adsorption 
are negligibly small [77]. Further, the proper 18F-labelling reaction must be carried out in absence 
of protons or e.g. metallic cations, which would also inactivate the naked [18F]fluoride. 
The direct nucleophilic 18F-fluorination of aliphatic compounds proceeds according to a 
SN2-mechanism, where halogens or sulphonic acid ester functions such as mesylate, tosylate 
and triflate act as leaving group [63]. Generally, triflate (trifluoromethane sulphonic acid ester) 
precursors give the best results [for an overview see: 78, 79]. 
 
Scheme 1.2: Nucleophilic n.c.a. 18F-fluorination and subsequent hydrolysis of acetylated 
mannose triflate for [18F]FDG [80] 
 
When the leaving group is replaced by the [18F]fluoride the stereochemistry is changed by the 
concertedly proceeding Walden inversion according to the stereospecific SN2-mechanism. In this 
way the most widespread radiopharmaceutical [18F]FDG (2-[18F]fluoro-2-deoxy-D-glucose) is 
synthesised starting from a completely acetylated mannose precursor by a 18F-for-triflate 
exchange and a subsequent hydrolysis (cf. Scheme 1.2) [80]. Routinely RCY of more than 40 % 
are attained. Furthermore, the nucleophilic aromatic n.c.a. 18F-fluorination is of great importance 
for the development of 18F-labelled radiopharmaceuticals. Besides multiple possible aromatic 
radiotracers, the generally good metabolic stability of the resulting 18F-labelled aromatic 
compounds is a major advantage. Nucleophilic aromatic 18F-fluorinations call for activated 
aromatic molecules, consequently electron withdrawing substituents in ortho- or para-position to 
the leaving group are indispensable (cf. Scheme 1.3). Particularly function with high positive 
Hammett constants, such as nitro, cyano and carbonyl groups, are suitable for the activation [81]. 
As leaving group nitro, halogens and the trimethylammonium salts prove to be well adapted. For 
O
OAc
AcO
AcO
AcO
OTf 1. [K⊂2.2.2]18F
2. Hydrolysis
O
OH
HO
HO
HO
18F
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example, several butyrophenone neuroleptics can be directly 18F-labelled starting with the 
corresponding para-nitro precursor which is activated by a carbonyl function, e.g. [18F]N-methyl-
spiperone can be obtained in good RCY [82]. Additionally, fluorine as well is a very adequate 
leaving group, but its use introduces isotopic carrier. Within the trimethylammonium group, which 
shows the best quality as nucleofugic group, the counter ions give the following order of 
increasing RCY: iodide < perchlorate < tosylate < triflate. In cases of less activating substituents 
with low Hammett constants e.g. iodine and bromine (σp = 0.18 and 0.23 [83]) an aliphatic 
substitution results on the N(CH3)3-group and [18F]fluoromethane formation competes to the 
aromatic 18F-labelling. Nonetheless, RCY of about 12 % of 1-[18F]fluoro-4-haloderivatives are 
attainable with the mentioned less activating substituents [84]. 
For nucleophilic 18F-radiolabelling of non-activated aromatic compounds two general procedures 
are possible. In the first one, the deactivated arene is transferred to an activated species with the 
help of modified original by present moieties or introduction of additional activating groups. This 
procedure implies a multi-step radiosynthesis, where modification or removing steps of the 
activating groups are required after the 18F-introduction [85]. 
 
Scheme 1.3: Nucleophilic aromatic 18F-fluorination with activated arenes (X = NO2, N(CH3)3+ 
(counter ions: TfO-, TsO-, ClO4-, I-), Br, Cl, I; R = NO2, CN, CHO, RCO, COOR, 
Cl, Br, I; PTC = [K⊂2.2.2]2CO3, [K⊂2.2.2]2C2O4/CO3, [K⊂2.2.2]HCO3, R4N+; Cs+; 
Rb+) 
 
Secondly, the use of substituted diaryliodonium salts as precursors offers a more elegant route 
(see subchapter 1.6 for details). For the latter method the resulting product distribution after the 
nucleophilic attack of the n.c.a. [18F]fluoride strongly depends on the electronic and steric 
character of each aryl ring and its substituents, respectively. Generally, the more electron 
deficient ring of the diaryliodonium salt is preferred for the 18F-labelling. Furthermore, steric 
influences, especially for ortho-substituents, have an impact and increase usually the RCY. 
18F-Fluorination via prosthetic groups 
As mentioned above, the 18F-fluorination via prosthetic groups is an indirect method. This means 
a primary 18F-fluorinated labelling group is coupled with a second molecule to form the product 
X
n.c.a. [18F]fluoride
o-, p-R
18F
o-, p-RPTC
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molecule. Important procedures via prosthetic groups are the 18F-fluoroalkylation [77, 86], the 
18F-fluoroacylation [87, 88], and the 18F-fluoroamidation [89] (cf. Scheme 1.4). 
Applications for these 18F-labelling pathways via prosthetic groups are widespread and can be 
applied with almost every molecule carrying a protic function such as a thiol, amino or hydroxyl 
group. In practise, several bio-relevant molecules e.g. receptor ligands of the dopamine system 
[90] and the serotonin system [91], benzodiazepines [92], amino acids [33] and analogues for 
cocaine [93] are 18F-labelled via 18F-fluoroalkylation. In contrast, the 18F-fluoroacylation and the 
18F-fluoroamidation are of great interest for the 18F-labelling of proteins and peptides since they 
allow radiosyntheses under amide-bond formation in aqueous systems [94]. As a result, β-18F-la-
belled esters were successfully coupled with e.g. biotin [95] and the protein octreotide, the first 
18F-labelled peptide [96]. 
 
Scheme 1.4: 18F-fluorination via prosthetic groups; top: 18F-fluoroalkylation; middle: 18F-fluoro-
acylation; bottom: 18F-fluoroamidation (X, Y = Br, I, OTs, OTf; Z = N, O, S; 
R = alkyl, aryl) 
 
18F-labelling synthons for built-up radiosyntheses 
A further, recent developed built-up 18F-labelling method is the 18F-fluoroarylation. This procedure 
is based on metallorganic molecules like 4-[18F]fluorophenyl lithium as versatile metallorganic 
compound for general coupling reactions or on synthons like 1-[18F]fluoro-4-haloarenes as 
reagents for palladium-(0)-catalysed reactions such as the Stille [97], the Hartwig-Buchwald [98] 
and the Sonogashira reaction [ 99 ]. 4-[18F]Fluorophenyl lithium can be synthesised from 
1-[18F]fluoro-4-haloarenes, which in turn are obtainable from the appropriate symmetrical 
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diaryliodonium salts in good RCY of about 50 – 60 % [99, 100 ]. The wide applicability of 
18F-fluoroarylation was demonstrated with several different model compounds [101]. 
Beside 1-[18F]fluoro-4-haloarenes, further primary 18F-labelling synthons are known and 
commonly used in multi-step radiosyntheses of radiopharmaceuticals. Thus 4-cyano-1-
[18F]fluorobenzene was employed in the built-up 18F-labelling procedure of several 18F-labelled 
butyrophenone neuroleptics, e.g. [18F]haloperidol, [18F]benperidol, etc. [ 102 ]. More versatile 
synthons are given by molecules such as 4-[18F]fluorobenzaldehyde, 4-[18F]fluoro-1-nitrobenzene 
or 4-[18F]fluoroaniline, e.g. in recent studies 4-[18F]fluorobenzaldehyde was employed in a two-
step 18F-labelling procedure of peptides [103]. 
 
Scheme 1.5: Improved radiosynthesis of n.c.a. 4-[18F]fluorophenol via Baeyer-Villiger 
oxidation [108] 
 
Another useful primary synthon for 18F-fluorinations is represented by 4-[18F]fluorophenol, which 
is part of several bioactive substrates [104, 105]. In the last decade various attempts have been 
made to improve the synthesis and the availability of 4-[18F]fluorophenol. The first practicable 
radiosynthesis of n.c.a. 4-[18F]fluorophenol proceeded via hydrolysis of a 4-[18F]fluorophenyl-
diazonium salt, but reached only 15 – 33 % RCY after 60 min [106]. An enhancement was the 
radiosynthesis via Baeyer-Villiger oxidation of 18F-labelled benzaldehydes, acetophenones and 
benzophenones. As oxidant m-chloroperbenzoic acid proved useful in the presence of 
trifluoroacetic acid and gave a RCY of about 25 % within 40 – 50 min [107]. An optimisation of 
this route included detailed studies of effects of various substituents and led to (4-(trifluoro-
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methyl)phenyl)-benzoyl-4’-N,N,N-trimethylammonium triflate as ideal precursor for the labelling 
reaction, the hydrolysis and purification. The cationic precursor as well as polar impurities are 
easily removed in an intermediate C18-cartridge purification. An optimised product ratio in the 
final hydrolysis resulted in 60 % RCY of 4-[18F]fluorophenol within 60 min (cf. Scheme 1.5) [108]. 
Due to the improved radiosynthesis of n.c.a. 4-[18F]fluorophenol and a subsequent coupling with 
alkylhalides various 4-[18F]fluoroarylalkylethers became available [108]. Further on, n.c.a. 
4-[18F]fluorophenol was used for 18F-labelling of the dopamine D4 receptor antagonist (3-(4-fluoro-
phenoxy)propyl)-(2-(4-tolyloxy)ethyl)amine (FPTEA) (cf. Scheme 1.6) [109]. 
 
Scheme 1.6: Structures of the 4-[18F]fluorophenoxy moiety containing compounds 2-(4-
[18F]fluorophenoxy)-N-dimethylbenzylamine (R = CH3) and 2-(4-[18F]fluoro-
phenoxy)-N-methylbenzylamine (R = H) (left). [18F]FPTEA (right) 
 
In a recent study radiosyntheses of n.c.a. 2-(4-[18F]fluorophenoxy)-N-dimethylbenzylamine and 
n.c.a. 2-(4-[18F]fluorophenoxy)-N-methylbenzylamine were realized. An Ullmann ether coupling of 
the corresponding 2-bromobenzoic acid amides using tetrakis(acetonitrile)copper(I)hexafluoro-
phosphate as catalyst and a subsequent reduction of the amides leads to the products (cf. 
Scheme 1.6) [110]. Both compounds are structural analogues of known radiotracers for serotonin 
reuptake transporter sites (SERT) [111]. 
 
1.5.2 Radiolabelling with radioiodine 
From more than thirty radioactive isotopes of iodine only iodine-120 and iodine-124 bring along 
suitable properties for PET. However, their low abundance of positron emission (56 % for 120I and 
22 % for 124I), their high positron energies (4.1 MeV for 120I and 2.1 MeV for 124I) and an extensive 
production route make them less attractive. Significantly more importance for life sciences have 
iodine-123 (100 % EC, 159 keV γ-line (main)) as SPECT nuclide, iodine-125 (100 % EC, 35 keV 
γ-line (main)) for long-term in vitro studies and radioimmunoassays and the β--emitter iodine-131 
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as nuclide in therapy of thyroid gland and other tumours. Because of the convenient longer half-
life (T½ = 8.02 d), the well-detectable γ-line of 364 keV (85.5 %) and the good availability, 131I 
lends itself as model isotope for radiotracer development. The main pathways for radioiodine 
labelling can be classified in four general procedures [for an overview see: 112, 113]: 
 
- direct electrophilic radioiodination 
- electrophilic demetallation 
- non-isotopic exchange 
- prosthetic group labelling (indirect method) 
 
Direct electrophilic radioiodination 
The direct electrophilic substitution is the most commonly used radioiodination method. A lot of 
various techniques are available, which lead to high RCY in uncomplicated labelling reactions, 
which can be often carried out at room temperature. Due to its high volatility, low reactivity and 
the need of carrier addition, molecular iodine (I2) is excluded for the n.c.a. scale. These problems 
to achieve reactive electrophilic species are easily circumvented by an in situ oxidation of iodide, 
which is obtained straight from the target. The generally used oxidants are Chloramine-T (CAT; 
para-tosylchloramide sodium), IodogenTM (1,3,4,6-tetrachloro-3α,6α-diphenylglycouril) and 
N-halogensuccinimides. The exact chemical nature and oxidation state of the iodinating species 
is not fully clarified so far. In case of aqueous solutions with strong acidic conditions a hypoiodite, 
and for neutral and alkaline conditions an iodine-analogue of e.g. CAT are postulated [114]. Due 
to the insignificant differences in their redox potentials the choice of the proper oxidant is 
depended on the reaction conditions and the character of the iodine substrate. CAT allows 
oxidations in homogeneous aqueous solutions, whereas IodogenTM is insoluble in water and thus 
it is the proper substance for a heterogenic reaction route, which is advantageous for oxidation 
sensible precursors. In the group of N-halogensuccinimides N-chlorotetrafluorosuccinimide 
(NCTFS), N-chlorosuccinimide (NCS) and rarely N-bromosuccinimide (NBS) are applied for 
in situ oxidation [ 115 , 116 ]. When using NCS in trifluoromethane sulphonic acid, even 
deactivated aromatic compounds can be labelled with radioiodine in acceptable RCY [117]. 
Besides these oxidants, conventional oxidising reagents are in use, such as hydrogen peroxide, 
respectively peracids [ 118 ] and metal cations (Ag+, Tl3+, Pb4+ and Ce4+) [ 119 ]. Rather 
unconventional, but also utilisable are enzymatic [120] or electrochemical [121] methods for 
oxidation. As a disadvantage the electrophilic radioiodination may raise the problem of a regio-
unselective attack, as a result isomeric derivatives may occur.  
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Electrophilic demetallation 
Contrary to the direct electrophilic procedure, the electrophilic demetallation provides an almost 
regiospecific radioiodination. Especially for automated syntheses it offers simple purification and 
isolation of the radiotracer and is therefore the first choice. Nonetheless, the syntheses of the 
organometallic precursors may become complex and extensive [122]. Suitable precursors for 
demetallation radioiodine-labelling are organometallic compounds of thallium [123], boron [124], 
mercury [ 125 ] and particularly the organometallics of the elements of the group IVb. An 
exceptional position of these takes the organotins, which show in many times excellent RCY in 
very short reaction time (few minutes), generally the RCY increases with Si < Ge < Sn [126]. 
Presently, the radioiodo-destannylation is the most suitable radioiodination procedure and thus it 
is the most commonly employed method. 
 
Non-isotopic exchange 
Another labelling procedure for regiospecific radioiodine introduction is the non-isotopic 
exchange. Non-isotopic exchange is generally Cu(I)-catalysed and is suitable for electron-rich as 
well as for electron-deficient aromatic molecules [127]. In case of iodine-for-bromine exchange 
high specific activities are available. In Cu(I)-promoted reactions the readiness of the 
displacement follows the nucleofugality of the halogens (I- > Br- > Cl-). In the Cu(I)-mediated 
substitution mechanism a quadratic-planar complex was suggested, including Cu(I) as coordinat-
ed central atom, whereby the activation energy for the substitution process is reduced and the 
iodine can be introduced [128]. In variations the Cu(I)-salts are in situ synthesised by a mild 
reduction of Cu(II)-salts (reducing agent: ascorbic acid, bisulfite or Sn(II)-compounds). Hereby 
Cu2SO4 is more applicable than the use of copper halides, because the formation of halogenated 
side-products is excluded [129]. One of the important advantages is the much easier precursor 
preparation and their high stability. Moreover, it is again a highly regiospecific labelling route for 
radioiodine. In comparison to the electrophilic radioiodination disadvantages are relatively high 
reaction temperatures up to 180 °C and vastly longer reaction times up to hours. In given cases 
the separation and isolation of the radiotracer provokes difficulties due to its chemical and 
physical similarities to the bromine precursor. 
 
Prosthetic group labelling 
If molecules are sensitive to oxidative reagents or functional groups for iodination are lacking, the 
above mentioned direct radioiodination methods fail. As alternative, small molecules can be 
radioiodinated as labelling synthons and subsequently coupled with the desired compound. This 
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is principally the same procedure as for the 18F-labelling via prosthetic groups (cf. subchapter 
1.5.1). The first approach on prosthetic groups for radioiodination was the so-called Bolton-
Hunter reagent, N-succinimidyl-3-(4-hydroxyphenyl)propionate (SHPP), an activated ester as 
labelling synthon for proteins via coupling with a free amino function, normally of the amino acid 
lysine [130, 131]. It is still widely used for radioiodination of proteins and macromolecules, thus a 
124I-labelled VEGF antibody (VEGF = vascular endothelial growth factor, a number of genes 
associated with angiogenesis; a process necessary for tumours) was e.g. recently radioiodinated 
via a derivative of the Bolton-Hunter reagent [132]. The Bolton-Hunter principle for radioiodination 
of proteins led to further developments of prosthetic groups such as methyl-p-
hydroxybenzimidate (Wood reagent) which is an activated imidate ester and also a versatile and 
convenient radioiodination synthon [133]. In addition, aldehydes, isothiocyanates [134] and 
activated -carbonyl halides [135] are further prosthetic groups for labelling via free amino 
functions. In case of aldehydes, the radioiodo-tyramine-cellobiose is an important compound 
which, for example, was used for labelling monoclonal antibodies [136]. Several other coupling 
methods of prosthetic groups with functional groups of proteins or large molecules are known. 
Another common example for suitable functions is the thiol group of cysteine, where appropriate 
prosthetic groups are malimide derivatives [137]. 
 
1.6 Use of diaryliodonium salts in (radio-)chemistry 
Since C. Willgerodt first synthesised an iodine(III)-compound containing an organic moiety, 
(dichloroiodo)benzene, in 1886 [138] and in 1892 another one, (diacetoxyiodo)benzene [139], an 
uncountable number of organic iodonium compounds have been developed until today [for an 
overview see: 140]. All theses iodonium salts are employed in widespread fields of chemistry and 
related sciences. Besides their advantageous properties as photopolymerisation initiators [141, 
142] and as chemical amplifications in imaging systems, microlithography and nanopatterning 
[143, 144], they display biological, antimicrobial and antifungal activities [145, 146]. Furthermore, 
iodonium reagents resemble in their reactivity characteristics mercury(II), thallium(III) and 
lead(IV) compounds and can serve as substitutes without the toxic and environmental problems 
associated with these heavy metal species. In organic chemistry diaryliodonium compounds are 
applied for direct arylation reactions, cross coupling reactions (Suzuki [147], Stille [148], Heck 
[149]) and mild chemoselective oxidations [150]. [for an overview see: 151, 152] 
Relatively recent iodine(III) species are the alkenyliodonium and the alkynyliodonium salts. The 
former undergo reactions with a wide variety of nucleophiles and are excellent reagents in metal-
catalysed cross-coupling reactions, the latter serve as electrophilic acetylene equivalents in 
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reactions with nucleophiles as well as superb cycloaddition partners, e.g. for Diels-Alder-
reactions [for an overview see: 153, 154]. 
The radiochemical interest in iodonium salts is based on their use as precursors for direct 
nucleophilic 18F-fluorination, especially since even electron rich arenes can be 18F-labelled in 
one-step. The first nucleophilic 18F-labelling reaction via diaryliodonium salts was carried out by 
Pike and Aigbirhio in 1995 [155]. 
 
1.6.1 Production routes for diaryliodonium salts 
Diaryliodonium salts can be synthesised by a variety of ways [for an overview see: 151, 152, 
156]. Several methods involve the use of a strong acid medium while other methods require 
neutral organic solvents. The commonly employed procedures occur according a typical 
electrophilic aromatic substitution. Generally, these acid-catalysed methods require an iodoaryl 
species containing iodine(III), which is coupled with an arene or a proper derivative. Alternative 
routes are available from treatment of organometallic aryl compounds with Koser’s reagent 
([hydroxy(tosyloxy)iodo]benzene) or its derivatives [ 157 ]. These molecules undergo an 
ipso-demetallation and lead to the iodonium tosylates or in variations (only for symmetric 
diaryliodonium salts) with CF3SO3I=O and FSO3I=O to triflates or fluorosulfonates, respectively. 
Another access to diaryliodonium salts is offered by the coupling of trans-β-functionalised 
vinyl(aryl)iodonium salts with aryllithiums, whereby electron withdrawing groups (good leaving 
groups) are necessary in the trans-β-position. 
 
Electrophilic aromatic substitution 
In most cases the necessary iodo(III)arene can be oxidised either in situ or by an individual 
oxidation procedure. The resulting iodonium compounds are generally iodosoarenes or 
(diacetoxyiodo)arenes. Both are suitable substrates for synthesis of diaryliodonium salts. One 
disadvantage of the iodosoarenes is, that they may suffer reduction to the corresponding 
iodoarenes instead of coupling with aromatic substrates [158]. Consequently, (diacetoxyiodo)-
arenes are the more successful compounds in these syntheses and they are widely employed. 
Over the years several oxidants have shown their suitability for selective mild oxidation of 
iodine(0) to iodine(III). Examples are chromium(VI) oxide [159], peracetic acid [150, 160], sodium 
perborate [ 161 , 162 ], sodium periodate [ 163 ], sodium percarbonate [ 164 ] and even 
electrochemical procedures [165]. 
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Scheme 1.7: General synthesis of a diaryliodonium bromide via oxidation to the (diacetoxy-
iodo)arene and subsequent electrophilic aromatic substitution catalysed by 
sulphuric acid 
 
In a typical reaction the iodoarene is converted by the oxidant (e.g. sodium perborate) in acetic 
acid into its diacetoxyiodo analogue. For subsequent formation of the desired diaryliodonium 
hydrogensulfate the (diacetoxyiodo)arene and the appropriate aromatic compound is treated with 
concentrated sulphuric acid in a mixture of acetic acid and acetic anhydride. Finally, by an 
addition of aqueous chloride, bromide or iodide solution the desired diaryliodonium halide 
precipitates (cf. Scheme 1.7). Numerous symmetric (R = R’) and asymmetric (R ≠ R’) 
diaryliodonium salts have been synthesised by this method. In case of the iodoarene and the 
aromatic coupling reagents various substituted and non-substituted aromatic, heteroaromatic and 
bicyclic molecules can be adopted. 
 
 
Scheme 1.8: Oxidative anion metathesis of diaryliodonium bromides and chlorides (Y = Br, Cl; 
X = HSO4, Cl, NO2, BF4, TsO, CF3SO3, CF3CO2) with cyclohexene as “halogen 
scavenger” 
 
The resulting diaryliodonium chlorides, bromides and iodides can easily be transferred into 
various iodonium salts differing in counter ions by an oxidative anion metathesis in very high 
yields [166, 167]. In practice, the diaryliodonium halide, the acid corresponding to the intended 
anion and hydrogen peroxide are heated to reflux in methanol (rarely: ethanol or propanol) for a 
short reaction time (~10 min) [noteworthy is, that diaryliodonium halides are thermally unstable 
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on prolonged heating]. Suitable anions are hydrogensulfates, bromides (only from iodides), 
chlorides, nitrates, tetrafluoroborates, triflates, tosylates and trifluoroacetates. For halide-halide 
transfers their reduction potential tendency has to be taken into account, thus those metatheses 
are only feasible according this order: iodide → bromide → chloride. In case of bromides and 
chlorides as starting materials any liberated bromine or chlorine evolving in the oxidative reaction 
can be trapped by cyclohexene (cf. Scheme 1.8). 
 
Ipso-demetallation 
An inherent weakness of arenes as coupling partners in electrophilic substitutions is that regio-
isomers may be formed. This drawback can be avoided by using organometallic compounds for a 
regiospecific demetallation (ipso-demetallation). Typical regiospecific coupling of diaryliodonium 
salts is carried out with [hydroxy(tosyloxy)iodo]benzene (Koser’s reagent) and various substituted 
aryltrimethylsilanes in acetonitrile what gives the corresponding diaryliodonium tosylates in 
absolute isomeric purity [157]. Since this method offers a general, mild and regiospecific 
synthesis of diaryliodonium salts, diverse ipso-demetallation reactions have been developed. 
Commonly employed organometallics for these are silanes [157], mercurials [168], stannanes 
[169] and boronic acids [170] (Scheme 1.9). 
 
Scheme 1.9: General principle of diaryliodonium salts syntheses via ipso-demetallation 
reactions (M = Si(alkyl)3, Sn(alkyl)3, Hg(OAc), B(OH)2; X =  TsO, CF3SO3, 
CF3CO2)  
 
However, the electrophilicity of Koser’s reagent and its derivatives is somewhat attenuated in 
comparison to (diacetoxyiodo)arenes and iodosoarenes. Those compounds react most readily 
with weaker bonds, thus the reaction conditions need to become stronger in the order of the 
Caryl-metal bond strengths (C-Hg < C-Sn < C-Si < C-B) [171]. Otherwise these nuances offer a 
selection of demetallation precursors differing in reactivity. Thus, a choice can be made 
according to the sensitivity of the aromatic coupling substrate. For example electron rich aromatic 
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compounds (e.g. heteroaryls) show high amounts of by-products during the procedure using 
heteroaryltrialkystannanes and make an isolation of the product salts from the highly coloured 
reaction mixture very complicate or even impossible. Using electron rich arylboronic acids reduce 
such problems due to their decreased sensitivity. Furthermore, the reactivity of the iodine(III) 
component has also to be taken into consideration. In this way 2-thienyl(phenyl)iodonium triflate 
could not be obtained in analytical purity via the 2-thiopheneboronic acid and trifluorosulphonic 
acid; a change to the Koser’s reagent made the 2-thienyl(phenyl)iodonium available as its 
tosylate [170]. In addition, the arylboronic acids help to avoid toxic substrates such as the heavy 
metal organometallics, what is very important with regard to the production of radiotracers for 
human application in PET studies. 
 
trans-β-Functionalised vinyl(aryl)iodonium salts 
Ligand exchange reactions are well-known for iodonium salts and build the basis for their ability 
as arylation substrates. In case of vinyliodonium salts this can be used for the synthesis of 
symmetric and asymmetric diaryliodonium salts [151, 156]. Accordingly, the coupling of trans-
β-functionalised vinyl(aryl)iodonium salts with aryllithium compounds leads to the diaryliodonium 
salts. In the  trans-β-position a highly nucleofugic group is required to cause an elimination at the 
stage of the ligand exchange. 
 
Scheme 1.10: Synthesis of various aryl(phenyl)iodonium triflates via ligand exchange of trans-
β-trifyloxyvinyl(phenyl)iodonium triflates (R = n-propyl; Ar = 2-benzothienyl, 2-thi-
enyl, 2-tolyl, 2-anisyl, 3-anisyl) [from 172] 
 
The reaction proceeds via an initial formation of a tricovalent iodine(III) intermediate (diaryl(vinyl)-
iodane) which subsequently decomposes to the diaryliodonium salt and via a coeval elimination 
to the corresponding acetylene derivative [151]. By using trans-β-trifyloxyvinyl(phenyl)iodonium 
triflates and aryllithium reagents, various diaryliodonium triflates were synthesised in good yields 
(cf. Scheme 1.10) [172]. Trans-β-functionalised vinyl(aryl)iodonium salts are attainable by several 
reactions of β-functionalised acetylene derivatives and reactive iodine(III) species such as 
Koser’s reagent and derivatives [153, 154, 173]. 
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1.6.2 18F-Radiofluorination via diaryliodonium salts 
It is well-known that diaryliodonium salts react with a wide range of nucleophiles and give the 
substituted arenes and the corresponding iodoarenes [151]. The first use of fluoride as 
nucleophile and the fluorination via diaryliodonium salt was performed by Grushin et al. in 1983 
[174]. A reaction of diphenyliodonium fluoroborate and potassium fluoride in the presence of a 
crown ether led to fluorobenzene in high yields. Based on this, Pike and Aigbirhio made the first 
attempt for nucleophilic 18F-labelling with diaryliodonium salts in 1995 [155]. They used 
diaryliodonium salts with diverse substituents and counter ions to label them in acetonitrile with 
n.c.a. [18F]fluoride, activated by the Kryptofix© 2.2.2/K2CO3-system. Since that time a variety of 
arenes has been 18F-labelled via diaryliodonium salts. Further, it has been demonstrated that via 
diaryliodonium salts even 18F-labelled electron rich arenes become available by using 
nucleophilic n.c.a. [18F]fluoride. The nucleophilic way has distinct advantages over alternative 
electrophilic procedures, which employ molecular [18F]F2 or reagents derived thereof, since n.c.a. 
[18F]fluoride can be produced in higher amounts and particularly with higher specific activity 
which is of great importance for in vivo radiotracers. [99, 100, 155, 175-178] 
 
Scheme 1.11: General principle of 18F-labelling via diaryliodonium salts (X = Cl, Br, I, TsO, 
CF3SO3, CF3CO2; R, R’ = H, Cl, Br, I, NO2, CH3, OCH3, …) 
 
During the 18F-labelling the reaction proceeds via a SN-Ar-mechanism and leads to the n.c.a. 
[18F]fluoroarenes and the non-radioactive iodoarenes as by-products (cf. Scheme 1.11). 
According to the reactions of the SN-Ar type, in an asymmetric diaryliodonium salt the electron 
deficient ring is preferably attacked by the [18F]fluoride. As a consequence, this is reflected in the 
product ratios of the [18F]fluoroarenes formed. In case of para-substituted aryl(phenyl)iodonium 
salts the electronic influence of the substituent lead to expected product yields as follows 70 % 
(bromo), 60 % (chloro), 40 % (methyl), and 0 % (methoxy); the corresponding percentages of the 
[18F]fluorobenzene increased with the same sequence [100, 155, 177]. As a result, the outcome 
of the substitution process can be predicted or controlled by the electronic character of 
substituents. Under this consideration, a subsequent methylation of one arylring should lead to a 
clear ratio in favour of [18F]fluorobenzene. However, experiments show that an increasing 
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number of methyl groups at one aromatic ring of up to four is accompanied by a decreasing 
percentage of [18F]fluorobenzene (cf. Figure 1.2) [176]. In spite of an increasing steric hindrance 
and electronic deactivation of the multi-methylated arylrest in the diaryliodonium salt the very 
same shows a higher probability for the nucleophilic attack. 
 
Figure 1.2: Increasing number of methyl-substituents leads to higher RCY [from 176]; 
trigonal bipyramidal geometry of the intermediate [18F]fluoride complex of the 
nucleophilic attack 
 
This fact is explainable by trigonal bipyramidal geometry of an iodine(III) intermediate formed 
upon the nucleophilic attack of [18F]fluoride (cf. Figure 1.2). First indications for the so-called 
“ortho-effect” in these reactions were mentioned in 1967 by Le Count et al. [ 179 ]. The 
phenomenon was confirmed and the trigonal bipyramidal geometry incipiently postulated as 
explanation by Yamada et al. in 1972 [180]. Furthermore, the same interpretation was used to 
explain similar results in corresponding radiofluorination reactions via diaryliodonium salts [176, 
181, 182]. It has been proposed that the intermediate is fluxional and the “reactive” ring is 
occupying the equatorial position syn to the nucleophile [183, 182]. 
Hence, in addition to the electron density the substitution pattern and its steric influence, 
especially with ortho-substituents, determine the regioselectivity of the nucleophilic attack. With 
regard to the electronic influence highly electron rich moieties such as heteroaromatic rings come 
into consideration. Consequently, various reactions of non-radioactive nucleophiles including 
fluoride as caesium or potassium fluoride have been carried out and show very high 
regioselectivity up to regiospecificity [180, 182, 184]. However, only non-radioactive nucleophiles 
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have been reacted with aryl(heteroaryl)iodonium salts so far and studies with n.c.a. [18F]fluoride 
are still open. 
 
1.6.3 18F-Labelled radiotracers via diaryliodonium salts  
In fluorine-18 radiochemistry the diaryliodonium method established their applicability especially 
for smaller aromatic compounds as primary 18F-labelling synthons. A very versatile synthon is 
n.c.a. 4-halo[18F]fluorobenzene (cf. Scheme 1.12), which was used as iodine and bromine 
derivative. Both can be obtained from the appropriate symmetric di-(4-halophenyl)iodonium salts 
in RCY of 60 – 70 % [99, 100], which is a much improved procedure than the earlier used 
method with N,N,N,-trimethylammonium precursors [84, 177]. The former was successfully 
coupled in a Sonogashira reaction to 18F-label two estradiol derivatives, which were the first 
approaches of Sonogashira-coupling in 18F-chemistry [99]. The latter proved its routine 
applicability in Stille [97] and Hartwig-Buchwald [98] reactions as well as in various 18F-
fluoroarylations after a subsequent transfer into its lithium or manganese organometallic 
derivative [101]. Also in cases of Stille and Hartwig-Buchwald reactions the diaryliodonium route 
is more convenient, leads to higher RCY and saves reaction time and steps. 
 
Scheme 1.12: Versatile application of 4-halo-[18F]fluorobenzene (X = Br, I; M = Li, MgX): Stille- 
[97]; Hartwig-Buchwald- [98]; Sonogashira- [99] coupling and 18F-arylation [101] 
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In recent years the diaryliodonium salts became more and more popular due to all the above 
mentioned advantages. Anyway, in case of complex molecules a limiting factor is indicated by 
molecule size and complexity. Approaches to label a complex molecule in one step with 
[18F]fluoride via its iodonium salt often led to low RCY or failed completely. Thus the triflate 
precursor 7-methoxy-8-phenyliodotriflate tetralone (cf. Scheme 1.13) was chosen as model 
compound for 2-[18F]fluoroestradiol, but only the starting material, 7-methoxytertalone, and 
iodobenzene were recovered from the reaction mixture [181]. 
 
Scheme 1.13: Iodonium precursors of complex radiotracer for PET; left: model compound for 
18F-labelling of estradiol (no 18F-labelling!); middle: precursor for an 18F-labelled 
steroid (RCY = 0.2 % (R = H); 2.0 % (R = CH3)); right: precursor for 6-[18F]fluoro-
m-tyramine as model for 6-L-[18F]fluoroDOPA (P1-3 = protecting group; 18F-label-
ling successful; RCY = ?) 
 
Another attempt to label a relevant biomolecule via its iodonium salt was made for a 
corticosteroid as potential PET ligand for imaging brain glucocorticoid receptors (cf. Scheme 
1.13). For this purpose, the iodonium precursor was synthesised as tosylate with both phenyl and 
tolyl counter rings. The RCY were very low, but an increase from the phenyl (RCY = 0.2 %) to the 
tolyl (RCY = 2.0 %) group was observable, accordingly to the assumption of directing the 
regiochemical outcome by electronic effects [185]. 
Recent investigations using iodonium salts report on the preparation of 6-[18F]fluoro-m-tyramine 
as model compound for 6-L-[18F]fluoroDOPA. Initial studies should lead to a nucleophilic access 
of this important radiotracer. The protected iodonium precursor (cf. Scheme 1.13) was 
successfully 18F-labelled and influences of protection groups, substituents in the non-intended 
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ring and counter ions were examined. The data are not yet published in detail and only a 
symposium abstract gives an idea of the expected results [186]. 
 
1.7 The role of AMPA receptors 
1.7.1 Basic neurophysiology of cerebral synapses 
The central nervous system (CNS) consists of a highly complex aggregation of cells, part of 
which is a communication network and another part a supportive and structural matrix (glial cells) 
[for an overview see: 187, 188, 189]. Neurons forming the communication network consist of a 
cell body (soma) with extensions (dendrites and an axon). The axon and dendrites make 
connections to the other neurons and they intercommunicate by means of specialised junctional 
complexes (synapses). In a synapse the presynaptic and the postsynaptic site are separated by 
the synaptic cleft, which is a gap of 15 – 20 nm. Almost all synapses involved in signal 
transmission in CNS are chemical synapses. However, only a very small number are electric 
synapses whose membranes are fused and the neurons are directly connected by ion channels. 
 
Figure 1.3: Principle of Ca2+ mediated neurotransmitter release (exocytose) into the synaptic 
cleft in a synaptic junction [modified from 188] 
action 
potential
protein 
neuro-
transmitter
vesicle
presynaptic 
terminal
metabotropic 
receptor
postsynaptic 
membrane 
synaptic 
cleft 
exocytose
ionotropic 
receptor
34  Introduction 
Along a neuron, information is transmitted by conduction of an electrical signal (action potential) 
from the soma or the dendrites to a synaptic ending, where a chemical neurotransmitter transfers 
the signal from the presynaptic to the postsynaptic site of the synapse (cf. Figure 1.1).  
For the synthesis of the neurotransmitter in the soma of presynaptic cells appropriate precursor 
molecules are taken up into the neuron. The resulting neurotransmitter is stored in vesicles in the 
presynaptic terminal. One part of the vesicles is linked to the presynaptic membrane and is 
intended for the exocytic release (exocytose) into the synaptic cleft. The remaining main part of 
the vesicles is bound to the protein synapsin as a reservoir. While an action potential moves 
along the axon and reaches the axon tip, voltage-gated Ca2+ channels open and allow Ca2+ entry 
into the presynaptic neuron. The increase of the internal Ca2+ concentration triggers the exocytic 
release of the neurotransmitter into the synaptic cleft. Beside the exocytose, Ca2+ activates the 
calmodulin-dependent protein kinase II, which phosphorylates synapsin for the release of stored 
vesicles for the next exocytose. Within approximately 0.1 ms the released neurotransmitter 
diffuses through the synaptic cleft to the postsynaptic site, where it is recognised and bound by 
postsynaptic receptor proteins to form a receptor-ligand complex. The receptor sites are 
classified in two types, the ionotropic and the metabotropic receptors. In ionotropic receptors the 
ion channel is part of the receptor protein and is gated or closed directly by changes of the 
receptor conformation. In case of ionotropic receptors, the binding by receptor-ligand complex 
formation cause a change in the conformation of ligand-gated ion channel proteins in the 
membrane. Resulting ion flux (Na+, K+ or Cl-) though the opened channel provoke a 
depolarisation of the membrane and a new electric signal arises (postsynaptic potential) and 
moves along the cell body and the axon to the next neuron. Depending on the type of receptors 
and synapses, different ion channels are opened. Thus inward flows of Cl- activate and stabilise 
the resting potential (hyperpolarisation) and inhibit the excitation, in the same way efflux of 
positive ions (K+, Na+) hyperpolarises the membrane (inhibitory postsynaptic potential). 
Conversely, efflux of Cl- or influx of positive ions depolarise the membrane and produce an 
excitatory postsynaptic potential, which amplifies the forwarded signal. 
Metabotropic receptors are coupled with so-called G proteins (guanosine nucleotide-binding 
protein). The G protein, stimulated by the activated receptor, triggers nearby ion channels or 
generates an intracellular second messenger by interaction with enzymes. To stop the synaptic 
transmission and regenerate the post synaptic membrane for new processes, the neurotrans-
mitters need to be deactivated from the synaptic cleft. Therefore they are metabolised by 
enzymes, taken up into the presynaptic terminal (re-uptake) or removed from the cleft and 
metabolised by the glial cells.  
In addition to the specific neurotransmitter (e.g. acetylcholine, amino acids (glutamate, glycine, 
and γ-aminobutyric acid (GABA), monoamines (serotonin, histamine, dopamine, noradrenaline 
(norepinephrine) adrenalin (epinephrine)) and some oligopeptides (neuropeptides)) several 
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natural substances (e.g. hormones, antibodies and -genes) and even NO are known to be active 
on specific receptors as agonists. Furthermore, foreign molecules such as pharmaceuticals show 
high specific affinities to neuronal receptors as agonists and antagonists, respectively. Thus, 
agonism and antagonism generally divide all possible receptor ligands in two classes. Agonists 
cause the same effect as the natural neurotransmitter, and antagonists block the binding site and 
generally inhibit any response. Within the agonists, full agonists and partial agonist are known. 
The former is able to produce the full tissue response whereas the latter provokes a response, 
but the response is less than the maximum to a full agonist. Antagonism is divided in competitive, 
non-competitive, chemical and functional one. In principle, competitive antagonism provokes a 
(ir)reversible blocking at the binding site, whereas non-competitive antagonists cause an 
(ir)reversible blocking by binding to another location at the receptor molecule. In contrast, 
functional antagonism is based on an indirect effect provoked at the neuron of the receptor or 
even at different neuronal cells. 
Many synapses have further receptors for regulatory functions in both the postsynaptic and the 
presynaptic membrane. Presynaptic autoreceptors (specific for the own transmitter) and 
heteroreceptors (specific for other substances) generate secondary messenger compounds to 
regulate the exocytose. Accessorily, heteroreceptors can affect preliminary mechanisms like 
neurotransmitter synthesis and storage (neuromodulation). In the postsynaptic membrane the 
heteroreceptors normally provoke a neuromodulation of the G protein processes or in case of 
ionotropic synapses they act directly of the ion channels. Artificial ligands for these receptors are 
referred to as neuromodulators and show agonistic and antagonistic function; several such 
substances are known and they are commonly used as pharmaceuticals. 
 
1.7.2 Ionotropic glutamate receptors 
The structure and function of glutamate receptors were recently reviewed in several reports, the 
following gives a short overview [from 190]. 
Glutamate receptors can be found in the cerebellum and the hippocampus and convey most of 
the fast excitatory transmission in the CNS. In addition, they appear to be crucially involved in 
memory functions and formation. Furthermore, the glutamate receptor system is assumed to play 
an important role in several degenerative neuronal dysfunctions and diseases, e.g. ischaemia 
and seizures, epilepsy, schizophrenia, Alzheimer’s, Huntington’s, and Parkinson’s disease [191, 
192]. Glutamate receptors generally subdivide into ionotropic and metabotropic receptors, which 
are classified into further subunits depending on the mechanism of their signal transduction 
(cf. Table 1.4). In case of the ionotropic glutamate receptors (iGluRs) there are three major types, 
which are named after the agonists that were originally identified to activate them selectively. 
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Thus they are called N-methyl-D-aspartate (NDMA), α-amino-3-hydroxy-5-methyl-4-isoazolepro-
pionic acid (AMPA) and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainic acid / kain-
ate (KA)) receptors (cf. Scheme 1.14). 
 
Table 1.4: Overview of the glutamate receptor system, classification into ionotropic and 
metabotropic receptors as well as their subunits and the corresponding signal 
transduction mechanisms (Gq/11/i/o = classes of the coupled G protein; Gq/11 
proteins activate the enzyme phospholipase C (PLC); Gi/o proteins inhibit the 
enzyme adenylate cyclase (AC)) [from 190] 
Glutamate Receptors 
Ionotropic (iGluRs) Metabotropic (mGluRs) 
NDMA AMPA Kainate Group I Group II Group III 
NR1 GluR1 GluR5 mGluR1 mGluR2 mGluR4 
NR2A GluR2 GluR6 mGluR5 mGluR3 mGluR6 
NR2B GluR3 GluR7   mGluR7 
NR2C GluR4 KA-1   mGluR8 
NR2D  KA-2   ↓ 
NR3A   
NR3B   Gq / G11 Gi / Go 
↓ ↓ ↓ ↓ ↓ 
Ca2+ 
Na+ 
Na+ 
(Ca2+) 
Na+ 
(Ca2+) ↑ PLC ↓ AC 
 
 
Scheme 1.14: Chemical structures of the original agonists naming the ionotropic glutamate 
receptors: NDMA (left), AMPA (middle) and kainic acid (KA) (right) 
 
The structure of ionotropic glutamate receptors is assumed to be tetrameric, which is similar to 
that of voltage-gated potassium channels. Although the amino acid sequences of the large 
number of glutamate receptor subunits are not identified completely (only ~20-30 % are 
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identified), they share common structural features, which place them into a single large 
superfamily.  
Figure 1.4: Schematic depiction of an ionotropic glutamate receptor (iGluR) family member 
[from 190] 
 
Whereas the topology of classic metabotropic receptors usually correspond to a four 
transmembrane domain model of the nicotinic acetylcholine receptors, the ionotropic glutamate 
receptors show only three transmembrane domains and one pore forming domain in the 
intracellular membrane surface (cf. Figure 1.4). The classic transmembrane domain exhibits the 
amino and the carboxy termini extracellularly and a large intracellular loop between the third and 
the fourth transmembrane domains. In contrast, the ionotropic glutamate receptors possess an 
intracellular carboxy terminus and an extracellular amino terminus (N-terminal domain). That 
amino terminus is followed by a polypeptide and the first transmembrane domain (S1 region in 
Figure 1.4). Then one domain forms an intracellular pore in the surface of the membrane. The 
second and third transmembrane domains are linked by a large extracellular loop (S2 region in 
Figure 1.4)) and finally it ends with an intracellular carboxy terminal domain (C-terminus). The 
agonist binding domain is located in a pocket formed between the N-terminal region and the 
extracellular loop between the second and third transmembrane domain (cf. Figure 1.4). 
 
NDMA receptors 
The NDMA receptor family is composed of seven subunits, NR1, NR2A to D and NR3A and B. 
Functional NDMA receptors appear to be comprised of NR1 and at least one NR2 subunit, or 
NR1 and both, NR2 and NR3 subunits. Accordingly, in NR1, NR2 and NR3 receptors the NR3 
unit likely substitutes one of the NR2 subunits. The NDMA receptor is unique amongst ligand-
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gated ion channels due to its requirement for two obligatory co-agonists binding on two different 
binding sites, the NR1 glycine site and the NR2 glutamate site. For receptor activation the 
occupation of two independent glycine sites and two independent glutamate sites are necessary. 
Thus the minimum need for a functional NDMA receptor seems to be a tetramer composed of 
two NR1 and two NR2 subunits, what is likely achieved by pairs or dimers of dimers (e.g. an NR1 
dimer in combination with an NR2A-D dimer). 
 
Scheme 1.15: Structures of the NDMA receptor full agonist L-glutamic acid (left) and the very 
high affine and selective competitive NDMA receptor antagonist (1RS,1’S)-
PEAQX (right) 
 
Besides NDMA as most commonly used agonist, glutamate (cf. Scheme 1.15) represents a full 
agonist for the NDMA receptor system. NDMA is not affected by the glutamate metabolism, 
therefore it is much more effective, although it is not quite a full agonist and of lower potence than 
glutamate. Furthermore, the ligand NDMA shows very good selectivity over non-NMDA ionotropic 
and metabotropic glutamate receptor families, but little selectivity between the NDMA receptor 
subtypes.  
A large number of competitive and non-competitive antagonists for the glutamate recognition site 
of the NDMA receptor have been synthesised. Competitive antagonists are usually α-amino 
carboxylic acids containing a ω-phosphonic acid group. They penetrate the blood-brain barrier 
(BBB) relatively poorly due to their high charged nature and equilibrate slowly in the brain. In 
general, they show only modest NDMA receptor subtype selectivity, although there are 
exceptions. One is (1RS,1’S)-PEAQX (cf. Scheme 1.15), which has an affinity in the nanomolar 
range at human NR1/NR2A receptors and > 100-fold selectivity over NR1/NR2B receptors. One 
of the potentially most important recent developments in NDMA receptor pharmacology has been 
the identification of highly subtype selective antagonists, which act allosterically though an 
interaction with the extracellular N-terminal domain of the NR2 subunits. Most of these 
compounds are selective to the NR2B subunits. A large number of substrates with high NR2B 
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affinity and selectivity over other NDMA receptor subtypes have been developed, which readily 
penetrate the brain and are systemically active. 
Kainate receptors 
Kainate receptors are subdivided in two subunit families, GluR5 to 7 and KA-1 and -2. They show 
again structural features of tetrameric combinations, where both, homomeric and heteromeric 
combinations are possible. Concerning KA-1 and -2 subunits, no homomeric combination can be 
found, thus they only occur in heteromeric combinations with one or more members of 
GluR5 to 7 subunits. At first the lack of selective agonists for kainate receptors has hampered the 
discovery of the kainate receptor physiology. Since then several selective agonists with different 
selectivity across the GluR5 to 7 subfamily have been developed, including the substituted 
AMPA-analogue 5-tert-butyl-4-isoxazolepropionic acid (ATPA) (cf. Scheme 1.16), which shows 
selectivity for GluR5 receptors and only low affinity to GluR6 and 7 receptor subtypes. 
 
Scheme 1.16: Structures of the kainate receptor agonist ATPA (left) and the very potent non-
competitive antagonist UBP296 (right) 
 
In addition, several competitive and non-competitive antagonists have been developed as ligands 
for the kainate receptor family. Especially, the further development of the non-competitive 
antagonists, selective at the GluR5 subtype, lead to the recent most potent member of this group, 
(R,S)-3-(2-carboxybenzyl)willardiine (UBP296) (cf. Scheme 1.16). UBP296 exhibits selectivity for 
GluR5 containing receptors over GluR6 and AMPA receptors, whereby the activity is residing in 
the S enantiomer. Another class of kainate receptors affecting compounds is represented by the 
positive allosteric modulators. Only the lectin concanavalin A has been identified thus far. 
Although it has been proven to be a valuable tool for the study of kainate receptors, it shows also 
activity at AMPA and NDMA receptor sites. 
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AMPA receptors 
The AMPA receptor family is composed of four subunits, GluR1 to 4, and functional AMPA 
receptors are assumed to assemble as tetramers. Like NDMA receptors, AMPA receptors occur 
likely in heteromeric combinations. The GluR2 subunit plays a critical role in the permeability of 
the heteromeric receptors to Ca2+. So AMPA receptors that do not contain the GluR2 subunit are 
Ca2+-permeable, what is a result of a voltage-dependent block of the ion channel by intracellular 
polyamines. In contrast, the Ca2+ impermeability of GluR2 containing receptors is based on a 
molecular modification, which is identified as an arginine (R) at a critical site in the pore loop (2m 
domain), which is a glutamine (Q) at the corresponding position in the other subunits. Further 
complexity is introduced in all AMPA subunits by alternative splicing in the extracellular S2 
domain. Two alternatively spliced forms are present, known as Flip and Flop. Flip variants are 
predominant prenatally, whereas Flop variants become expressed postnatally and reach 
equivalent levels to those of Flip in the adult. These splice variations have effects on the rate and 
extent of desensitisation of heteromeric AMPA receptors and also influence their sensitivity to 
allosteric modulators. In the same way GluR2 and 4 have further C-terminal splice variants, 
which likely play roles in intracellular protein-protein interactions and receptor clustering. 
Indications speak for AMPA receptors, lacking the GluR2 and with high Ca2+ permeability located 
in hippocampus and amygdala. They predominate in inhibitory interneurones, whereas pyramidal 
cells have AMPA receptors containing GluR2 subunits and thus largely Ca2+-impermeability. 
There is also evidence that in stellate cells activity-induced Ca2+ influx through AMPA GluR2-
lacking receptors controls the designing of GluR2-containing AMPA receptors, implying a self-
regulating mechanism of the Ca2+ permeability of synapses. 
 
1.7.3 Ligands of AMPA receptors 
AMPA receptor agonists  
A large number of AMPA receptor agonists have been described and many of them, like AMPA 
itself, are derived from classic structure-activity-relationship (SAR) studies using ibotenic acid, 
quisqualic acid and willardiine as lead structures (cf. Scheme 1.17). One of the interesting 
aspects of AMPA receptor agonists is that they can vary dramatically in the amount of receptor 
desensitisation that they induce. The receptor desensitisation effect can be described as a 
self-control or –protection mechanism against too high signal frequencies, signal overdose and 
receptor or neuron damage. While a neurotransmitter binds to the receptor it also induces 
generally a specific receptor desensitisation, which affects the recovery rate of the receptor and 
its binding sites, respectively. In some cases a strong desensitisation can lead to temporarily 
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complete deactivation of the receptor. Desensitisation depends on particular agonist structures; 
for example, glutamate and AMPA act as full agonists and induce a rapid desensitisation 
response at the AMPA receptors, while kainate acts as partial agonist and induces only little 
desensitisation response [193]. 
 
Scheme 1.17: Lead structures used for the development of AMPA agonists; ibotenic acid (left); 
L-quisqualic acid (middle); willardiine (right) 
 
The degree of partial agonism is correlated with the extent of domain closure of the bi-lobed 
agonist binding (cf. Figure 1.4), thus partial agonists induce domain closure, but not the closed 
state induced by full agonists. The degree of desensitisation appears to be directly correlated 
with the degree of dimerisation between the pairs of subunits within the tetrameric receptor. 
 
AMPA receptor antagonists 
AMPA receptor subtypes are involved in learning and memory but can also mediate neuronal 
degeneration and even cell death [for an overview see: 190, 194, 195]. For this reason particular 
attention has been devoted to selective AMPA receptor antagonists as potential neuroprotective 
agents. Several AMPA receptor antagonists inhibit glutamatergic transmission in a competitive 
way, whereas only a few classes of selective, non-competitive AMPA receptor ligands (e.g. 2,3-
benzodiazepines, phthalazines, quinazolines and more recently tetrahydroisoquinolines) have 
been developed. 
However, the first compounds identified as competitive AMPA antagonists shows also activity at 
the glycine sites of NDMA receptors and therefore insufficient selectivity to be useful agents. 
Furthermore, most of them were quinoxaline derivatives and have a limited, or even poor water 
solubility, that causes nephrotoxicity in some cases and the compounds have failed the clinical 
trials. One promising member of the quinoxalines is [2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-
1,2,3,4-tetrahydro-1-quinoxalinyl]-acetic acid (YM872 / zonampanel) (cf. Scheme 1.18), which 
succeeded in clinical trials for the treatment of acute ischaemic stroke. The trial phase II has 
been completed, but, so far, no further information is available [196]. 
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The main advantage of non-competitive AMPA receptor antagonists is that they use different 
binding sites than those of glutamate and therefore the normal glutamatergic activity is not 
influenced after prolonged use. Hence, they are also referred to as negative allosteric 
modulators. With 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 
52466) as first prototype of non-competitive AMPA receptor antagonists and lead structure, 
several 2,3 benzodiazepines have been identified as selective ligands for AMPA receptors. 
Although they exhibit relatively little selectivity between AMPA receptor subtypes, they are 
selective for AMPA over kainate and NDMA receptors. (R)-7-Acetyl-5-(4-aminophenyl)-8,9-
dihydro-8-methyl-7H-1,3-dioxolo(4,5-h)-2,3-benzodiazepine ((-)-GYKI 53773/(R)-LY300164 / tala-
mpanel) (cf. Scheme 1.18) has entered in clinical trials for indications including epilepsy and 
shows positive results in patients with severe epilepsy not responsive to other drugs and so it is 
selected as antiepileptic drug candidate [197, 198]. 
 
Scheme 1.18: Structures of AMPA receptor antagonists; left: competitive antagonist zonam-
panel (YM872); middle: non-competitive antagonist talampanel ((-)-GYKI 53773); 
right: series of tetrahydroisoquinoline derivatives as non-competitive antagonists 
(R = H, Br, Cl, F, NO2, NH2) 
 
Tetrahydroisoquinolines were recently identified as highly potent non-competitive AMPA receptor 
antagonists (cf. Scheme 1.18) and demonstrated anticonvulsant effects. The 2-acetyl-1-(4‘-
chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (R = Cl) proved to be more potent 
than other known AMPA antagonists, which require a 100-fold higher dose to show similar 
effects. In addition, the fluoro-substituted compound 2-acetyl-6,7-dimethoxy-1-(4‘-fluorophenyl)-
1,2,3,4-tetrahydroisoquinoline also showed a potence in the range of GYKI 52466 and it is very 
interesting for 18F-labelling in the original position of the fluorine with regard to get a AMPA 
radiotracer for PET. 
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Positive allosteric modulators (potentiators)  
The desensitisation and deactivation of AMPA receptors can be controlled by positive allosteric 
modulators. Thus, these so-called potentiators regulate the magnitude and kinetics of AMPA 
receptor-mediated synaptic currents. A number of positive allosteric modulators have been 
identified which modulate receptor desensitisation and / or deactivation but do not activate the 
receptor when applied alone. Only a few chemical classes have been reported to show effects as 
AMPA receptor modulators, benzamides (AMPAkines), benzothiadiazides and biarylpropylsulfon-
amides (cf. Scheme 1.19). Such compounds demonstrated mediated synaptic activity in various 
in vitro and in vivo studies, most notably in models of cognition. 
 
Scheme 1.19: Structures of AMPA receptor potentiators of different chemical classes; left: 
CX614, a benzamide (AMPAkines); middle: cyclothiazide, a benzothiadiazide; 
right: LY404187, a biarylpropylsulfonamide) 
Moreover, known and commonly used drugs for diseases affecting memory and learning appear 
likely to act as AMPA receptor modulators. The positive modulators exhibit discrete mechanistic 
profiles and selectivity for individual AMPA receptor subunits and their isoforms (splice variants). 
As a result, the AMPAkine 2H,3H,6aH-pyrrolidino[2’’,1’’-3’2’]1,3-oxazino[6’5’-5,4]benzo[e]1,4-di-
oxan-10-one (CX614) enhances the AMPA receptor-mediated currents by blocking the desensiti-
sation and slowing the deactivation (cf. Scheme 1.19), whereas the benzothiadiazide 6-chloro-
3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiazidiazine-7-sulfonamide-1,1-dioxide (cyclo-
thiazide) inhibits the receptor desensitisation but has only little effect on receptor deactivation (cf. 
Scheme 1.19). 
However, also the biarylpropylsulfonamide N-2-[4-(4-cyanophenyl)phenyl]propyl 2-propanesulf-
onamid (LY404187) suppresses receptor desensitisation but with a distinct time dependence in 
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the presence of an agonist. The AMPAkines exhibit somewhat higher potencies at flop than flip 
isoforms of recombinant homomeric receptors and have only little selectivity between the 
subfamily members of AMPA receptors. In contrast, cyclothiazide and LY404187 show higher 
potencies at flip than flop isoforms and increased potencies at flip isoforms of GluR2 and 4 vs. 
GluR1 and 3. The binding site of cyclothiazide was identified at the dimer interface between 
AMPA receptor subunits. There is evidence within the benzamides for different binding sites of 
some members, thus there are likely multiple binding sites for positive allosteric modulators, even 
for compounds of the same chemical class. These differences in the mechanism of action and 
receptor subunit / isoforms selectivity provide the potential for special in vivo profiles for the 
different positive allosteric modulators for AMPA receptors. 
 
1.7.4 Radioligands of AMPA receptors 
There is a lack of suitable radiotracers for in vivo investigations of the AMPA receptor family. So 
far, only a few specific substances have been labelled, but only with tritium, which is only suitable 
for in vitro or ex vivo applications. Thus, there is enormous demand for PET or SPECT tracers for 
the AMPA receptor system. 
 
Scheme 1.20: 3H-labelled radiotracers for the AMPA receptor system; left: (S)-[3H]-5-fluoro-
willardiine; middle: [3H]CNQX; right: [3H]NBQX 
 
Besides [3H]glutamate and [3H]AMPA as labelled agonists, which offered the first insight into the 
AMPA receptor family, only (S)-5-[3H]fluorowillardiine ([3H]FW) as agonist and 6-cyano-7-
[3H]nitroquinoxaline-2,3-dione ([3H]CNQX) as well as 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-[3H]be-
nzo(F)quinoxaline-7-sulfonamide ([3H]NBQX) as antagonists are available for further investiga-
tions (cf. Scheme 1.20). 
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 Aims and Scope 
Especially in vivo studies using positron emission tomography (PET) call for very high standards 
in purity and specific activity of 18F-labelled compounds. However, for the positron emitter 
fluorine-18 a high specific activity is only achievable with n.c.a. [18F]fluoride. This implies a 18F-
radiochemistry almost reduced to nucleophilic substitution reactions. Whereas electron deficient 
arenes can directly be labelled with no-carrier-added [18F]fluoride in one step, electron rich 18F-
labelled aromatic molecules are only available by electrophilic methods with [18F]F2 or via multi-
step radiosyntheses using accessory activating groups. Both accesses are accompanied by 
severe drawbacks; the former leads to low specific activities due to necessary carrier addition 
and the latter requires additional radiosynthetic steps for converting or removing the activating 
groups. Here, diaryliodonium salts represent an alternative, since they have been proven as 
potent precursors for direct nucleophilic 18F-labelling of arenes including even relatively electron 
rich derivatives. Furthermore, the 2-thienyl group represents a highly electron rich moiety and is 
known to induce a high regioselectivity in reactions of aryl(2-thienyl)iodonium salts with 
nucleophiles. However, the 2-thienyl group so far has only been employed in non-radioactive 
studies. 
The aim of this work was to develop a new direct nucleophilic n.c.a. 18F-labelling method for 
arenes based on aryl(2-thienyl)iodonium salts as precursors, where particularly non-activated 
molecules were of interest. As model electron rich molecules n.c.a. [18F]fluoroanisoles should be 
radiofluorinated by using this new method. 
As first approach, a reliable synthesis route for the employed aryl(2-thienyl)iodonium salts had to 
be elaborated. Since different methods are described in the literature, especially for electron rich 
molecules, a reliable and convenient synthesis was of importance.  
In order to optimise the general conditions of the 18F-substitution procedure with the 2-thienyl-
iodonium leaving group, the focus was particularly on the solvent system, precursor concentra-
tion, and reaction temperature. 
A major concern was the influence of the highly electron rich 2-thienyl group on a very high 
induced regioselectivity. Therefore influences of counter anions of the precursor salts on RCY 
and reaction rate had to be systematically examined. For a comparison between organic and 
inorganic counter anions, the iodonium precursors were employed as bromides, iodides, tosylat-
es and triflates. In addition, the influence of the substitution pattern was of interest as determining 
factor. Especially, the so-called ortho-effect was expected to show distinct impact on the 
orientation of the 18F-labelling reactions. 
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One important focus should be on the influence of the electronic character of the precursor 
molecules on the RCY and reaction rate of the 18F-substitution reaction. Therefore the study was 
extended to a series of substituted aryl(2-thienyl)iodonium salts with systematically varying 
electron density. Thus, the aryl(2-thienyl)iodonium salts ranged from highly activated (electron 
deficient) to deactivated (electron rich) precursors. 
Since the empirical Hammett relation is the most commonly used linear-free-energy relationship 
for studying and investigating organic reactions and their mechanisms, the reaction rates of the 
n.c.a. 18F-exchange reactions should be correlated with the appropriate Hammett constants of 
the aryl substituents in the precursors. 
In order to demonstrate the applicability and versatility of the new method by direct no-carrier-
added 18F-labelling via aryl(2-thienyl)iodonium salts, two deactivated molecules relevant for 
radiopharmaceutical chemistry should be 18F-labelled. 
First, the primary 18F-labelling synthon n.c.a. 4-[18F]fluorophenol, which has proven its applica-
bility in various radiosyntheses of radiopharmaceuticals, should be prepared via an appropriate 
aryl(2-thienyl)iodonium precursor. Thus, a more convenient and time-saving procedure would be 
attained in comparison to the so far alternative five-step radiosynthesis. 
Second, a more complex molecule should be 18F-labelled via aryl(2-thienyl)iodonium salts. Thus 
far, only a few complex molecules were 18F-labelled via diaryliodonium salts and all showed a 
very small RCY of 3 % and below. Radioligands for in vivo studies of the AMPA neuroreceptor 
system are lacking and in great demand. 2-Acetyl-6,7-dimethoxy-1-(4‘-fluorophenyl)-1,2,3,4-tetra-
hydroisoquinoline (F-ADTQ) was characterised as a non-competitive AMPA receptor antagonist, 
which is not available as 18F-labelled radioligand so far. Accordingly, F-ADTQ should be 
synthesised by a direct 18F-labelling procedure using (2-thienyl)iodonium salts. 
For the synthesis of precursor molecules for the 18F-labelling of F-ADTQ the iodine derivative 
2-acetyl-6,7-dimethoxy-1-(4‘-iodophenyl)-1,2,3,4-tetrahydroisoquinoline (I-ADTQ) had to be 
prepared as well as its corresponding trimethyltin compound. Since I-ADTQ, unlike other 4’-sub-
stituted analogues, has not yet been characterised as AMPA receptor antagonist, it should be 
labelled for comparison with radioiodine in order to make preliminary radiopharmacological 
evaluation studies possible and possibly enlarging the very low number of radiolabelled AMPA 
ligands. 
In terms of radioanalytical methods, suitable systems and conditions for radio thin layer 
chromatography and radio high performance liquid chromatography needed to be developed for 
identification and quantitation of the 18F- and 131I-labelled compounds. Finally, reference 
compounds and standards had to be synthesised for this purpose. 
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Diaryliodonium salts are well-known as stable and well-manageable compounds which are light-
sensitive. In chemistry they show widespread applications [151, 152]. Furthermore, diaryl-
iodonium salts have earlier been proven as potent precursors for nucleophilic 18F-labelling 
reactions (see subchapter 1.6). A wide range of symmetric and asymmetric diaryliodonium salts 
were employed with n.c.a. [18F]fluoride for direct nucleophilic 18F-labelling reactions. Of particular 
interest is their ability to serve as precursors for a direct nucleophilic 18F-introduction into electron 
rich aromatic compounds [155, 175-178]. Such nucleophilically deactivated aromatic molecules 
can generally be labelled only with electrophilic reactions or with the help of accessory activating 
groups, which decrease the electron density in the arenes and enable a nucleophilic 18F-labelling 
approach. However, additional activating groups have to be removed or converted after the 
18F-intoduction process. In terms of [18F]fluorotracers for nuclear medicine diagnosis two 
important facts call for high specific activity. Firstly, toxic and pharmacological effects or 
responses can be excluded in the n.c.a. range and secondly, special applications such as brain 
imaging and determination of receptor occupancy and density become available. For 18F-labelled 
compounds with high specific activity, labelling reactions have to be carried out at n.c.a. scale, 
which is only accessible for nucleophilic fluoride-18. 
Nucleophilic reactions with diaryliodonium salts are well investigated and they proceed according 
to a classic SNAr-mechanism. As a result, the more electron deficient ring in the diaryliodonium 
salt is preferably attacked by the nucleophile and thus, the regiochemical outcome of the reaction 
can be directed or controlled by the electronic character of the arylrests, i.e. their substituents. 
Besides electronic properties, the steric hindrance of attached groups must be considered. 
Based on a trigonal bipyramidal intermediate during the substitution process, the “ortho-effect” 
causes a favoured attack of ortho-substituted compounds in the nucleophilic reaction even in 
case of deactivated rings. 
Concerning the dependence on electronic influences the direct nucleophilic n.c.a. 18F-labelling of 
electron rich aromatic molecules receives major interest. For the development of radiopharma-
ceuticals via diaryliodonium salt precursors it is much more practicable in most cases to modify 
the undesired aromatic ring electronically for better product ratios, faster kinetics and thus higher 
RCY, than finding an object molecule carrying originally an ortho-substituent. 
In principle, product ratios of 18F-labelling reactions with asymmetric diaryliodonium precursors 
mirror the difference between the relative electron densities of the aryl-moieties, when steric 
influences are negligible. Thus the more the undesired ring becomes deactivated the more the 
preference of 18F-labelled electron rich molecules increases. Considering this, heteroaromatic 
48  Results and Discussion 
rings with a high electron density as intended moieties not for labelling offer the way to a variety 
of electron rich 18F-compounds, where generally a direct nucleophilic access is lacking or 
inefficient. 
Based on auspicious reports of reactions with aryl(2-thienyl)iodonium salts and non-radioactive 
nucleophiles [182, 184], this class of precursors is investigated in this work. In detail, they are 
tested for their suitability and practicability in direct nucleophilic n.c.a. 18F-labelling chemistry of 
electron rich arenes. 
For a systematic approach, a group of precursors for 18F-labelling of the electron rich [18F]fluoro-
anisoles (ortho [18F]1, meta [18F]2 and para [18F]3) was employed. This group includes all 
structural isomers for investigation of the influence of substitution pattern. Furthermore, the highly 
electron rich 2-thienyl moiety was expected to direct the product ratio in favour of the [18F]fluoro-
anisoles (cf. Scheme 3.1). 
 
Scheme 3.1: Expected results of the nucleophilic n.c.a. 18F-labelling of methoxyphenyl-
(2-thienyl)iodonium salts 1 to 3 (X = Br (c), I (d), OTs (e), OTf (f); 
position of OCH3: ortho 1, meta 2 and para 3) 
 
The molecules investigated in this work are numbered systematically as described in the 
following, where still numbers indicate the fluoroarenes, added letters define the corresponding 
iodoarenes as a, the (diacetoxyiodo)arenes as b, the aryl(2-thienyl)Iodonium bromides as c, 
iodides as d, tosylates as e and triflates as f (cf. Scheme 3.1, Scheme 3.2 and Scheme 3.3). 
Each methoxyphenyl(2-thienyl)iodonium salt 1 to 3 is employed as its bromide (c), iodide (d), 
tosylate (e), and triflate (f) in order to cover different counter anion effects. Especially the 
differences between organic and inorganic ions are here of primary interest.  
In view of a systematic examination of this method, a second group of para-substituted aryl-
(2-thienyl)iodonium bromides 4c to 9c is used in this work (cf. Scheme 3.2) in order to study the 
effect of electronic influences. Within this group of molecules, the products show a decreasing 
tendency of electron density. A main focus for these precursors is on a complete correlation 
between the electronic character of the intendeds and the 18F-substitution kinetics. 
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Since the precursor 4-benzyloxyphenyl(2-thienyl)iodonium bromide 4c represents a benzyl-
protected 4-[18F]fluorophenol as 18F-labelling product, a new convenient two-step (18F-labelling 
and deprotection) radiosynthesis of the versatile synthon n.c.a. 4-[18F]fluorophenol is offered by 
this method. 
 
Scheme 3.2: Para-substituted precursor molecules 4c to 9c with different electron density in 
the homoaryl group (X = Br) 
 
Further, the appropriate iodonium precursors for the preparation of a complex, 18F-labelled radio-
pharmaceutical are synthesised to show the efficiency of the method. The molecule 2-N-acetyl-
6,7-dimethoxy-1-(4‘-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline [F-ADTQ] 10 (cf. Scheme 3.3) 
was identified as non-competitive AMPA receptor antagonist, but not yet really pharmacologically 
evaluated (cf. subchapter 1.7.3). Thus, the radioligand [18F]F-ADTQ [18F]10 should enable further 
pharmacological evaluation studies of this AMPA receptor ligand.  
 
Scheme 3.3: Structures of non-competitive AMPA receptor antagonist F-ADTQ (10) and 
potential non-competitive AMPA receptor antagonist I-ADTQ (10a) 
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In addition, the iodine analogue 2-N-acetyl-6,7-dimethoxy-1-(4‘-iodophenyl)-1,2,3,4-tetrahydroiso-
quinoline [I-ADTQ] 10a (cf. Scheme 3.3) has not been pharmacologically evaluated, either. In 
order to make pharmacological evaluation studies of 10a possible, 10a was labelled with 
radioiodine ([131I]I-ADTQ [131I]10a). 
Both radioligands formed can be compared and their pharmacological evaluation should give 
more detailed information of the potence of this category of molecules as non-competitive AMPA 
receptor ligands. Furthermore, the iodine derivative was not included in the original study, where 
only the fluorine, chlorine and bromine derivatives were examined. These show good but very 
diverse results and thus the potence of I-ADTQ as AMPA receptor antagonist is of interest [194]. 
 
3.1 Syntheses of precursors 
3.1.1 Syntheses of (diacetoxyiodo)arenes and oxidation methods 
For the synthesis of diaryliodonium salts various procedures are described in the literature, three 
of which were shortlisted for this work as shown in Scheme 3.4. All those routes need a 
preliminarily oxidised iodine(III) species for the formation of the diaryliodonium salt as pointed out 
before (cf. subchapter 1.6.1). This can be done in situ or in an individual oxidation step. Due to 
the fact that the choice of the suitable method for the diaryliodonium salt synthesis is depended 
on the desired type and character of the salt, it is more practicable to use an individual oxidation 
step and the resulting iodine(III) compound can be employed for different further syntheses. 
According to the various production pathways of diaryliodonium salts, the (diacetoxyiodo)arenes 
are very stable and versatile iodine(III) reagents. 
Hence, in the first step all iodoarenes were oxidised to their diacetoxyiodo derivatives. For this 
procedure the oxidation with sodium perborate [161, 162] and with sodium periodate [163] were 
tested. The main differences are harsher conditions (reflux in acetic acid/acetic anhydride) and 
shorter reaction times (~2h) with the periodate oxidation. In case of sodium perborate a much 
more gentle procedure was used. Here, the reaction was carried out at 40 °C in pure acetic acid, 
but it took up to 24 hours for completion. However, the major advantage is the purity of the 
obtained (diacetoxyiodo)arenes; they are formed with very little side-products and less impurities 
by the milder perborate method. An important fact here is to keep the temperature strictly below 
45 °C, because at higher temperatures the oxidation proceeds further to the iodine(V) species 
(iodylarenes). These are very sensitive substrates and tend to explosive decomposition. The 
perborate oxidation was suitable for the most iodoarenes employed and gave good yields of 
42 - 74 % of the (diacetoxyiodo)arenes in 20 – 24 h. Only two exceptions need a different 
treatment. First, the 4-benzyloxy-1-iodobenzene 4a, which could not be oxidised by the perborate 
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method and where only starting material was recovered, even after extended reaction times of up 
to 48 h. Therefore in this case, it was necessary to use the periodate system, which led to a yield 
of 66 % after 2 h, but this implied the above mentioned additional effort of a purification process. 
Second, the 1,4-diiodobenzene 9a, which poses the challenge to oxidise only one iodine in order 
to assure an unaltered iodine-function in the final iodonium precursor. Both oxidation methods 
described, work with large excesses of oxidant and lead always to bis-1,4-(diacetoxyiodo)-
benzene as product. The reverse approach via 2-(diacetoxyiodo)thiophene and iodobenzene 
always led to an isomeric mixture of the ortho and para derivative (ratio: ~5:95), which are hard 
to separate by re-crystallisation. Thus, the selective oxidation of only one iodine group was 
necessary. This became possible by the equimolar use of peracetic acid as oxidant [99]. 4-Iodo-
1-(diacetoxyiodo)benzene 9b was obtained in yields of up to 42 % after ~1 h reflux, but the yields 
strongly differ. Too fast addition of the peracetic acid as well as too long reaction times can 
decrease the yield due to probable consecutive oxidation of the second iodine function and/or 
redox processes between the different iodine species (e.g. via disproportionation). Most of the 
(diacetoxyiodo)arenes here synthesised are known compounds and were only characterised by 
comparison of their melting points. However, some melting points disagree to those reported in 
the literature. In these cases the identity was additionally confirmed by mass spectrometry. Even 
in the literature diverse melting points with huge differences are found for some (diacetoxyiodo)-
arenes. Only 4-benzyloxy-1-(diacetoxyiodo)benzene 4b was characterised by 1H- and 13C-NMR 
spectroscopy, mass spectrometry and elemental analysis, due to the fact that 4b was not 
described in the literature so far. 
 
3.1.2 Syntheses of aryl(2-thienyl)iodonium salts 
As mentioned above (cf. Scheme 3.4), three reaction routes were considered for the preparation 
of the aryl(2-thienyl)iodonium salts. In the first one, the (diacetoxyiodo)arene and thiophene react 
in form of a classic electrophilic aromatic substitution in presence of concentrated sulphuric acid 
as catalyst to the aryl(2-thienyl)iodonium hydrogensulfate, which is subsequently precipitated as 
the bromide or iodide (path A in Scheme 3.4). 
Path B described the same reaction, but the functional groups of the heteroaromatic and 
aromatic compound are exchanged, i.e. 2-(diacetoxyiodo)thiophene is coupled with appropriate 
arenes. The compounds resulting via path A and B seem to be identical (cf. Scheme 3.4). 
However, due to the highly activated 2-position of thiophene, path A led exclusively to one aryl-
(2-thienyl)iodonium salt, while via path B generally an isomeric mixture of ortho- and para-
derivatives was obtained. 
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Scheme 3.4: Examined pathways to aryl(2-thienyl)iodonium salts (X = Br, I, OTs) 
 
As a third route, the regiospecific ipso-demetallation of boronic acid derivatives was examined 
(path C in Scheme 3.4). Especially for the electron rich molecules this way caused problems due 
to impurities and side-products, which are assumed to originate from internal redox processes 
and other side-reactions of the highly reactive 2-(hydroxy(tosyloxy)iodo)thiophene. Several 
crystallisation steps had to be performed and diminished the moderate yields. Furthermore, this 
procedure led only to tosylate counter ions and was not applicable to prepare bromides or 
iodides. Moreover, the Koser’s derivative of 2-iodothiophene is very reactive and has to be 
handled and stored under inert gas, what makes its application more inconvenient. 
Consequently, path A proved to be the most suitable method. This route had the advantage to 
achieve reliable and good yields even with electron rich molecules. The aryl(2-thienyl)iodonium 
bromides 1c to 8c are obtained in yields of 36 – 67 %, while the yield of 4-iodophenyl(2-thien-
yl)iodonium bromide 9c of 18 % was an exception. This outlier was the most complicate 
precursor to be synthesised. The difficulties of the 4-iodo-1-(diacetoxyiodo)benzene 9b 
preparation were continued with the preparation of 9c. A lot of side-products evolved during the 
synthesis and also starting iodoarene from reductive processes and deiodinated arene was 
found. As a consequence, several purification and re-crystallisation steps for 9c were necessary. 
All other bromides were obtainable in good yields and with high purity. Generally, one re-crystal-
lisation step from methanol/ether mixtures gave analytically pure samples. The methoxyphenyl-
(2-thienyl)iodonium iodides 1d to 3d showed similar results. They were obtained in yields of 36 –
 60 %. In some cases they needed more re-crystallisation steps and showed a higher sensitivity 
to light and air. 
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Due to the disadvantageous effects of path C mentioned before, the triflates and tosylates were 
received from the bromides 1c to 3c by an oxidative anion metathesis [167]. The bromide was 
oxidised by hydrogen peroxide and free molecular bromine was trapped by addition of 
cyclohexene in excess. The appropriate acids of the organic anions, para-toluenesulphonic acid 
or triflic acid, were added and the corresponding salts precipitated. Only the 4-methoxyphenyl(2-
thienyl)iodonium triflate 3f was hard to crystallise; several work-up methods with extractions by 
dichloromethane, re-crystallisations and long storing times at -25 °C led at last to pure crystalline 
samples in 37 % yield. Derivatives 1e and 2e are easily obtained in very high yields of 98 % and 
81 %, respectively. The triflates are the most sensitive salts and darken quickly in contact with 
air. The conversion to the tosylates resulted in similar high yields of 76 % for 1e, 93 % for 2e and 
93 % for 3e. They were obtained as very pure samples of white crystals. Tosylates are much 
more stable and can be stored at room temperature in the dark, whereas the triflates have to be 
stored under inert gas or in an exsiccator at 4 °C. Concerning their application for n.c.a. 18F-label-
ling reactions, all precursors are stored in an exsiccator at 4 °C. All synthesised aryl(2-thienyl)-
iodonium salts were analytically characterised by their 1H- and 13C-NMR spectra, mass spectra 
and elemental analyses. 
 
3.2 N.c.a. 18F-radiofluorination of arenes via aryl(2-thienyl)iodonium 
salts 
3.2.1 Optimisation of reaction conditions using 2-methoxyphenyl(2-thienyl)-
iodonium bromide 
In a first attempt an investigation of the general reaction conditions of the n.c.a. 18F-labelling of 
arenes via aryl(2-thienyl)iodonium salts was carried out. Since 1c represents an electron rich 
model compound and it includes an ortho-substituent, it was employed for these optimisation 
studies. In addition, the ortho-effect of 1c was generally expected to lead to higher RCY than 
reactions with the precursors 2c or 3c; thus small influences of general reaction conditions 
become better visible. 
Earlier studies showed that the Kryptofix© 2.2.2/K2CO3-System for activation of the n.c.a. 
[18F]fluoride is suitable for 18F-labelling reactions with diaryliodonium salts. Therefore, it was used 
to activate the n.c.a. [18F]fluoride as nucleophile after the aqueous [18F]fluoride solution was dried 
by an azeotropic distillation with acetonitrile. For the 18F-labelling 1c together with the solvent of 
choice was given to the dry cryptate complex. During the labelling process a slight overpressure 
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of 1100 mbar argon was necessary to avoid losses of the volatile product 2-[18F]fluoroanisole 
[18F]1. 
It is well-known that the kind of the solvent has a strong influence on nucleophilic aromatic 
substitution reactions. Generally, SNAr-reactions call for polar solvents and particularly in n.c.a. 
18F-labelling reactions diplor-aprotic solvents are highly demanded. Accordingly, acetonitrile 
(ACN), dimethylacetamide (DMAA), dimethylformamide (DMF) and dimethyl sulphoxide (DMSO) 
were used to examine the solvent effect on this reaction (cf. Figure 3.1). The reactions were 
carried out at 130 °C, only for acetonitrile a lower bath temperature of 90 °C (closed vessel) was 
chosen to avoid problems with too high pressure due to its low boiling point of 81 - 82 °C. 
 
Figure 3.1: Radiochemical yield of n.c.a. 2-[18F]fluoroanisole via 2-methoxyphenyl(2-thienyl)-
iodonium bromide as a function of reaction time in different solvents; 
[37 MBq n.c.a. [18F]fluoride, c(1c) = 25 mmol/l, 1 ml solvent, 1100 mbar, 130 °C 
(90 °C in case of ACN)] 
 
The best results were achieved in DMF, where a RCY of [18F]1 of up to 60 % could be obtained. 
ACN and DMAA gave only a low RCY of 10 - 15 %. Although DMSO is one of the most suitable 
aprotic dipolar solvents and a highly effective medium for nucleophilic 18F-labelling reactions, it 
did not work for this reaction and led only to a RCY of ~1 – 2 %. This order of dependence on 
solvents in the nucleophilic 18F-fluorination of 1c was also found in other studies of n.c.a. 
18F-labelling with diaryliodonium salts. 
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Furthermore, the unfavourable use of DMSO in cases of diaryliodonium salts was also earlier 
reported in literature [99, 100, 176]. There are two assumable explanations for this outcome. On 
one hand, the low reduction potential of DMSO presumably causes redox processes between 
iodine(III) species and DMSO molecules. On the other hand, the S-O binding in DMSO has a 
semipolar character in favour of a S+-O- binding and shows distinct nucleophilicity and a strong 
solvation of cations [199], what would lower or even prevent their reactivity. Furthermore, there is 
evidence that DMSO affects diaryliodonium cations in a special way, in which the oriented 
oxygen atom partially neutralises the positive charge. Such a neutralisation process was also 
assumed with proton magnetic resonance studies of diphenyliodonium cations in deuterated 
water [200]. Additionally, Fraenkel et al. showed that DMSO neutralises the positive charge in p-
chloroanilinium chloride by ion-pair formation, so that the chemical shifts of ring protons corres-
pond to those of chlorobenzene [201]. Likely a combination of both processes with a preliminary 
strong solvation and subsequent redox processes was assumed to explain the inappropriateness 
of DMSO in 18F-labelling reactions with diaryliodonium salts which is obvious from the time 
dependence depicted in Figure 3.1. 
In the case of DMAA, only a RCY of 10 % was obtained. Due to the ET(30) based polarity of 
DMAA of 42.9 kcal/mol (cf. Table 3.1), which is only slightly lower than that of DMF of 
43.2 kcal/mol, probably additional effects as discussed for DMSO appear to contribute to the total 
solvent effect of DMAA. As a result, analogue solvation effects as with DMSO presumably occur, 
thus the nucleophilic attack is hindered by a partial charge neutralisation and sterically by a 
strong solvation shell. The low RCY obtained in ACN is mainly due to the low reaction 
temperature of 90 °C. The course of the time dependence of the radiofluorination in ACN in 
Figure 3.1 shows the expected slow rate for low temperatures, but even extended reaction times 
did not increase the RCY and the maximum of ~15 % was reached within 15 – 20 min. However, 
in literature contradicting reports exist about the utility of ACN in 18F-labelling reactions with 
diaryliodonium salts. Whereas Shah et al. reported high RCY by using ACN at lower 
temperatures (80 – 100 °C) and long reaction times up to 40 min [155], other studies could not 
reproduce these results and show similar observations as those of this work [99, 100]. 
 
Table 3.1: Polarity of important solvents as derived from measurements of the longest 
waved UV/Vis/NIR absorption band of the pryridinium N-phenolate betaine dye 
ET(30) at 25 °C and 1 bar [from 202] 
Solvent benzene acetone DMAA DMF DMSO ACN H2O 
ET(30)-Value 
[kcal/mol] 
34.3 42.2 42.9 43.2 45.1 45.6 63.1 
 increase of polarity 
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The ET (30) scale represents an empirical scale of solvent polarity by means of UV/Vis/near-IR 
spectroscopic measurements of the negatively solvatochromic pyridinium N-phenolate betaine 
dye ET(30) [202]. The corresponding values of the solvents employed in this work are listed in 
Table 3.1 along with some ET(30) polarities of benzene and water; higher values comply with 
increasing polarities. 
As a further important reaction parameter the concentration of the precursor was optimised in the 
range from 6 mmol/l to 75 mmol/l (DMF). Whereas in case of 6 mmol/l only 1 to 3 % RCY of 
[18F]1 was found, more than 25 mmol/l did not notably improve the RCY. As a result, a 
concentration of 25 mmol/l was kept as optimal. Further, higher concentrations involved problems 
in solubility and led to suspensions, which in turn cleared within seconds when adding the 
mixture to the warm reaction vial. 
Raising the concentration of the aminopolyether complex [K⊂2.2.2]2CO3 to more than 13 mmol/l 
did not affect the RCY nor the reaction rate. However, less than 13 mmol/l considerably reduced 
the RCY. Very high concentrations of 26 mmol/l and above surprisingly led to traces of an 
unidentified radioactive side-product (< 5 %) with higher polarity. Consequently, the use of 
13 mmol/l [K⊂2.2.2]2CO3 as 1 M solution was not changed and is obviously optimal for these 
18F-labelling reactions. This is in agreement with earlier studies on n.c.a 18F-labelling using 
diaryliodonium salt precursors [84, 100]. 
An increase of the reaction temperature leads generally to higher yields and faster rates in case 
of SNAr-reactions. In terms of kinetics this can be confirmed for the nucleophilic n.c.a. 
18F-fluorination of 1c. Hence, the reaction rate of the 18F-introduction becomes faster along with 
the increase of temperature from 90 to 150 °C (cf. Figure 3.2).  
Accordingly, the RCY shows the same trend in the range of 90 to 130 °C. Unexpectedly, at 
higher temperatures the initial exchange rate is still going faster whereas the maximum RCY 
descends. This may be a result of the thermal instability of the diaryliodonium salt precursor, so 
its decomposition competes with the 18F-substitution. Diaryliodonium halides are known to 
decompose under heating in polar solvents by an internal attack of the counter ion [203, 204]. 
This cleavage proceeds according the SNAr-mechanism and leads here to 2-bromoanisole and 
2-iodothiophene. Since the decomposition process is caused by the internal nucleophilic attack, it 
is strongly influenced by the reactivity of the diaryliodonium cation, the solvent used and the 
nucleophilicity of the counter anion. Hence, it appears necessary to determine the thermal 
decomposition sensitivity of new diaryliodonium salts individually, especially for complex 
diaryliodonium salts. 
In order to find the optimal range of temperature, where the 18F-introduction proceeds effectively 
while the decomposition of the precursor does not become the crucial factor yet, the RCY of 
[18F]1 was plotted against the temperature as shown in Figure 3.3.  
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Figure 3.2: RCY of [18F]1 via 1c as a function of temperature and time 
[37 MBq n.c.a. [18F]fluoride, c(1c) = 25 mmol/l, 1 ml DMF, 1100 mbar argon] 
 
Figure 3.3: Temperature dependence of the nucleophilic 18F-substitution on 1c 
[c(1c) = 25 mmol/l, 1 ml DMF, 30 min reaction time, 1100 mbar argon] 
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The function confirms the distinct dependence of the RCY on the temperature. Until 120 °C the 
RCY rises slightly and than rapidly from 120 to 130 °C. At temperatures higher than about 130 °C 
the reaction shows a strong decrease in RCY. As a consequence, the highest RCY of [18F]1 can 
be obtained in a narrow range of 130 + 3 °C and 130 °C was selected as the most suitable 
reaction temperature. The same range of temperature was found as optimal for the radio-
fluorination via 1d. Despite of the different nucleophilicity of iodide and bromide, the temperature 
range is not significantly influenced by this change; presumably the reactivity of the 
diaryliodonium cation is here a more crucial factor. 
In all reactions described so far, the 18F-labelling with 1c led to n.c.a. [18F]1 as an electron rich 
18F-labelled product with regiospecific purity without any radioactive side-products (cf. Scheme 
3.5). Since 1 represents the highest electron density in the arene moiety of the group of 
precursors examined in this study, the strong electronic influence of the 2-thienyl group is 
expected to induce regiospecificity for all n.c.a. 18F-labelling reactions using aryl(2-thienyl)-
iodonium salts investigated. According to this expectation, in fact in all 18F-labelling reactions the 
2-thienyl group led always to the desired regiospecific 18F-introduction into the aromatic ring as 
graphically depicted in Scheme 3.5. Only non-radioactive side-products were detected, thus the 
2-iodothiophene as well as in case of the bromide and iodide precursors the appropriate bromo- 
and iodoarenes were found. The latter confirm the internal decomposition mechanism as 
discussed before. Tosylates and triflates led only to 2-iodothiophene as major non-radioactive 
side-product, probably their decomposition processes has more radical character rather than a 
nucleophilic one. The radical decomposition process becomes very likely, since diaryliodonium 
salts are known as photopolymerisation initiators in radical reactions [141, 142]. 
 
Scheme 3.5: Regiospecific 18F-labelling reactions on aryl(2-thienyl)iodonium salts 1a to 9f 
results to the desired compounds [18F]1 to [18F]9 and to 2-iodothiophene and X-
substituted arenes as non-radioactive side-product  
(R = 2-OCH3 (1), 3-OCH3 (2), 4-OCH3 (3), 4-OBn (4), 4-CH3 (5), H (6), 4-Cl (7), 
4-Br (8), 4-I (9)) 
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The analysis of the specific activity was carried out exemplarily with [18F]4 via HPLC. No UV-
signal corresponding to 4 was detected, thus only a lower limit of the specific activity of 
> 58 TBq/mmol could be determined. This confirmed that the 18F-labelling reactions proceeded 
under n.c.a. conditions. 
 
3.2.2 Influence of counter anions of iodonium precursors 
Different counter anions of diaryliodonium salts are known to effect strongly the reaction of the 
latter with nucleophiles. Earlier studies show slightly differing results and characteristics for the 
influence of counter ions on the RCY of 18F-labelling via iodonium salts [100, 175], but the 
highest RCY were found by using an inorganic counter ion and preferably with bromide. An 
advantage of an inorganic counter ions is the effective ion pair separation of diaryliodonium salts 
in polar solvents [204, 205]; although there are also indications for partially dimeric and trimeric 
structures of the iodonium salt with inorganic counter ions, even in polar solvents [206, 207]. 
However, these species are more relevant for non-polar solvents, wherein iodonium salts can 
also be present as quadrupole complexes [203, 208]. 
On one side, the nucleophilic attack of [18F]fluoride is favoured by a dissociated diaryliodonium 
salt and hence a “naked” diaryliodonium cation. On the other side, ions with a high nucleophilicity 
compete with [18F]fluoride for the substitution reaction and induce the decomposition of the 
precursor. Considering their low nucleophilicity, organic counter ions can be ruled out for this 
aspect. Otherwise their bond to iodine has a more covalent character and they form not well 
separated ion pairs. Thus they cause a steric and electronic hindrance of the direct nucleophilic 
attack of [18F]fluoride. This entails a two step synthesis of the 18F-fluorination in which the 
[18F]fluoride at first has to replace the organic counter anion and to form an ion pair including a 
reactive diaryliodonium cation, which is then attacked by the [18F]fluoride [206, 207].  
The effects of different counter ions were therefore examined with the bromides, iodides, 
tosylates and triflates of methoxyphenyl(2-thienyl)iodonium precursors in DMF at 130 °C on the 
yield of [18F]fluoroanisoles [18F]1 to [18F]3. The following dependence on the type of counter 
anion in the order of increasing RCY was obtained: tosylates < iodides < triflates < bromides. For 
n.c.a. 18F-labelling reactions with 1c to 1f the RCY of [18F]1 is exemplarily graphically depicted in 
Figure 3.4 as a function of the counter anion and the reaction time. The radiofluorinations with 
the salts of the meta- and para-derivative show the same dependence on the type of counter 
anions as the ortho-substances. However, the obtained RCY were generally lower than those of 
the ortho-derivatives and the differences for each anion were much better noticeable for the 
latter. The bromides prove the assumptions and reports mentioned before for inorganic counter 
anions just as the tosylates do for the organic counter anions. Only the triflates stand out and 
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show a slightly higher RCY than iodides, that may be caused by their very high reactivity as 
leaving group [209, 210, 211]. Nevertheless, this sequence is in agreement with previous studies 
of nucleophilic 18F-fluorination of arenes via dihomoaryliodonium salt precursors [175]. 
 
Figure 3.4: Dependence of radiochemical yield of the nucleophilic 18F-substitution on 
2-methoxyphenyl(2-thienyl)Iodonium bromide on the type of counter anion 
[c (1c) = 25 mmol/l, 130 °C, 1 ml DMF, 1100 mbar argon)] 
 
In terms of kinetics the triflates and iodides give the highest initial reaction rates and from this 
point of view a different series of increasing rates can be listed: tosylates < bromides < iodides 
< triflates (cf. Figure 3.4). The tosylates show the lowest rates as well as the lowest yields, this 
may be attributed to the above mentioned fact that their electronic deactivation by a rather 
covalent bond combines with a major steric demand. However, the triflates give the fastest rate, 
which correlates with their high reactivity as leaving group. The iodides show a slightly higher 
rate than the bromides, although bromides are the better leaving group considering highest RCY 
obtainable [212, 213]. 
The strong influence of the character of counter anions argues for incomplete dissociated 
diaryliodonium salts, even with iodides and bromides. 
Evidence for the grade of dissociation of diaryliodonium salts in different solvents can be 
received from investigations of the nuclear magnetic resonance (NMR) spectra of these 
solutions. Particularly the proton shifts of the arylrests are of interest. In case of fully dissociated 
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iodonium salts the proton shifts of the cations would be identical, regardless of the nature of the 
anion. This was confirmed by studies of various diphenyliodonium salts varying in counter 
anions, which show all the same proton shifts in protic, polar solvents such as methanol and 
deuterated water, whereas the signals in dipolar aprotic dichloromethane and DMSO differ. The 
grade of dissociation was also confirmed by cryoscopic, conductance and osmometric measure-
ments [200, 205, 214]. Consequently, the NMR spectra of 1c to 1f were measured in d6-DMF as 
DMF proved the best solvent for the 18F-exchange. Although the 18F-fluorination was examined in 
DMF at 130 °C and a higher grade of dissociation can be expected at higher temperatures, the 
NMR spectra measured at room temperature should give an indication on the relative degree of 
dissociation in different solutions.  
 
Table 3.2.: Proton shifts δ [ppm] of the diaryliodonium cations of 1c to 1f in d6-DMF 
δ [ppm] 
2-methoxyphenyl-ring 2-thienyl-ring counter ion 
OCH3 H3 H4 H5 H6 H3 H4 H5 
bromide 
(non-dissociated, 92 %) 4.166 7.437 7.736 7.169 8.432 7.973
(i) 7.209 7.973(i) 
bromide 
(dissociated, 8 %) 4.014 
(ii) 7.522 6.901 (ii) (ii) (ii) 7.939 
iodide 
(non-dissociated, 87 %) 4.104 7.451 7.770 7.198 8.466 8.036
(i) 7.242 8.036(i) 
iodide 
(dissociated, 13 %) 4.016 7.280 7.525 6.903 
(ii) 7.829 7.039 7.939 
tosylate 4.199 7.521 7.820 7.242(iii) 8.513 8.142 7.313 8.184 
triflate 4.223 7.549 7.846 7.267 8.531 8.172 7.342 8.214 
(i) Signals are overlaid and show a multiplet (ii) Signals are too small or overlaid completely 
(iii) Signals show a multiplet with tosylates’ H2 + H6 
 
As expected, the proton shifts in the NMR spectra of 1c to 1f, measured in d6-DMF at room 
temperature, diverge (cf. Table 3.2). Clear differences between the proton shifts disprove the 
presence of fully dissociated iodonium salts. Even between the inorganic 1c,d and organic 
anions 1e,f deviations are well notable. Especially the spectra of the bromide and the iodide 
show both proton shifts of non-dissociated salt and proton shifts of free aryl(2-thienyl)iodonium 
cations. The signals of the latter are identical with signals obtained from spectra in d6-DMSO (cf. 
subchapter 4.2.3), where almost identical signals, even with the organic counter anions, were 
observed and thus can be attributed to originate from dissociated salts. Although the signals of 
the latter are very small and some are largely overlaid, they are significant for the free cation and 
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similar with both counter anions, expectedly. The grade of dissociation was determined for 1c 
and 1d by integration of the peak-areas, the results are given in Table 3.2. The tosylate and the 
triflate present more similarities in their proton shifts, but small differences can be noticed. Their 
proton spectra show only one set of signals which are in favour of non-dissociated salts 1e and 
1f. Despite of the concluded partial covalent binding, the differences in proton shifts of 1e and 1f 
are unexpectedly small. It can be assumed that the inductive effects of both counter anions on 
the proton shifts are nearly the same, due to the fact that the anions are both sulphonic acids and 
consequently the immediate vicinity of the iodine(III) in 1e and 1f is similar. 
Both, the variation in the proton shifts and the outcome of the nucleophilic 18F-fluorination 
reactions are in favour of non-fully dissociated aryl(2-thienyl)iodonium salts. In case of the iodide 
and the bromide, a disagreement between maximum obtainable RCY and initial reaction rates 
occurs. Presumably, this is an effect of the mentioned thermal instability and the tendency of the 
precursors to decompose, which depends on the nucleophilicity of the counter anion. As a result, 
the iodide is more reactive to both, the 18F-introduction and the decomposition, which causes a 
faster loss of reactive precursor and leads to lower RCY. This is also confirmed by a slightly 
higher grade of dissociation of the iodide. The proton spectra of 1e and 1f as well as the strong 
influence of the organic counter anions on the 18F-radiofluorination reaction confirm the partial 
covalent binding expected for organic anions. However, both, 1e and 1f differ in RCY and initial 
reaction rates, thus it appears that the iodine-triflate binding is more polar and causes a faster 
release of the triflate than it can be assumed for the tosylate which favours for a highly covalent 
character of the binding to the iodine. 
 
3.2.3 Influence of the substitution pattern of iodonium precursors 
In general, the influence of the substitution pattern in SNAr-reactions is well predictable for 
common arenes. By making a rough estimate the reactivity of the ortho- and para-position is 
approximately comparable and differs from that of the meta-position. This dependence from the 
position of the substituent is explainable by the resonance stabilisation of a negative charge in 
the transition state, where a meta-substituent offers no such resonance stabilisation. While a 
nucleophile attacks the ipso-carbon of an aromatic compound a so-called Meisenheimer complex 
is formed as transition state which includes a negative charge. Subsequent removing of the 
leaving group carrying the negative charge forms the product. Whereas the Meisenheimer 
complex can be stabilised by resonance with electron withdrawing groups in ortho- and para-
position, electron donating group, regardless of their position, can obviously not conjugate with 
the negative reaction centre and stabilise it. 
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Considering diaryliodonium salts, the nucleophilic attack on is strongly affected by the 
substitution pattern. Especially a huge difference between ortho- and para- and meta-substituted 
rings, is not explainable by the regular character of the SNAr-mechanism as described above and 
is due to the influence of the ortho-effect mentioned before (cf. Figure 1.2). 
The precursors 1c to 3c were labelled under the optimised conditions, viz 130°C, 25 mmol/l 
precursor in DMF and 1100 mbar argon. In Figure 3.5 the RCY of [18F]1 to [18F]3 are plotted as 
functions of the position of the methoxy group and reaction time. The results correspond to the 
expectations and indeed a strong ortho-effect was observed. The para-derivative showed a 
moderate RCY of 25 to 30 % and the meta-derivative only reached a RCY of ~20 %. The ortho-
derivative gave a twofold higher RCY of ~60 % than the para-derivative after a reaction time of 
35 min. Obviously, this results originates from the ortho-effect alone. 
 
Figure 3.5: Dependence of the radiochemical yield of [18F]1 to [18F]3 on the substitution 
pattern of 1c to 3c 
[c (1c-3c) = 25 mmol/l, 130 °C, 1 ml DMF, 1100 mbar argon)] 
 
In terms of kinetics, all precursors showed relatively fast reaction rates. The meta-derivative 
shows even a slightly higher initial reaction rate than the ortho- and para-derivative with identical 
rates, but ends at lower optimum RCY. Hence, the meta-derivative is relatively activated for 
substitution but also for the decomposition by an ipso-attack of the counter anion, which reduces 
the amount of the precursor and eventually results in low RCY. 
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As described above, the methoxy group is not able to stabilise a negative charge in the transition 
state of the SNAr-reaction due to its electron-donating character. However, the aryl(2-thienyl)-
iodonium cation represents a positive charged initial state and can be stabilised by conjugation 
with methoxy substituents in ortho- and para-position, whereas in the meta-position of course no 
such resonance stabilisation can occur (cf. Scheme 3.6). By a resonance stabilisation of the 
initial state the C-I-bond is strengthened, this reduces the initial rate of both the 18F-introduction 
and the ipso-attack of the counter anion which leads to the decomposition. Therefore 1c and 3c 
show nearly the same reaction rate which is much slower than that of 2c. No stabilisation of the 
aryl(2-thienyl)iodonium cation in 2c leads to faster rates of both reactions, accordingly the 
radiofluorination proceeds much faster in the same way as the decomposition causes earlier loss 
of precursor and leads in turn to lower RCY. 
 
Scheme 3.6: Relevant resonance forms of the diaryliodonium cation in dependence of the 
position of a methoxy group; the meta-position offers no resonance stabilisation 
 
Table 3.3.: Comparison of RCY and product ratios of 18F-substitutions of para-substituted 
aryl(phenyl)iodonium salts from literature data with results of this work 
     This work 
    
 
 
   
 
 Product ratio      
Ref. [
18F]Fluoro- 
arene 
[18F]Fluoro- 
benzene RCY [%] X R 
RCY [%] 
[18F]Fluoroarene 
[176] 75 25 51 OTf I 60 
[100] 70 30 50 OTf Br 70 
[176] 60 40 51 OTf Cl 62 
[176] 36 64 64 OTf CH3 32 
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In comparison of the here developed method with previously described 18F-substitution methods 
via diaryliodonium salts, one principal drawback of the latter is that the radiofluorination leads 
mostly to both 18F-labelled arenes in different product ratios (cf. Table 3.3). This problem can now 
be avoided by using aryl(2-thienyl)iodonium precursors due to the regiospecificity of the 18F-intro-
duction induced by the 2-thienyl group. Particularly for electron rich molecules this is of major 
interest. Furthermore, also the electron deficient n.c.a. 4-halo-[18F]fluoroarenes can be prepared 
in higher RCY by this new method and obviously without any radioactive side-products. 
 
3.2.4 Influence of the homoarene substituent of aryl(2-thienyl)iodonium 
bromides 
As described in the introduction (cf. subchapter 1.6.2), the attack of the n.c.a. [18F]fluoride on 
diaryliodonium salts depends on the electronic character of the aromatic rings. If differences in 
electron density are present, the outcome will generally be a product ratio with preference of the 
fluorination of the more electron deficient group. For a detailed insight in the influence of the 
electronic character on the nucleophilic 18F-fluorination a comparison of the aryl(2-thienyl)-
iodonium bromides was carried out with substituted phenyl rings systematically differing in 
electron density. 
1c to 9c were labelled under the optimised conditions as elaborated above with the precursor 1c. 
The obtained RCY of [18F]1 to [18F]9 are listed in Table 3.4. Expectedly, the RCY generally 
increased with a decrease of the electron density in the designated molecule; the ortho-methoxy 
derivative 1c being an exception, which reached a RCY of 61 + 5 %. This could be explained by 
a strong ortho-effect. Based on increasing RCY the following series of substituent-activation was 
obtained: 
4-Br > H > 4-Cl > 2-OCH3 > 4-I > 4-OBn > 4-CH3 > 4-OCH3 > 3-OCH3 
 
Indeed, for all investigated aryl(2-thienyl)iodonium bromides 1c to 9c it can be reemphasised that 
the highly electron rich 2-thienyl group induced a regiospecific 18F-introduction in the homoaryl 
ring and led only to the desired n.c.a. [18F]fluoroarenes [18F]1 to [18F]9 (cf. Scheme 3.5). 
The n.c.a. 18F-labelling of arenes via diaryl(2-thienyl)iodonium salts represents reactions proce-
eding according to pseudo-first order kinetics due to the high excess of precursor. Thus the 
reaction A + B → C can be written as (cf. subchapter 1.4): 
 
[ ] [ ] ( ) = lmol  e - 1 B  C t'-k0t  
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where k’ is the rate coefficient of pseudo-first-order type, [B]0 is the decay corrected starting 
activity of n.c.a. [18F]fluoride and [C]t the decay corrected activity of the 18F-labelled products 
[18F]1 to [18F]9 after the reaction time t. Here the activities of the substances instead of 
concentrations are employed, because the radioactivity is proportional to the concentration of the 
corresponding substance. In order to determine the rate constant k’ this equation can be 
converted to: 
 
[ ]
[ ] [ ] t   B - B
B  ln k'=
t0
0
 
 
The corresponding plots of this term as a function of time for the molecules [18F]1 to [18F]9 are 
shown in Figure 3.6. By linear regression the rate constant k’ is obtained from the slopes of least 
square fits (LSF). The obtained rate constants k’ are listed in Table 3.4.  
In this kinetic approach the differences of electronic substituents’ effect on the substitution 
reaction are better visible. The k'-values show a distinct dependence on the electronic character 
of the substituents. As a result, the following order of decreasing reaction rate k’ was obtained 
(cf. Figure 3.6): 
4-Br > 4-I > 4-Cl > 3-OCH3 > H > 4-CH3 > 2-OCH3 > 4-OBn > 4-OCH3 
 
Figure 3.6: Term ln([B]0/([B]0-[B]t) as function of reaction time for [18F]1 to [18F]9 for 
determination of rate constants k’ from slopes of linear square fits 
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This series corresponds to the expectations and mirrors the effects of the substituents on the 
reaction rate. In case of activated 4-halo derivatives [18F]7 to [18F]9 the fastest rates were 
obtained. Again the high reactivity of the meta-derivative 2c is prevalent, which is presumably 
entailed by the lack of resonance stabilisation of the aryl(2-thienyl)iodonium cation (cf. Scheme 
3.6). As anticipated, the other electron rich radiofluorinated products [18F]1, [18F]3 and [18F]4 
show the slowest rates, where the ortho-effect of 1c causes a faster rate than the 18F-labelling of 
3c and 4c. 
 
Table 3.4: RCY and k’-values (rate constants) for the 18F-radiosyntheses of [18F]1 to [18F]9  
R RCY [%] k’ [min-1] 
4-Br 70 0.2325 + 0.045 
4-I 60 0.1750 + 0.020 
4-Cl 62 0.1437 + 0.017 
3-OCH3 20 0.1072 + 0.006 
H 64 0.0865 + 0.009 
4-CH3 32 0.0625 + 0.013 
2-OCH3 61 0.0518 + 0.002 
4-OBn 38 0.0305 + 0.004 
4-OCH3 29 0.0187 + 0.001 
 
Generally, systematic treatments of quantitative effects on organic reactions are accomplished by 
analyses of empiric correlations of linear relations between logarithms of rate constants and/or 
equilibrium constants of the appropriate reactions. Those relations are referred to as linear free 
energy relationships (LFER), which is reflected by the following equations: 
 
RT  2.303
G - K  lg
0
⋅
∆=  
 
h  N
RT lg  
RT  2.303
∆G -  k lg
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‡
⋅+⋅=  
 
where K is the reaction equilibrium constant; ∆G0 is the Gibbs free energy (standard free energy), 
R is the gas constant (8.31441 J · K-1 · mol-1); T is the temperature in Kelvin; k is the reaction rate 
constant; ∆G‡ is the Gibbs activation energy (standard activation energy); NA is the Avogadro 
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constant (6.023 · 1023 mol-1); and h is the Planck constant (6.626 · 10-34 J · s). Accordingly, the 
aforementioned correlations of lg k and/or lg K at constant temperatures are in fact relations of 
Gibbs energies [215]. 
In 1937, Hammett found empirically a linear relation between the effects of meta- and para-
arylsubstituents on equilibrium constants of a reaction, in which the reaction takes place in a 
attached side chain of the benzene ring, and the electronic character of the substituents [216]. As 
a result, the Hammett equation was formulated as: 
 
σ ρ  
 lg
 lg 
0
=
k
ki  
 
here ki and k0 are the rate constants for the reaction of the substituted and the unsubstituted 
(R = H) compound, respectively; σ is the individual substituent constant which depends solely on 
the nature and position of the substituent R; and ρ is the reaction constant for the given reaction 
under a given set of conditions. The validity of the Hammett equation is restricted to substituents 
in meta- and para-position of the benzene ring, since no steric interactions as occurring in case 
of ortho-substituents were considered. The Hammett equation is one of the best-known LFER 
and has been one of the most widely used means for the study and interpretation of organic 
reactions and their mechanisms [83, 217]. 
The empirical Hammett correlation is always related to a reference compound which is normally 
the unsubstituted benzene derivative (R = H). From linear regression of the graphical depiction of 
lg (ki/k0) as a function of Hammett constants σ, ρ results as the slope of the LSF. With ρ > 0 
stabilisation effects of substituents on a positively charged reaction centre are confirmed; in the 
same manner ρ < 0 proves the stabilisation of a negatively charged reaction centre. The absolute 
value of ρ indicates the sensitivity (susceptibility) of the reaction to polar substituent effects. Also 
it gives information about the relative changes of the charge density at the reaction centre during 
the formation of the transition state. The substituent constants σ represent the total electronic 
effects, which can be summarised as inductive/field and resonance effects. Deviations from the 
Hammett equation and its correlation can be found for certain substituents (e.g. p-NO2, p-CN, p-
OCH3), which are able to conjugate with the reaction centre (charged intermediate state) in a 
similar way as described in Scheme 3.6. This problem was solved by an extension of the 
Hammett constants σ with a set of σ- and σ+ constants which generally result from reactions of 
phenols and anilines. σ- parameters describe the effects of substituents conjugating an electron 
rich reaction centre (nucleophilic substitution reactions) and σ+ values derive from substituents 
which are able to delocalise a positive charge of the reaction centre (electrophilic substitution 
reactions). The σ- and σ+ constants have amplified the applicability of the Hammett equation. 
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Since σ, σ- and σ+ constants are only suitable for meta- and para-substituents further 
investigations, also for the ortho-position as well as for di-substituted compounds, have been 
carried out [for overviews see: 83, 215, 217]. 
In general, for a wide range of substituents the Hammett equation leads to well-fitting linear 
relations in combination with σ and σ+/- constants, respectively. A good linear regression/relation 
provides important mechanistic information and confirms a consistent reaction mechanism for all 
investigated substituents. Furthermore, an occasional failure of the Hammett equation and a 
non-linear function point to a more complex mechanism, which can be examined by that way in 
greater detail [218]. 
 
The pseudo-first order reaction rates k’i of the syntheses of [18F]1 to [18F]9 resulting from the 
linear regressions in Figure 3.6 were taken and correlated with the Hammett constants σ of the 
substituents (R) (cf. Table 3.5). The general Hammett constants σ were used from Hansch et al. 
[83] and only for 4c from Jaffé [217] as listed in Table 3.5. However, both show almost no 
difference in the σ constants, but Hansch’s data are more current and the values are based on 
more studies and investigations. Subsequently the lg k’/k0 values were plotted against the 
Hammett substituent constants (cf. Figure 3.7). 
 
Table 3.5: The lg ki’/k0 values of the n.c.a. 18F-fluorination of aryl(2-thienyl)iodonium 
bromides in dependence on para-substituents (R) and their Hammett constants 
σ and σp-, respectively 
 
R σ [83] σp-  [83] lg ki’/k0  
4-OBn - 0.415[217] - - 0.4527 + 0.1043 
4-OCH3 - 0.268 - 0.26 - 0.5172 + 0.0230 
4-CH3 - 0.170 - 0.17 - 0.1411 + 0.0586 
H 0.000 0.00 0.0000 + 0.0507 
3-OCH3 0.115 - 0.0933 + 0.0238 
4-Cl 0.227 0.19 0.2205 + 0.0205 
4-Br 0.232 0.25 0.4294 + 0.0440 
4-I 0.276 0.27 0.3060 + 0.0265 
2-OCH3 - - 0.2224 + 0.0185 
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Figure 3.7: Hammett diagram (lg ki’/k0 = ρ · σ) for the n.c.a. 18F-substitution on the aryl-
(2-thienyl)iodonium bromides 2c to 9c; ki’- and k0-values are determined by 
linear regression (cf. Figure 3.6), σ constants are taken from Hansch et al. and 
Jaffé [83, 217]; 
[25 mmol/l precursor, 130 °C, DMF, 1100 mbar argon] 
 
The relationship in the Hammett diagram shows a reasonable good linear fit, which leads to the 
implication of the expected SNAr-mechanism of the 18F-substitution on aryl(2-thienyl)iodonium 
salts. The determined slope of ρ = + 1.16 + 0.2 confirms the nucleophilic mechanism and a 
consistent mechanism over the range of investigated substituents, even for electron donating 
groups. Since the reaction parameter of the nucleophilic 18F-substitution on substituted aryl-
(2-thienyl)iodonium bromides is ρ > 1, the reaction is positively influenced by electron 
withdrawing groups, which can stabilise the negatively charged transition state. As mentioned 
above, the absolute value of ρ indicates the sensitivity of the reaction to substituent effects. For 
example, the reference reaction for the Hammett equation, the hydrolysis of meta- and para-
substituted benzoic acid derivatives has a reaction parameter of ρ = +1.00 as consequence of 
the definition of the Hammett equation. For comparison some ρ-values of various reactions are 
listed in Table 3.6. The reaction parameter ρ = + 1.16 + 0.2 implies a mechanism with strong 
changes in the charge density of the reaction centre. Although the ρ-value is not in the range of 
the “extreme” reactions, its high reactivity indicates a relatively low sensitivity of the reaction to 
substituent effects.  
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Table 3.6: Reaction parameters (ρ) of various reactions in comparison to that of the 
nucleophilic 18F-substitution on substituted aryl(2-thienyl)iodonium bromides 
(Ar = aryl) 
Reaction Solvent (T [°C]) ρ Ref. 
ArX + Hg(CH3COO)2 Acetic acid (25) - 4.00 [219] 
ArO- + C2H5I Ethanol (25) - 0.99 [220] 
ArCH2Cl + I- Acetone (20) + 0.79 [220] 
ArCOOH + OH-  H2O (25) + 1.00 [218] 
Ar(2-thienyl)I+ + 18F- DMF (130) + 1.16 This work 
ArBr + C6H5Li Ether (25) + 4.00 [218] 
ArF + CH3O- Methanol (0) + 7.55 [218] 
 
Besides the 4-OCH3 group the 4-Br group give the widest deviations. The former is known for its 
strong resonance effects which presumably cause this difference, although there is no ability of 
4-OCH3 to conjugate the electron rich intermediate state, only the initial state. Therefore the σ 
and σp- values of the para-methoxy group are identical, whereas its constant σp+ = 0.78 [83] 
proves its strong resonance stabilisation of electron deficient reaction centres as electron 
donating group. The deviation of 4-Br can not be completely clarified. Due to the ability of the 
para-bromine group to stabilise an electron rich reaction centre by resonance, a conjunction 
effect could be assumed. However, the σ and σp- constants of the para-bromine group also show 
only little differences and point out the moderate resonance effect of the para-bromine 
substituent (cf. Table 3.5). The use of σp- instead of σ values here leads to no significant 
improvements. In all other cases, the σ and σp- values of the substituents differ hardly. Thus, the 
employment of σp- instead σ constants gives no better relation and furthermore, σp- data exist 
only for a few of the examined substituents. 
 
Due to the high activation of the ipso-arylcarbon in aryl(2-thienyl)iodonium salts, the nucleophilic 
radiofluorination shows high reactivity. In spite of this, positional specificity can be observed 
which is due to the activated ipso-arylcarbon where exclusively 18F-substitution takes place. This 
is also supported by the strong electronic influence of the highly electron rich 2-thienyliodonium 
leaving group. 
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3.3 18F-Labelling of pharmaceutically relevant molecules 
3.3.1 N.c.a. 4-[18F]fluorophenol via 4-benzyloxyphenyl(2-thienyl)iodonium 
bromide 
The versatile primary 18F-labelling synthon n.c.a. 4-[18F]fluorophenol has proved its applicability in 
various radiosyntheses of biological relevant molecules or radiopharmaceuticals and several 
attempts have been made in the last decade to improve the access to n.c.a. 4-[18F]fluorophenol 
(cf. subchapter 1.5.1). 
With regard to the commonly used complex multi-step radiosynthesis of n.c.a. 4-[18F]fluorophenol 
via Baeyer-Villiger oxidation using benzophenones as precursors, a more direct and convenient 
pathway via aryl(2-thienyl)iodonium salts was anticipated in this work; also in order to save 
losses of radioactivity by shortening preparation times. 
 
Figure 3.8: Radiochemical yield of n.c.a. 4-benzyloxy-1-[18F]fluorobenzene [18F]4 as function 
of reaction time 
[c(4c) = 25mmol/l, 130 °C, DMF, 1100 mbar argon] 
 
The need of aprotic systems in the n.c.a 18F-labelling step excludes a direct 18F-introduction into 
an unprotected phenol-substituted iodonium compound. Since the benzyl-protection group offers 
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an easy and gentle protection procedure via condensation with benzyl bromide and also various 
ways of deprotection, it is very suitable for this attempt. Thus the 4-benzyloxyphenyl(2-thienyl)-
iodonium bromide 4c was employed as precursor. 4c was prepared according to the mentioned 
before general methods for aryl(2-thienyl)iodonium bromides. The precursor was synthesised in 
good and reliable yields of 55 % by pathway A (cf. subchapter 3.1). 
Starting from the dry and activated n.c.a. [18F]fluoride-cryptate complex, 4c was added to the 
reaction vial using DMF. The n.c.a. 18F-labelling reaction was carried out under the optimised 
conditions as described above (c (4c) = 25mmol/l, 130 °C, DMF, 1100 mbar argon). 
The RCY of the benzyl protected 4-[18F]fluorophenol as function of time is graphically depicted in 
Figure 3.8. Due to no activating but rather deactivating effects of the para-benzyloxy group 
(σ = 0.415), the reaction rate is expectedly moderate. However, the 18F-labelling reaction led 
regiospecifically to a good RCY of 38 + 4% of n.c.a. [18F]4 within 20 - 30 min as only radioactive 
product. 
For the preparation of the deprotection procedure, a short purification via Sep-Pak© Plus C18 and 
ALOX cartridges followed. Consequently, a solvent change to methanol was possible and the 
system was free of polar substances and particularly free of water which had been added to 
enable the fixation of [18F]4 on the reversed phase cartridge and to remove DMF. As eluent 
methanol is suitable and moreover, also used as solvent in the following deprotection step. For 
the subsequent displacement of the benzyl-protection group a reductive deprotection via 
ammonium formate and palladium black as catalyst in methanol was elaborated. First attempts 
with ammonium formate and palladium on activated charcoal led to the desired n.c.a. 4-
[18F]fluorophenol, but showed problems in removing fine particles of the charcoal via a 
subsequent filtration. In addition, the system with palladium on activated charcoal gave a RCY of 
the deprotection step of 75 – 80 % within 15 min at 100 °C, whereas the palladium black system 
yielded in 90 – 95 % RCY of n.c.a. 4-[18F]fluorophenol under the same conditions. By filtration of 
the reaction suspension via a LiChrolut© glass column containing a PTFE frit, n.c.a. 4-[18F]fluoro-
phenol was obtained in an anhydrous methanol system. A flow chart of the radiosynthesis is 
depicted in Scheme 3.7. 
In comparison to the so far best alternative procedure for n.c.a. 4-[18F]fluorophenol preparation 
from Ludwig et al. [108] the route via 4c points out two major improvements. First, the 
radiosynthesis is more convenient, since instead of a 3 + 2 step procedure (3 synthesis steps; 2 
purification steps), the developed process via 4c provides an easier 2 + 1 radiosynthesis. This 
bears great advantages for automation or remode controlled radiosynthesis. Second, the new 
route saves 20 min of total synthesis time which is one of the primary concerns in 18F-radio-
syntheses. Additionally, the resulting 4-[18F]fluorophenol is obtained in an anhydrous methanol 
system which allows further radiosynthesis steps including compounds susceptible to moisture 
without time-consuming drying procedures. However, a weakness is the lower RCY of 35 + 1 % 
74  Results and Discussion 
compared to that of 55 % with the benzophenone method which is only partly compensated by 
the shorter synthesis time. In contrast, the synthesis of the precursor 4c is easier, faster and 
finally less expensive than the preparation of (4-(trifluoromethyl)phenyl)benzoyl-4’-N,N,N-tri-
methylammonium triflate as precursor. In conclusion, the n.c.a. 4-[18F]fluorophenol preparation 
via 4-benzyloxyphenyl(2-thienyl)iodonium bromide (4c) presents an improved radiosynthesis of 
this primary 18F-labelling synthon, especially in terms of practicability of labelling. 
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Scheme 3.7: Radiosynthesis of n.c.a. 4-[18F]fluorophenol via the O-benzyl-protected 4-phenol-
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3.3.2 Radiosynthesis of [18F]F-ADTQ 
As outlined in the introduction (cf. subchapter 1.7), radioactive labelled AMPA receptor ligands 
are in great demand for studying this receptor family. Particularly, the labelling with positron- and 
single-photon-emitting nuclides for PET and SPET is of major interest; primarily in order to allow 
human studies. 
F-ADTQ (10) was classified as non-competitive AMPA receptor antagonist, but only the ED50-
value (ED = effective dose) of anticonvulsant effects was determined which gives no concrete 
information about the direct interaction with the AMPA receptor [194] (cf. Scheme 3.3). Thus, 
pharmacological data and information about the AMPA receptor system would become available 
by in vitro and in vivo investigations using [18F]10. 
The synthesis route for 10 from the literature via a Pictet-Spengler reaction was adopted for 
preparation of the standard compound and led to an overall yield of 10 % within three synthesis 
steps. Two intermediate products which were not completely described thus far were isolated, 
purified and characterised by 1H-, 13C- and 19F-NMR spectroscopy, mass spectrometry and 
elemental analysis (CHN). Moreover, the iodoanalogue I-ADTQ (10a), which is not known from 
the literature, was also successfully synthesised following the Pictet-Spengler approach and was 
obtained in an overall yield of 27 % (3 steps). The trimethyltin compound 11 was attained from 
the iodine compound 10a, hexamethyldistannane and tetrakis(triphenylphosphine) palladium as 
catalyst in a standard procedure which led to good yields of 11 of 68 %. 11 was employed for 
ipso-demetallation reactions to 10e and 10g as well as for the 131I-labelling to [131I]10a as 
described later. 
For the synthesis of an iodonium precursor for the 18F-labelling of 10 first the diacetoxyiodo 
compound route was tested. The oxidation of 10a was not successful using the sodium perborate 
system and even after extended reaction times of 48 h mostly starting material was recovered. 
Consequently, the sodium periodate system was tested next. This method led in several attempts 
to elemental iodine formation after 1 to 1.5 h reaction time and under milder conditions or shorter 
reaction times no oxidation could be observed. When stopping the reaction at the begin of 
elemental iodine formation (~1.5 h), only 6 % of the desired diacetoxyiodo derivative 10c was 
obtained. However, this result was only attained once and could not be repeated. Thus, an 
alternative one-pot procedure was applied for the precursor synthesis. Probably due to a 
necessary preliminary in situ oxidation step in this method, the one-pot procedure was not 
successful, either, and only 3 % (36 mg) of the iodonium bromide precursor 10c could be 
obtained. In two 18F-labelling experiments (cf. Scheme 3.8) only some unidentified radioactive 
and non-radioactive side-products were observed and were assumed to be a result of impurities 
of the precursor which had not been purified due to the small amount of substance. In addition, 
for the same reason no analytics of 10c were carried out. 
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In another attempt, ipso-demetallation of 11 was used to get iodonium precursors for the 
18F-labelling of 10. For an ipso-demetallations iodine(III) reagent compounds like Koser’s reagent 
([hydroxy(tosyloxy)iodo]benzene) are needed and the appropriate 2-iodothiophene derivative 2-
[hydroxy(tosyloxy)iodo]thiophene was synthesised according to the literature. The oxidation of 2-
iodothiophene to 2-(diacetoxyiodo)thiophene gives 55 % yield and the subsequent conversion to 
2-[hydroxy(tosyloxy)iodo]thiophene succeeds nearly quantitative with 98 % yield and is very fast 
within 5 min. This Koser derivative was used for the preparation of 10e by the ipso-demetallation 
of 11 and gave very high yields of 80 % of 10e (cf. Scheme 3.8). In the same procedure using 
[hydroxy(tosyloxy)iodo]benzene good yields of 10g of 50 % were obtained (cf. Scheme 3.8). 
 
Scheme 3.8: Molecule structure of the iodonium precursors for the 18F-labelling of the non-
competitive AMPA receptor antagonist F-ADTQ; yields: 3 % (10c), 80 % (10e) 
and 50 % (10g) 
 
For the 18F-labelling the appropriate precursor was dissolved in DMF (25 mmol/l) and given to the 
reaction vial containing the dry and activated n.c.a. [18F]fluoride-cryptate complex. The 
18F-labelling reaction was carried out under the optimised conditions of 1100 mbar argon at 
130 °C. Aliquots were taken and analysed via radio-TLC and/or radio-HPLC, respectively. The 
RCY of [18F]10 is shown in Figure 3.9 as a function of the time and the type of precursor. Due to 
the above mentioned problems in the synthesis of 10c, these results are presented as dashed 
line in grey.  
The results from reactions with 10c show the best RCY of [18F]10 of about 3.6 %. However, this 
was anticipated for the bromide precursor with regard to the above discussed results of the 
18F-labelling studies on [18F]fluoroarenes via aryl(2-thienyl)iodonium salts. Comparing the 
precursors 10e and 10g, the RCY and reaction rate show an increase from the phenyliodonium 
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group to the 2-thienyliodonium group, as expected for the electronic differences between these 
both iodonium leaving groups, thus the 2-thienyliodonium group leads to higher a RCY (10g: 
1.2 %, 10e: 2.9 %) and a faster reaction rate. In contrast, in the 18F-labelling reactions with 10g 
the formation of [18F]fluorobenzene with high yields of up to 96 % was observed, whereas 10e 
regiospecifically only yields [18F]10. 
 
Figure 3.9: Radiochemical yield of [18F]10 as a function of the reaction time and the type of 
precursor (cf. Scheme 3.8) 
[c(precursor) = 25mmol/l, 130 °C, DMF] 
 
Unfortunately, however, all radiofluorination reactions of the complex molecule [18F]10 exhibit a 
very low RCY and therefore the product was not isolated or prepared for pharmacological 
evaluation studies so far. 
Earlier studies reported about similar effects, where the 18F-labelling via iodonium precursors of 
complex structures or molecules of larger size gave only very low yields or were completely 
unsuccessful [181, 185]. It is assumed that the 18F-labelling via iodonium precursors is somehow 
limited by the molecule size and complexity of the structure. The effect is not clearly understood 
but appears to be based mainly on steric influences. In addition, the problems in the oxidation 
procedure of 10a and the synthesis of 10c presumably originate from the same reason. 
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Considering the problems occurred in the synthesis of 10c and the low RCY of the 18F-labelling 
reactions, further optimisation studies in order to make one step nucleophilic radiofluorination of 
complex molecules via iodonium precursor possible, seem to be necessary. 
3.3.3 Radiosynthesis of [131I]I-ADTQ 
The lead structure of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (ADTQ) (cf. 
Scheme 1.18) was identified as non-competitive AMPA receptor antagonist [194]. So far, the 
iodine derivative I-ADTQ was not examined/prepared, but could also be expected to show activity 
as non-competitive AMPA receptor antagonist and therefore it was 131I-labelled for a preliminary 
pharmacological evaluation. 
Since the synthesis of I-ADTQ as well as the trimethyltin analogue Sn-ADTQ (11) became 
necessary for the precursor syntheses for the 18F-labelling of F-ADTQ, they offered conveniently 
the radioiodination of 10a. The standards and the precursor for the radiosynthesis of [131I]10a 
were synthesised as described in the above paragraph. The structure of the trimethyltin 
precursor Sn-ADTQ is shown in Scheme 3.9. 
 
Scheme 3.9: Structure of the trimethyltin precursor Sn-ADTQ for the preparation of [131I]10a 
 
For the 131I-labelling procedure 11 was treated in ethanol with [131I-]iodide and chloramine T as 
oxidant. After 2 min reaction time at room temperature, a very high RCY of 97 + 2 % of [131I]10a 
was obtained. Hence, no further optimisation for this procedure seemed necessary. 
[131I]10a was isolated by radio-HPLC (cf. Figure 3.10) and was employed in pharmacological 
studies for preliminary evaluation. The radio-HPL chromatogram shows a very good separation 
of [131I]10a and the precursor 11. Furthermore, no radioactive side-product could be detected and 
only a few minor unidentified non-radioactive compounds can be observed, which are separated 
by HPLC. 
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Figure 3.10: Radio-HPL chromatogram after radiosynthesis of [131I]10a  
(Column: Luna 5µ (Phenomenex®), eluent: methanol/water (70/30)) 
 
The analysis of specific activity of [131I]10a was carried out via HPLC. The applied amount of 
non-radioactive references is proportional to the integral of the UV-signals obtained by the 
UV/Vis-detector (cf. Figure 4.2). In the radiosynthesis of [131I]10a, with a starting activity of 
~7.5 MBq, an average specific activity of [131I]10a of 681 GBq/mmol (18.4 Ci/mmol) could be 
obtained. 
 
3.3.4 Preliminary evaluation studies of [131I]I-ADTQ 
The pharmacological evaluation studies were carried out by the Pharmacology Group of the 
Institute of Nuclear Chemistry (Forschungszentrum Jülich GmbH). 
Two studies were elaborated. First an ex vivo study was performed to investigate the ability of 
[131I]10a to pass the blood-brain barrier (BBB). For this test, [131I]10a was injected into the tail 
vein of female NMRI mice. After 10 min and 60 min the brains were removed, blotted dry, and 
measured with a γ-counter for radioactivity. In addition, the brains were cut into slides (horizontal) 
and measured autoradiographically. 
[131I]10a penetrated the blood-brain barrier, accumulating in the whole brain to an extent of 
2.1 % ID/g 10 min after injection and wash-out to 0.2 % ID/g after 60 min. The ex vivo autoradio-
graphy showed uniformly distributed radioactivity, both, 10 min and 60 min after injection.  
Radioactivity 
80  Results and Discussion 
Second, in vitro autoradiography was carried out. Frozen brain section of Wistar rats were 
employed and preincubated with Tris-HCl buffer. After incubation with [131I]10a alone, in 
combination with non-radioactive 10a, and in combination with the AMPA receptor antagonist 
CNQX (cf. Scheme 1.20), the sections were analysed via autoradiography. 
Image scanning again revealed a uniform distribution of [131I]10a and no influence of the 
unlabelled substances on the binding, assuming that the uptake of the radioligand represents a 
remarkable part of non-specific binding. The depletion in the buffer was 13 % (7.5 nM) and 21 % 
(0.5 nM). 
The preliminary pharmacological evaluation studies of [131I]10a show evidence for a too high 
non-specific binding which is often noticed with iodinated compounds (cf. subchapter 1.3). 
Although the brain uptake is excellent no specific distribution is observed when [131I]10a is 
washed out. Nevertheless, this results point out that the investigated structure is able to pass the 
BBB and it can be assumed that analogous molecules like F-ADTQ show similar or identical 
behaviour, however, possibly without such high non-specific binding. 
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 Experimental 
4.1 General 
All chemicals and solvents were purchased from Aldrich (Germany), Fluka (Switzerland), KMF 
(Germany), Acros Organics (Belgium), or Merck (Germany). They were reagent grade or better 
and were used without further purification. Sep-Pak© Plus C18 and ALOX cartridges were 
obtained from Waters (USA) and LiChrolut© glass columns and appropriate PTFE frits (porosity 
10 µm) from Merck (Germany). Column chromatography was performed with Merck silica gel 60 
(0.063 – 0.200 mm) and flash-chromatography with Fluka silica gel 60 (mesh 220 – 440). The 
eluent mixtures are given as v:v ratios. Thin-layer chromatography (TLC) was carried out with 
Macherey-Nagel (Germany) precoated silica gel plates (PolyGram SIL G/UV254, 40 x 80 mm) 
visualised under an UV-lamp (254 nm). The employed high performance liquid chromatography 
(HPLC) system consists of a Knauer WellChrom Mini-Star K-500 HPLC pump, a Rheodyne-
Injector block 7125 and a Merck/Hitachi UV/Vis photometer L4000. HPLC was performed on a 
Phenomenex© Luna 5µ C18 column (3 x 250 mm) and various eluent mixtures of methanol/water 
or acetonitrile/water all given as v:v ratios. 
Melting points (mp) were determined on a Mettler FP-61 or a BÜCHI Melting Point B-540 
apparatus. They are uncorrected. Analytical gas chromatography was performed with a HP 6890 
Series GC System, G1530A gas chromatograph using a cross-linked 5% PHME siloxane HP-5 
capillary column (30 m x 0.32 mm) and a flame ionisation detector (FID). Mass spectra (MS) 
were obtained on a Thermoquest Automass Multi III mass spectrometer. 1H, 13C and 19F nuclear 
magnetic resonance (NMR) spectra were recorded at 200 or 400, 50 and 188 MHz, respectively, 
on a Bruker DPX Avance 200 spectrometer (Institut für Nuklearchemie, Forschungszentrum 
Jülich) or a Varian Inova 400 MHz NMR spectrometer (Zentralabteilung für Chemische Analysen, 
Forschungszentrum Jülich). For NMR measurements substances were dissolved in CDCl3, 
d6-DMSO or d6-DMF and the measured chemical shifts are specified in δ ppm related to the 
tetramethylsilane (TMS) standard using the signals of the solvents as references. CHN-elemental 
analyses (EA, microanalyses) were performed on a Leco CHNS-932 CHNS analyser (ZCH, 
Forschungszentrum Jülich). The samples were burned at a temperature of 1000 °C in flowing 
oxygen for the analysis. C and H were measured by selective IR absorption of their combustion 
gases CO2 and H2O. The combustion gas NOx of N was converted to N2 by reduction which was 
determined by thermal conductivity detection. 
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4.2 Syntheses of standards and precursors of n.c.a. [18F]fluoroarenes 
In the majority of cases the syntheses described below were carried out as modified versions of 
corresponding original literature. In few cases the syntheses were taken directly from literature 
without any changes and in some cases completely new syntheses were elaborated. 
 
4.2.1 Syntheses of fluoro- and iodoarenes 
Most of the fluoro- and iodoarenes employed are commercially available compounds and were 
purchased by the above mentioned companies. Only the following compounds had to be 
synthesised: 
 
4-Benzyloxy-1-fluorobenzene (4) 
Benzyl bromide (15 mmol), 4-fluorophenol (10 mmol) and potassium carbonate (15 mmol) were 
suspended in 50 ml acetone. The reaction mixture was heated to reflux until no 4-fluorophenol 
was left as checked by TLC or GC control. The solvent was removed by distillation and the 
residue was taken up in 50 ml water and the aqueous solution extracted with ether. The ether 
layer was dried over sodium sulfate and reduced to the crude product. Flash-chromatography on 
silica gel using pure petrol ether gave the purified 1-benzyloxy-4-fluorobenzene (Rf = 0.26). 
Yield: 1.0 g (33 %). 
Melting point: 55.5 °C. 
1H-NMR (DMSOd6): δ = 5.00 (s, 2H, CH2), 6.94 (m, 2H, H3 + H5), 7.05 (m, 2H, H2 + H6), 
7.28 (m, 1H, H11), 7.32 (m, 2H, H10 + H12), 7.38 (m, 5H, H9 + H13). 
13C-NMR (DMSOd6): δ = 70.08 (CH2), 116.2 (2C, CH, C2 + C6), 116.5 (2C, CH, C3 + C5), 128.1 
(2C, CH, C9 + C13), 128.3 (CH, C11), 128.8 (2C, CH, C10 + C12), 137.3 (C, C8), 155.0 (C, C1), 
158.2 (C, C4). 
19F-NMR (DMSOd6): δ = -124.12 (CF). 
MS: m/e 202 [M+, 100]. 
EA: C13H11FO, calculated: C 77.2, H 5.48; found: C 77.4, H 5.61. 
 
4-Benzyloxy-1-iodobenzene (4a) 
Benzyl bromide (15 mmol), 4-iodophenol (10 mmol) and potassium carbonate (15 mmol) were 
suspended in 50 ml acetone. The reaction mixture was heated to reflux until no 4-iodophenol was 
left as checked by TLC or GC control. The solvent was removed and the residue was taken up in 
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50 ml water and this solution was extracted with ether. The ether layer was dried over sodium 
sulfate and reduced to the crude product. Column chromatography on silica gel using n-
hexane/ether (9:1) gave the purified 1-benzyloxy-4-iodobenzene (Rf = 0.67). 
Yield: 2.05 g (66 %). 
Melting point: 68.1 °C. 
1H-NMR (CDCl3): δ = 5.08 (s, 2H, CH2), 6.82 (m, 2H, H3 + H5), 7.46 (m, 5H, H9 – H13), 7.62 (m, 
2H, H2 + H6). 
13C-NMR (CDCl3): δ = 70.50 (CH2), 83.57 (C, C1), 117.8 (2C, CH, C3 + C5), 127.9 (2C, CH, 
C9 + C13), 128.6 (CH, C11), 129.1 (2C, CH, C10 + C12), 136.9 (C, C8), 138.7 (2C, CH, 
C2 + C6), 159.1 (C, C4). 
MS: m/e 312 [M+, 100]. 
EA: C13H11IO, calculated: C 50.4, H 3.58; found: C 50.7, H 3.57. 
 
4.2.2 Syntheses of (diacetoxyiodo)arenes 
(Diacetoxyiodo)benzene 6b was purchased from Aldrich (Germany). The compounds 1b to 3b, 
5b, 7b and 8b were all synthesised according a general procedure as described below. All these 
(diacetoxyiodo)arenes are known from the literature and were only identified by their melting 
points. Some melting points differ strongly from the literature data, in those cases the identity was 
confirmed by mass spectrometry. The general procedure was not suitable for 4b and 9b, which 
consequently were prepared by different methods as explained. 
 
General procedure for the synthesis of 1 to 3b and 5-8b [following 161] 
The appropriate iodoarene (10 mmol) was dissolved in 90 ml of acetic acid and warmed up to 
40 °C. Over a period of 20 min sodium perborate tetrahydrate (110 mmol) was added in several 
portions. The mixture was stirred at 40 °C until no starting material was left or stopped after 24 h. 
Half of the solvent was distilled off under reduced pressure and 100 ml water were added. After 
1 to 2 h of cooling in the refrigerator, the precipitates were collected, washed with water and dried 
at the air in the dark. 
 
2-(Diacetoxyiodo)anisole (1b) 
Yield: 2.0 g (57 %). 
Melting point: 171-173 °C (mp (Lit.) 147-149 °C [163]). 
MS: m/e 293 [100] 
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3-(Diacetoxyiodo)anisole (2b) 
Yield: 2.6 g (74 %). 
Melting point: 177-178 °C (mp (Lit.) 133-135 °C [163]). 
MS: m/e 293 [100] 
 
4-(Diacetoxyiodo)anisole (3b) 
Yield: 2.2 g (62 %). 
Melting point: 85-87 °C (mp (Lit.) 88-90 °C [163]). 
 
4-(Diacetoxyiodo)toluene (5b)  
Yield 1.5 g (45 %). 
Melting point: 106-108 °C (mp (Lit.) 108-110 °C [163]). 
 
4-Chloro-1-(diacetoxyiodo)benzene (7b) 
Yield: 2.3 g (63 %). 
Melting point: 175°C (mp (Lit.) 114-116 °C [163]). 
MS: m/e 297 [100] 
 
4-Bromo-1-(diacetoxyiodo)benzene (8b) 
Yield: 1.8 g (45 %). 
Melting point: 180-185 °C (mp (Lit.) 120-122 °C [163]). 
MS: m/e 341 [100] 
 
Synthesis of 4-iodo-1-(diacetoxyiodo)benzene (9b) [from 99] 
1,4-Diiodobezene (10 mmol) was suspended in 19 ml peracetic acid (40 % in water) under 
stirring. The mixture was carefully warmed up to 40 °C and subsequently heated until reflux. 
During 1 h at reflux a yellow precipitate was formed. After cooling the precipitate was filtered and 
washed with acetic acid. The product was re-crystallised from acetic acid/acetic anhydride (4:1). 
Yield 1.9 g (42 %). 
Melting point: 175 °C (mp (Lit.) 170-172 °C). 
 
Synthesis of 4-benzyloxy-1-(diacetoxyiodo)benzene (4b) [following 163] 
Sodium periodate (13 mmol) and sodium acetate (26 mmol) were suspended in 20 ml of a 
mixture of acetic acid/acetic anhydride (9:1). 4-Benzyloxy-1-iodobenzene (10 mmol) was added 
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and the mixture was heated at reflux for 4 h. After cooling down to room temperature the mixture 
was poured into 60 ml of ice-water. The product was extracted with dichloromethane. The 
organic layers were collected and dried over Mg2SO4. The solvent was removed under reduced 
pressure and the oily residue treated with ether for crystallisation. The product was re-crystallised 
from ethyl acetate/acetic anhydride (9:1). 
Yield: 2.83 g (66 %). 
Melting point: 113 °C. 
1H-NMR (CDCl3): δ = 2.03 (s, 6H, CH3), 5.15 (s, 2H, CH2), 7.07 (d, 2H, H2 + H6), 7.39 – 7.47 (m, 
5H, CHPh, H9 – H13), 8.03 (d, 2H, H3 + H5). 
13C-NMR (CDCl3): δ = 20.8 (2C, CH3), 70.8 (CH2), 112.3 (C, C1), 117.9 (2C, CH, C3 + C5), 127.9 
(2C, CH, C9 + C13), 128.9 (CH, C11), 129.2 (2C, CH, C10 + C12), 136.2 (C, C8), 137.6 (2C, CH, 
C2 + C6), 161.8 (C, C4), 176.8 (2C, CO). 
MS: m/e 369 [M+, 100]. 
C17H17IO5 calculated: C 47.7, H 4.00; found: C 45.6, H 3.71. 
 
4.2.3 Syntheses of aryl(2-thienyl)iodonium bromides and iodides 
The corresponding (diacetoxyiodo)arene (2 mmol) and thiophene (6 mmol) were stirred in 10 ml 
acetic anhydride at –30 °C. Concentrated sulphuric acid (0.5 ml) was added dropwise over 1 h. 
The mixture was allowed to warm up to 5 °C and was further stirred at this temperature for 3 to 5 
h. The dark solution was poured into 15 ml ice-water. The organic compounds were extracted 
with ether and discarded. The aqueous layers were treated with activated coal for 10 min at 
40 °C to become a clear solution. To the filtered, clear solution 10 ml of a potassium bromide or a 
potassium iodide solution (25 %), respectively, was added. After 1h storage in the refrigerator, 
precipitates were collected, washed with a small portion of acetone and ether. The product was 
dried and stored in an exsiccator. The freshly produced precursors could be used for the n.c.a. 
18F-labelling without any further purification. For eventual re-crystallisation the compounds were 
dissolved in hot methanol and precipitated with ether. 
 
2-Methoxyphenyl(2-thienyl)iodonium bromide (1c) 
Yield: 0.31 g (39 %). 
Melting point: 174 °C. 
1H-NMR (DMSOd6): δ = 3.91 (s, 3H, OCH3), 6.99 (t, 1H, H5Ar), 7.03 (t, 1H, H4Th), 7.23 (d, 1H, 
H3Ar), 7.55 (t, 1H, H4Ar), 7.78 (d, 1H, H5Th), 7.80 (d, 1H, H3Th), 8.21 (d, 1H, H6Ar). 
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13C-NMR (DMSOd6): δ = 57.3 (CH3, OCH3), 104.9 (C, C2Th), 112.3 (C, C1Ar), 113.2 (CH, C3Ar), 
123.6 (CH, C5Ar), 129.4 (CH, C4Th), 134.8 (CH, C4Ar), 136.0 (CH, C3Th), 137.2 (CH, C6Ar), 139.1 
(CH, C5Th), 156.1 (C, C2Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10BrIOS, calculated: C 33.3, H 2.54; found: C 32.9, H 2.46. 
 
2-Methoxyphenyl(2-thienyl)iodonium iodide (1d) 
Yield: 0.51 g (58 %). 
Melting point: 183 °C. 
1H-NMR (DMSOd6): δ = 3.93 (s, 3H, OCH3), 7.01 (t, 1H, H5Ar), 7.06 (t, 1H, H4Th), 7.25 (d, 1H, 
H3Ar), 7.58 (t, 1H, H4Ar), 7.84 (d, 1H, H3Th), 7.84 (d, 1H, H5Th), 8.24 (d, 1H, H6Ar). 
13C-NMR (DMSOd6): δ = 57.4 (CH3, OCH3), 102.6 (C, C2Th), 111.1 (C, C1Ar), 113.3 (CH, C3Ar), 
123.7 (CH, C5Ar), 129.6 (CH, C4Th), 135.1 (CH, C4Ar), 136.5 (CH, C3Th), 137.2 (CH, C6Ar), 139.7 
(CH, C5Th), 156.2 (C, C2Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10I2OS, calculated: C 29.8, H 2.27; found: C 29.5, H 2.21. 
 
3-Methoxyphenyl(2-thienyl)iodonium bromide (2c) 
Yield: 0.54 g (67 %). 
Melting point: 161 °C. 
1H-NMR (DMSOd6): δ = 3.79 (s, 3H, OCH3), 7.11 (t, 1H, H4Th), 7.16 (d, 1H, H4Ar), 7.39 (t, 1H, 
H5Ar), 7.74 (d, 1H, H2Ar), 7.88 (d, 1H, H5Th), 7.89 (d, 1H, H3Th), 7.96 (d, 1H, H6Ar). 
13C-NMR (DMSOd6): δ = 56.7 (OCH3), 107.7 (C, C2Th), 117.8 (C, C1Ar), 121.0 (CH, C4Ar), 123.2 
(CH, C2Ar), 127.3 (CH, C5Ar), 130.0 (H4Th), 132.8 (CH, C6Ar), 136.6 (CH, C3Th), 139.7 (CH, C5Th), 
160.9 (C, C3Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10BrIOS, calculated: C 33.3, H 2.54; found: C 33.6, H 2.47. 
 
3-Methoxyphenyl(2-thienyl)iodonium iodide (2d) 
Yield: 0.32 g (36 %). 
Melting point: 155 °C. 
1H-NMR (DMSOd6): δ = 3.79 (s, 3H, OCH3), 7.11 (t, 1H, H4Th), 7.17 (d, 1H, H4Ar), 7.39 (t, 1H, 
H5Ar), 7.74 (d, 1H, H2Ar), 7.87 (d, 1H, H5Th), 7.89 (d, 1H, H3Th), 7.96 (d, 1H, H6Ar). 
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13C-NMR (DMSOd6): δ = 56.7 (OCH3), 107.6 (C, C2Th), 117.8 (C, C1Ar), 121.0 (CH, C4Ar), 123.2 
(CH, C2Ar), 127.3 (CH, C5Ar), 129.4 (CH, C4Th), 132.2 (CH, C6Ar), 136.6 (CH, C3Th), 139.7 (CH, 
C5Th), 160.9 (C, C3Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10I2OS, calculated: C 29.8, H 2.27; found: C 30.2, H 2.56. 
 
4-Methoxyphenyl(2-thienyl)iodonium bromide (3c) 
Yield: 0.50 g (62 %). 
Melting point: 196 °C (mp (Lit.) 180-185 °C [184]). 
1H-NMR (DMSOd6): δ = 3.79 (s, 3H, OCH3), 7.03 (d, 2H, H3Ar + H5Ar), 7.11 (t, 1H, H4Th), 7.87 (d, 
1H, H3Th), 7.92 (d, 1H, H5Th), 8.14 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 56.5 (OCH3), 107.3 (C, C2Th), 111.8 (C, C1Ar), 117.8 (2C, CH, C2Ar + 
C6Ar), 129.9 (CH, C4Th), 136.4 (CH, C3Th), 137.4 (CH, C3Ar), 139.3 (CH, C5Th), 162.2 (C, C4Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10BrIOS, calculated: C 33.3, H 2.54; found: C 33.3, H 2.39. 
 
4-Methoxyphenyl(2-thienyl)iodonium iodide (3d) 
Yield: 0.53 g (60 %). 
Melting point: 155 °C (mp (Lit.) 150-155 °C [184]). 
1H-NMR (DMSOd6): δ = 3.71 (s, 3H, OCH3), 6.96 (d, 2H, H3Ar + H5Ar), 7.05 (t, 1H, H4Th), 7.82 (d, 
1H, H3Th), 7.88 (d, 1H, H5Th), 8.08 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 56.1 (OCH3), 104.0 (C, C2Th), 110.0 (C, C1Ar), 117.6 (2C, CH, C3Ar + 
C5Ar), 129.6 (CH, C4Th), 136.6 (CH, C3Th), 137.1 (2C, CH, C2Ar + C6Ar), 139.4 (CH, C5Th), 162.0 
(C, C4Ar). 
MS: m/e 317 [M+, 100]. 
EA: C11H10I2OS, calculated: C 29.8, H 2.27; found: C 29.4, H 2.18. 
 
4-Benzyloxyphenyl(2-thienyl)iodonium bromide (4c) 
Yield: 0.52 g (55 %). 
Melting point: 202 °C. 
1H-NMR (DMSOd6): δ = 5.08 (s, 2H, CH2), 7.05 (2H, H3Ar + H5Ar), 7.06 (1H, H4Th), 7.25 – 7.40 (m, 
5H, CHPh), 7.83 (d, 1H, H3Th), 7.89 (d, 1H, H5Th), 8.01 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 70.07 (CH2), 104.6 (C, C2Th), 110.4 (C, C1Ar), 118.3 (2C, CH, C3Ar + 
C5Ar), 128.3 (2C, CH, C9Ar + C13Ar), 128.6 (CH, C11Ar), 128.9 (2C, CH, C10Ar + C12Ar), 129.7 
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(CH, C4Th), 136.5 (C, C8Ar), 136.7 (CH, C3Th), 137.0 (2C, CH, C2Ar + C6Ar), 139.6 (CH, C5Th), 
161.1 (C, C4Ar). 
MS: m/e 393 [M+, 100]. 
EA: C17H14BrIOS, calculated: C 43.2, H 2.98; found: C 43.2, H 2.93. 
4-Methylphenyl(2-thienyl)iodonium bromide (5c) 
Yield: 0.27 g (35 %). 
Melting point: 195 °C (mp (Lit.) 180-185 °C [184]). 
1H-NMR (DMSOd6): δ = 2.23 (s, 3H, CH3), 7.10 (1H, H4Th), 7.27 (d, 2H, H2Ar + H6Ar), 7.81 (d, 1H, 
H3Th), 7.85 (d, 1H, H5Th), 8.08 (d, 2H, H3Ar + H5Ar). 
13C-NMR (DMSOd6): δ = 21.7 (CH3), 107.8 (C, C2Th), 119.6 (C, C1Ar), 129.9 (CH, C4Th), 132.8 
(2C, CH, C2Ar + C6Ar), 135.4 (2C, CH, C3Ar + C5Ar), 136.5 (CH, C3Th), 139.4 (CH, C5Th), 142.5 (C, 
C4Ar). 
MS: m/e 301 [M+, 100]. 
EA: C11H10BrIS, calculated: C 34.7, H 2.65; found: C 34.8, H 2.58. 
 
Phenyl(2-thienyl)iodonium bromide (6c) 
Yield: 0,48 g (65 %). 
Melting point: 173 °C (mp (Lit.) 170-174 °C [221], 200-205 °C [184], 180 °C [166]). 
1H-NMR (DMSOd6): δ = 7.05 (d, 1H, H4Th), 7.41 (t, 2H, H3Ar + H5Ar), 7.55 (t, 1H, H4Ar), 7.82 (d, 
1H, H3Th), 7.89 (d, 1H, H5Th), 8.13 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 105.1 (C, C2Th), 121.6 (C, C1Ar), 129.7 (CH, C4Th), 131.9 (2C, CH, 
C3Ar + C5Ar), 132.0 (CH, C4Ar), 134.9 (2C, CH, C2Ar + C6Ar), 136.7 (CH, C3Th), 139.7 (CH, C5Th). 
MS: m/e 287 [M+, 100]. 
EA: C10H8BrIS, calculated: C 32.7, H 2.20; found: C 33.1, H 2.26. 
 
4-Chlorophenyl(2-thienyl)iodonium bromide (7c) 
Yield: 0.34 g (42 %). 
Melting point: 186 °C (mp (Lit.) 180-185 °C [184]). 
1H-NMR (DMSOd6): δ = 7.05 (t, 1H, H4Th), 7.48 (d, 2H, H3Ar + H5Ar), 7.82 (d, 1H, H3Th), 7.89 (d, 
1H, H5Th), 8.15 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 106.4 (C, C2Th), 120.2 (C, C1Ar), 129.7 (CH, C4Th), 131.7 (2C, CH, 
C3Ar + C5Ar), 136.5 (CH, C3Th), 136.7 (2C, CH, C2Ar + C6Ar), 137.0 (C, C4Ar), 139.5 (CH, C5Th). 
MS: m/e 321 [M+, 100], 323 [M+, 56]. 
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EA: C10H7BrClIS, calculated: C 29.9, H 1.76; found: C 29.5, H 1.74. 
 
4-Bromophenyl(2-thienyl)iodonium bromide (8c) 
Yield: 0.33 g (36 %). 
Melting point: 165 °C. 
1H-NMR (DMSOd6): δ = 7.05 (t, 1H, H4Th), 7.61 (d, 2H, H3Ar + H5Ar), 7.81 (d, 1H, H3Th), 7.88 (d, 
1H, H5Th), 8.06 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 106.3 (C, C2Th), 120.9 (C, C1Ar), 125.9 (C, C4Ar), 129.7 (CH, C4Th), 
134.6 (2C, CH, C3Ar + C5Ar), 136.6 (CH, C3Th), 136.9 (2C, CH, C2Ar + C6Ar), 139.6 (CH, C5Th). 
MS: m/e 366 [M+, 100], 365 (97). 
EA: C10H7Br2IS calculated: C 26.9, H 1.58; found: C 26.7, H 1.65. 
 
4-Iodophenyl(2-thienyl)iodonium bromide (9c) 
Yield: 0.17 g (18 %). 
Melting point: 161.9 °C. 
1H-NMR (DMSOd6): δ = 7.04 (t, 1H, H4Th), 7.56 (d, 2H, H3Ar + H5Ar), 7.81 (d, 1H, H3Th), 7.88 (d, 
1H, H5Th), 8.14 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 97.1 (C, C4ar), 106.3 (C, C2Th), 120.8 (C, C1ar), 129.7 (CH, C4Th), 136.0 
(2C, CH, C3ar + C5ar), 136.4 (CH, C3th), 137.2 (2C, CH, C2ar + C6ar), 139.6 (CH, C5th). 
MS 413 [M+, 100]. 
C10H7BrI2S, calculated: C 24.4, H 1.43; found: C 24.1, H 1.38. 
 
4.2.4 Syntheses of methoxyphenyl(2-thienyl)iodonium tosylates and 
triflates 
The corresponding methoxyphenyl(2-thienyl)iodonium bromide (2.5 mmol) and cyclohexene 
(2.5 mmol) were suspended in 8 ml pure methanol. p-Toluenesulphonic acid monohydrate 
(3 mmol) or trifluoromethane sulphonic acid (3 mmol), respectively, was added while stirring. 
Finally, 30 % aqueous hydrogen peroxide solution (3.4 mmol) was added. The mixture was 
heated to reflux until complete dissolution. The reflux was continued for further 15 min. Under 
reduced pressure the solvent and most of the water were removed. The crude product was 
dissolved in methanol at 60 °C and the solution quickly cooled down. The product was 
precipitated with addition of ether and n-hexane (v:v = 3:1) in excess. 
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2-Methoxyphenyl(2-thienyl)iodonium tosylate (1e) 
Yield: 0.9 g (76 %). 
Melting point: 140 °C. 
1H-NMR (DMSOd6): δ = 2.24 (s, 3H, (CH3)Ts), 3.94 (s, 3H, OCH3), 7.03 (t, 1H, H5Ar), 7.10 (d, 2H, 
H2Ts + H6Ts), 7.11 (1H, H4Th), 7.28 (d, 1H, H3Ar), 7.44 (d, 2H, H3Ts + H5Ts), 7.60 (t, 1H, H4Ar), 
7.89 (d, 1H, H3Th), 7.90 (d, 1H, H5Th), 8.27 (d, 1H, H6Ar). 
13C-NMR (DMSOd6): δ = 21.2 ((CH3)Ts), 57.5 (OCH3), 100.5 (C, C2Th), 109.7 (C, C1Ar), 113.4 (CH, 
C3Ar), 123.8 (CH, C5Ar), 125.9 (2C, CH, C2Ts + C6Ts), 128.6 (2C, CH, C3Ts + C5Ts), 129.8 (CH, 
C4Th), 135.5 (CH, C4Ar), 137.2 (CH, C6Ar), 137.3 (CH, C3Th), 138.3 (C, C4Ts), 140.5 (CH, C5Th), 
145.8 (C, C1Ts), 156.3 (C, C2Ar). 
MS: m/e 317 [M+, 100]. 
EA: C18H17IO4S2, calculated: C 44.3, H 3.51; found: C 43.6, H 3.39. 
 
2-Methoxyphenyl(2-thienyl)iodonium triflate (1f) 
Yield: 2.03 g (98 %). 
Melting point: 170-175 °C. 
1H-NMR (DMSOd6): δ = 3.95 (s, 3H, OCH3), 7.04 (t, 1H, H5Ar), 7.10 (1H, H4Th), 7.28 (d, 1H, H3Ar), 
7.61 (t, 1H, H4Ar), 7.89 (d, 1H, H3Th), 7.90 (d, 1H, H5Th). 
13C-NMR (DMSOd6): δ = 57.4 (OCH3), 100.4 (C, C2Th), 109.6 (C, C1Ar), 113.4 (CH, C3Ar), 121.1 
(C, CF3), 123.8 (CH, C5Ar), 129.8 (CH, C4Th), 135.5 (CH, C4Ar), 137.17 (CH, C6Ar), 137.23 (CH, 
C3Th), 140.5 (CH, C5Th), 156.3 (C, C2Ar). 
19F-NMR (DMSOd6): δ = -78.4 (CF3) 
MS: m/e 317 [M+, 100]. 
EA: C12H10F3IO4S2, calculated: C 30.9, H 2.16; found: C 30.7, H 2.13. 
 
3-Methoxyphenyl(2-thienyl)iodonium tosylate (2e) 
Yield: 1.1 g (93 %). 
Melting point: 161.0 °C. 
1H-NMR (DMSOd6): δ = 2.07 (s, 3H, (CH3)Ts), 3.57 (s, 3H, OCH3), 7.01 (d, 2H, C3Ts + C5Ts), 7.06 
(t, 1H, H4Th), 7.09 (t, 1H, H4Ar), 7.33 (t, 1H, H5Ar), 7.38 (d, 2H, C2Ts + C6Ts), 7.68 (d, 1H, H6Ar), 
7.81 (s, 1H, H2Ar), 7.85 (d, 1H, H3Th), 7.96 (d, 1H, H5Th). 
13C-NMR (DMSOd6): δ = 20.7 ((CH3)Ts), 55.8 (OCH3), 100.7 (C, C2Th), 117.7 (CH, C4Ar), 119.2 (C, 
C1Ar), 120.0 (CH, C2Ar), 125.4 (2C, CH, C2Ts + C6Ts), 126.5 (CH, C6Ar), 128.1 (2C, CH, 
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C3Ts + C5Ts), 129.5 (CH, C4Th), 132.3 (CH, C5Ar), 137.1 (CH, C3Th), 137.8 (C, C4Ts), 140.3 (CH, 
C5Th), 145.1 (C, C1Ts), 160.2 (C, C3Ar). 
MS: m/e 317 [M+, 100]. 
EA: C18H17IO4S2, calculated: C 44.3, H 3.51; found: C 44,6, H 3.61. 
3-Methoxyphenyl(2-thienyl)iodonium triflate (2f) 
Yield: 0.94 g (81 %). 
Melting point: 88.0 °C. 
1H-NMR (DMSOd6): δ = 3.73 (s, 3H, OCH3), 7.11 (t, 1H, H4Th), 7.14 (t, 1H, H4Ar), 7.38 (t, 1H, 
H5Ar), 7.72 (d, 1H, H6Ar), 7.85 (s, 1H, H2Ar), 7.89 (d, 1H, H3Th), 7.99 (d, 1H, H5Th). 
13C-NMR (DMSOd6): δ = 56.3 (OCH3), 101.1 (C, C2Th), 118.3 (CH, C4Ar), 119.5 (C, C1Ar), 120.5 
(C, CF3), 126.9 (CH, C6Ar), 130.0 (CH, C4Th), 132.8 (CH, C5Ar), 137.7 (CH, C3Th), 140.8 (CH, 
C5Th), 160.7 (C, C3Ar). 
19F-NMR (DMSOd6): δ = -77.9 (CF3) 
MS: m/e 317 [M+, 100]. 
EA: C12H10F3IO4S2, calculated: C 30.9, H 2.16; found: C 30.6, H 2.21. 
 
4-Methoxyphenyl(2-thienyl)iodonium tosylate (3e) 
Yield: 1.01 g (93 %). 
Melting point: 185.4 °C. 
1H-NMR (DMSOd6): δ = 2.21 (s, 3H, (CH3)Ts), 3.72 (s, 3H, OCH3), 6.98 (d, 2H, H3Ar + H5Ar), 7.04 
(d, 2H, C3Ts + C5Ts), 7.08 (t, 1H, H4Th), 7.41 (d, 2H, C2Ts + C6Ts), 7.87 (d, 1H, H3Th), 7.94 (d, 1H, 
H5Th), 8.10 (d, 2H, H2Ar + H6Ar). 
13C-NMR (DMSOd6): δ = 21.2 ((CH3)Ts), 56.1 (OCH3), 101.8 (C, C2Th), 108.7 (C, C1Ar), 117.7 (2C, 
CH, C3Ar + C5Ar), 125.9 (2C, CH, C2Ts + C6Ts), 128.5 (2C, CH, C3Ts + C5Ts), 129.9 (CH, C4Th), 
137.2 (2C, CH, C2Ar + C6Ar), 137.3 (CH, C3Th), 138.1 (C, C4Ts), 140.2 (CH, C5Th), 145.1 (C, 
C1Ts), 162.3 (C, C4Ar). 
MS: m/e 317 [M+, 100]. 
EA: C18H17IO4S2 calculated: C 44.3, H 3.51; found: C 43.8, H 3.50. 
 
4-Methoxyphenyl(2-thienyl)iodonium triflate (3f) 
Yield: 0.44 g (37 %). 
Melting point: 92.5 °C. 
1H-NMR (DMSOd6): δ = 3.72 (s, 3H, OCH3), 7.00 (d, 2H, H3Ar + H5Ar), 7.10 (t, 1H, H4Th), 7.86 (d, 
1H, H3Th), 7.93 (d, 1H, H5Th), 8.10 (d, 2H, H2Ar + H6Ar). 
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13C-NMR (DMSOd6): δ = 56.1 (OCH3), 101.6 (C, C2Th), 108.6 (C, C1Ar), 117.8 (2C, CH, 
C3Ar + C5Ar), 121.0 (C, CF3), 129.9 (CH, C4Th), 137.2 (2C, CH, C2Ar + C6Ar), 137.3 (CH, C3Th), 
140.2 (CH, C5Th), 162.4 (C, C4Ar). 
19F-NMR (DMSOd6): δ = -78.2 (CF3) 
MS: m/e 317 [M+, 100]. 
EA: C12H10F3IO4S2 calculated: C 30.9, H 2.16; found: C 31.1, H 2.26. 
 
4.3 Syntheses of standards and precursors for [18F]F-ADTQ and 
[131I]I-ADTQ  
As mentioned earlier, the here synthesised potential non-competitive AMPA receptor antagonists 
are derived from the lead structure of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroiso-
quinoline. The fluorine derivative is described in the literature and characterised as non-
competitive AMPA receptor antagonist and was synthesised as described earlier via the Pictet-
Spengler approach. The analytical data in the literature are only known for the final product and 
have not been reported for the intermediates so far. In contrast, the iodine derivative is not 
described in the literature, but the same approach of synthesis was suitable. 
 
4.3.1 Syntheses of fluorine, iodine and trimethyltin derivatives of ADTQ 
2-Acetyl-6,7-dimethoxy-1-(4’-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (10) [from 194] 
A mixture of 2-(3’,4’-dimethoxyphenyl)ethylamine (homoveratrylamine) (10 mmol) and 4-fluoro-
benzaldehyde (12 mmol) were heated at reflux for 3 h in anhydrous toluene (50 ml). Afterwards 
the solvent was evaporated under reduced pressure. The oily residue was treated with ether to 
give a solid product, which was re-crystallised from methanol to afford 4-fluorobenzyl[2-(3’,4’-di-
methoxyphenyl)ethyl]imine as a white solid. 
Yield: 1.09 g (38 %). 
Melting point: 101.2 °C. 
1H-NMR (CDCl3): δ = 2.91 (d, 2H, H2Et), 3.75 (s, 3H, C4’-OCH3), 3.80 (s, 3H, C3’-OCH3), 3.78 (d, 
2H, H1Et), 6.74 (s, 1H, H5’), 6.68 (s, 1H, H2’ ), 7.04 (d, 2H, H2 + H6), 6.72 (d, 1H, H6’), 7.64 (d, 
2H, H3 + H5), 8.04 (s, 1H, H5). 
13C-NMR (CDCl3): δ = 36.9 (CH2, C2Et), 55.7 (C4’-OCH3), 55.8 (C3’-OCH3), 63.2 (CH2, C1Et), 
111.1 (CH, C5’), 112.4 (CH, C2’), 115.6 (2C, CH, C2 + C6), 120.8 (CH, C6’), 129.8 (2C, CH, 
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C3 + C5), 132.4 (C, C1’), 132.4 (C, C4), 147.3 (C, C3’), 148.5 (C, C4’), 160.0 (CH, C5), 164.2 (C, 
C1). 
19F-NMR (CDCl3): δ = -115.5. 
MS: m/e 288 [M+, 100]. 
EA: C17H18FNO2 calculated: C 71.1, H 6.31, N 4.87; found: C 71.9, H 6.18, N 5.06. 
 
4-Fluorobenzyl[2-(3’,4’-dimethoxyphenyl)ethyl]imine (3.8 mmol) was given into 10 ml trifluoro-
acetic acid and the mixture was refluxed for 90 min. The reaction was quenched by adding water 
(~20 ml) and basified (pH ~8 – 9) with aqueous sodium hydroxide solution (50 %). The product 
6,7-dimethoxy-1-(4’-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline precipitated and was filtered off. 
Re-crystallisation from methanol gave the purified product. 
Yield: 0.43 g (39 %). 
Melting point: 82.8 °C. 
1H-NMR (CDCl3): δ = 2.69 (d, 1H, H4 pseudo eq.), 2.88 (d, 1H, H4 pseudo ax.), 3.00 (d, 1H, H3 
pseudo ax.), 3.15 (d, 1H, H3 pseudo eq.), 3.59 (s, 3H, C6-OCH3), 3.82 (s, 3H, C7-OCH3), 4.98 
(s, 1H, H1), 6.15 (s, 1H, H8), 6.58 (s, 1H, H5), 6.95 (d, 2H, H3’), 7.18 (d, 2H, H2’). 
13C-NMR (CDCl3): δ = 29.2 (CH2, C4), 41.9 (CH2, C3), , 55.8 (2C, OCH3), 60.7 (CH, C1), 110.7 
(CH, C8), 111.4 (CH, C5), 115.1 (2C, CH, C3’ + C5’), 127.6 (C, C4a), 129.6 (C, C8a), 130.4 (2C, 
CH, C2’ + C6’), 140.6 (C, C1’), 147.0 (C, C7), 147.6 (C, C6), 162.0 (C, C4’). 
19F-NMR (CDCl3): δ = -115.3. 
MS: m/e 288 [M+, 100]. 
EA: C17H18FNO2 calculated: C 71.1, H 6.31, N 4.87; found: C 70.3, H 5.80, N 4.39. 
 
6,7-Dimethoxy-1-(4’-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (1.5 mmol) was dissolved in 
acetic anhydride (10 ml) and heated until reflux for 90 min. The mixture was cooled and the 
reaction quenched by adding water (~10 ml). The organic layer was extracted with dichloro-
methane (3 x 10 ml), which was dried over Mg2SO4. The solvent was removed under reduced 
pressure until dryness. The oily residue was treated with ether for crystallisation and washed with 
ether. Flash-chromatography on silica gel using petrol ether/acetone (2:1) gave the purified 2-
acetyl-6,7-dimethoxy-1-(4’-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (F-ADTQ, 10) (Rf = 0.35). 
Yield: 0.36 g (74 %). 
Melting point: 160 °C (mp (Lit.) 158-160 °C [194]). 
1H-NMR (CDCl3): δ = 2.13 (s, 3H, CH3), 2.75 (d, 1H, H4 pseudo eq.), 2.92 (d, 1H, H4 pseudo 
ax.), 3.30 (d, 1H, H3 pseudo ax.), 3.72 (d, 1H, H3 pseudo eq.), 3.73 (s, 3H, OCH3), 3.83 (s, 3H, 
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OCH3), 6.47 (s, 1H, H8), 6.64 (s, 1H, H5), 6.81 (s, 1H, H1), 6.91 (d, 2H, H3’ + H5’), 7.18 (d, 2H, 
H2’ + H6’). 
13C-NMR (CDCl3): δ = 21.5 (CH3), 28.5 (CH2, C4), 40.1 (CH2, C3), 53.8 (CH, C1), 56.0 (2C, 
OCH3), 111.5 (2C, CH, C5 + C8), 115.0 (2C, CH, C3’ + C5’), 126.4 (C, C8a), 127.0 (C, C4a), 
130.3 (2C, CH, C2’ + C6’), 138.5 (C, C1’), 148.0 (C, C6), 148.5 (C, C7), 162.1 (C, C4’), 168.8 
(CO). 
19F-NMR (CDCl3): δ = -115.5. 
MS: m/e 330.2 [M+, 100]. 
EA: C19H20FNO3 calculated: C 69.3, H 6.12, N 4.25; found: C 70.3, H 6.12, N 4.37. 
 
2-Acetyl-6,7-dimethoxy-1-(4’-iodophenyl)-1,2,3,4-tetrahydroisoquinoline (10a) [following 194] 
A mixture of 2-(3’,4’-dimethoxyphenyl)ethylamine (homoveratrylamine) (10 mmol) and 4-iodo-
benzaldehyde (12 mmol) were heated to 100 °C for 3 h in anhydrous toluene (50 ml). Afterward 
the solvent was evaporated under reduced pressure. The oily residue was treated with ether to 
give a solid product which was re-crystallised from methanol to afford 4-iodobenzyl-[2-(3’,4’-
dimethoxyphenyl)ethyl]imine as a white solid. 
Yield: 2.45 g (62 %). 
Melting point: 89.3 °C. 
1H-NMR (CDCl3): δ = 2.90 (d, 2H, H2Et), 3.76 (s, 3H, C3’-OCH3), 3.80 (s, 3H, C4’-OCH3), 3.78 (d, 
2H, H1Et), 6.73 (s, 1H, H5’), 6.68 (s, 1H, H2’ ), 6.71 (d, 1H, H6’), 7.38 (d, 2H, H3 +H5), 7.70 (d, 
2H, H2+ H6), 8.0 (s, 1H, H5). 
13C-NMR (CDCl3): δ = 36.8 (CH2, C2Et), 55.7 (C4’-OCH3), 55.8 (C4’-OCH3), 63.3 (CH2, C1Et), 97.1 
(C, C1), 111.1 (CH, C5’), 112.4 (CH, C2’), 120.8 (CH, C6’), 129.5 (2C, CH, C3 + C5), 132.3 (C, 
C1’), 135.6 (C, C4), 137.7 (2C, CH, C2 + C6), 147.3 (C, C3’), 148.6 (C, C4’), 160.4 (CH, C5). 
MS: m/e 330 [M+, 100]. 
EA: C17H18INO2 calculated: C 51.7, H 4.59, N 3.54; found: C 52.2, H 4.63, N 3.76. 
 
4-Iodobenzyl[2-(3’,4’-dimethoxyphenyl)ethyl]imine (6.2 mmol) was given into 10 ml trifluoroacetic 
acid and the mixture was refluxed for 90 min. The reaction was quenched by adding water 
(~10 ml) and basified (pH ~8 – 9) with aqueous sodium hydroxide solution (50 %). The product 
6,7-dimethoxy-1-(4’-iodophenyl)-1,2,3,4-tetrahydroisoquinoline precipitated and was filtered off. 
Re-crystallisation from methanol gave the purified product. 
Yield: 1.33 g (54 %). 
Melting point: 152.7 °C. 
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1H-NMR (CDCl3): δ = 2.67 (d, 1H, H4 pseudo eq.), 2.84 (d, 1H, H4 pseudo ax.), 2.96 (d, 1H, H3 
pseudo ax.), 3.11 (d, 1H, H3 pseudo eq.), 3.59 (s, 3H, C7-OCH3), 3.80 (s, 3H, C6-OCH3), 4.92 
(s, 1H, H1), 5.04 (s, 1H, NH), 6.13 (s, 1H, H8), 6.56 (s, 1H, H5), 6.94 (d, 2H, H2’ + H6’), 7.58 (d, 
2H, H3’ + H5’). 
13C-NMR (CDCl3): δ = 29.1 (CH2, C4), 41.6 (CH2, C3), 55.7 (CH3, C6-OCH3), 55.8 (CH3, C7-
OCH3), 60.8 (CH, C1), 92.9 (C, C4’), 110.6 (CH, C8), 111.4 (CH, C5), 127.6 (C, C4a), 129.0 (C, 
C8a), 130.9 (2C, CH, C2’ + C6’), 137.4 (2C, CH, C3’ + C5’), 144.5 (C, C1’), 147.1 (C, C7), 147.7 
(C, C6). 
MS: m/e 396 [M+, 100]. 
EA: C17H18INO2 calculated: C 51.7, H 4.59, N 3.54; found: C 52.2, H 4.44, N 3.75. 
 
6,7-Dimethoxy-1-(4’-iodophenyl)-1,2,3,4-tetrahydroisoquinoline (3.4 mmol) was dissolved in 
acetic anhydride (10 ml) and heated to reflux for 90 min. The mixture was cooled and the 
reaction quenched by adding water (~10 ml). The organic layer was extracted with dichloro-
methane (3 x 10 ml), dried over Mg2SO4 and the solvent was removed under reduced pressure 
until dryness. The oily residue was treated with ether for crystallisation and washed with ether. 
Flash-chromatography on silica gel using n-hexane/acetone (5:2) gave the purified 2-acetyl-6,7-
dimethoxy-1-(4’-iodophenyl)-1,2,3,4-tetrahydroisoquinoline (I-ADTQ, 10a) (Rf = 0.23). 
Yield: 1.20 g (81 %). 
Melting point: 141.3 °C. 
1H-NMR (CDCl3): δ = 2.20 (s, 3H, CH3), 2.76 (d, 1H, H4 pseudo eq.), 2.94 (d, 1H, H4 pseudo 
ax.), 3.33 (d, 1H, H3 pseudo ax.), 3.43 (d, 1H, H3 pseudo eq.), 3.79 (s, 3H, OCH3), 3.92 (s, 3H, 
OCH3), 6.51 (s, 1H, H8), 6.70 (s, 1H, H5), 6.84 (s, 1H, H1), 6.99 (d, 2H, H3’ + H5’), 7.63 (d, 2H, 
H2’ + H6’). 
13C-NMR (CDCl3): δ = 22.1 (CH3), 28.9 (CH2, C4), 40.6 (CH2, C3), 54.4 (CH, C1), 56.3 (2C, 
OCH3), 93.6 (2C, CH, C3’+ C5’),111.5 (2C, CH, C5 + C8), 126.7 (C, C8a), 126.8 (C, C4a), 131.2 
(2C, CH, C2’ + C6’), 137.7 (C, C1’), 142.7 (C, C4’), 148.2 (C, C6), 148.7 (C, C7), 169.4 (CO). 
MS: m/e 438 [M+, 100]. 
EA: C19H20INO3 calculated: C 52.2, H 4.61, N 3.20; found: C 52.7, H 4.70, N 3.41. 
 
2-Acetyl-6,7-dimethoxy-1-(4’-trimethylstannylphenyl)-1,2,3,4-tetrahydroisoquinoline (11) 
A solution of I-ADTQ 10a (2 mmol), hexamethyldistannane (5.3 mmol) and tetrakis(triphenyl-
phosphine) palladium (30 µmol) in 50 ml toluene was heated until reflux for 3 h. The solvent was 
removed under reduced pressure and the crude product was purified by column chromatography 
96  Experimental 
using silica gel and n-hexane/ethyl acetate (1:10) to give 2-acetyl-6,7-dimethoxy-1-(4’-trimethyl-
stannylphenyl)-1,2,3,4-tetrahydroisoquinoline (Sn-ADTQ) (11) (Rf = 0.69). 
Yield: 0.65 g (68 %). 
Melting point: 117.2 °C. 
1H-NMR (CDCl3): δ = 0.21 (s, 9H, (CH3)3), 2.11 (s, 3H, CH3), 2.70 (d, 1H, H4 pseudo eq.), 2.89 
(d, 1H, H4 pseudo ax.), 3.34 (d, 1H, H3 pseudo ax.), 3.64 (d, 1H, H3 pseudo eq.), 3.71 (s, 3H, 
C7-OCH3), 3.84 (s, 3H, C6-OCH3), 6.48 (s, 1H, H8), 6.61 (s, 1H, H5), 6.82 (s, 1H, H1), 6.95 (d, 
2H, H3’ + H5’), 7.14 (d, 2H, H2’ + H6’). 
13C-NMR (CDCl3): δ = -9.6 (3C, (CH3)3), 21.6 (CH3), 28.5 (CH2, C4), 40.1 (CH2, C3), 54.3 (CH, 
C1), 55.8 (C6-OCH3), 55.9 (C7-OCH3), 111.0 (CH, C5), 111.2 (CH, C8), 126.3 (C, C4a), 126.9 
(C, C8a), 128.4 (2C, CH, C3’+ C5’), 135.7 (2C, CH, C2’ + C6’), 141.3 (C, C4’), 142.4 (C, C1’), 
147.6 (C, C7), 148.0 (C, C6), 168.8 (CO). 
MS: m/e 476 [M+, 100], 474 [76], 472 [39], 480 [16]. 
EA: C22H29NO3Sn calculated: C 55.7, H 6.16, N 2.95; found: C 55.4, H 6.19, N 3.09. 
 
4.3.2 Synthesis of the diacetoxyiodo compound of ADTQ 
Sodium periodate (5.1 mmol) and sodium acetate (11 mmol) were suspended in 8 ml of a mixture 
of acetic acid/acetic anhydride (9:1). I-ADTQ (10a) (5 mmol) was added and the mixture was 
heated to reflux, but it was stopped after 1.5 h due to I2-formation in the solution. After the 
mixture was allowed to cool down to room temperature, it was poured into 25 ml ice-water. The 
crude product was extracted with dichloromethane and iodine was removed by washing with 
sodium thiosulfate solution (10 %). The organic layers were collected and dried over Mg2SO4. 
The solvent was removed under reduced pressure and the oily residue treated with ether for 
crystallisation. A small amount of 2-acetyl-6,7-dimethoxy-1-(4’-(diacetoxyiodo)phenyl)-1,2,3,4-te-
trahydroisoquinoline (10b) as a yellow solid could be obtained [following 163]. 
Yield: 0.166 g (6 %). 
Melting point: 201 °C. 
MS: m/e 496 [M+, 100]. 
Due to the small amount of product no NMR analytics were carried out. 
EA: C23H26INO7 calculated: C 49.7, H 4.72, N 2.52; found: C 49.5, H 4.49, N 3.23. 
 
Experimental  97 
4.3.3 Syntheses of precursors for 18F-labelling of [18F]F-ADTQ 
The below described ipso-demetallation calls for compounds like Koser’s reagent ([hydroxy-
(tosyloxy)iodo]benzene), thus the appropriate 2-iodothiophene derivative 2-[hydroxy(tosyloxy)-
iodo]thiophene was synthesised according to the literature and is described in the following [222]. 
The [hydroxy(tosyloxy)iodo]benzene was purchased from Aldrich (Germany). 
 
1’-[2-Acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-4’-phenyl(2-thienyl)iodonium bromide 
(10c) [following 162] 
Sodium perborate monohydrate (6 mmol) was suspended in 10 ml acetic anhydride and stirred at 
30 °C for 90 min. 10a (2 mmol) was then given to the mixture and it was stirred at 40 °C for 
90 min. Thiophene (10 mmol) was added and the mixture was cooled to -15 °C. Concentrated 
sulphuric acid (0.5 ml) was added dropwise, under stirring and keeping the temperature below 
-10 °C. After addition was completed the mixture was allowed to warm up to 0 to 5 °C and stirred 
at this temperature for 5 h. The final reaction mixture was poured into 100 ml ice-water and 
stirred for 30 min. The non-reacted organic compounds were extracted by ether (2 x 10 ml) and 
discarded. The aqueous layer was treated with activated coal at 40 °C for 10 min. After filtration 
and cooling, 10 ml aqueous potassium bromide solution (25 %) was added and the mixture was 
stirred for 1 to 2 h for precipitation. The precipitates were collected, washed well with water, 
acetone and ether. For re-crystallisation the crude product was quickly dissolved in hot methanol 
and after cooling ether was added in excess. 
Yield: 0.036 g (3 %) 
Due to the very small yield, all the amount was used for preliminary 18F-labelling reactions, so 
analytical data could not determined. 
 
1’-[2-Acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-4’-phenyl(2-thienyl)Iodonium tosylate 
(10e) [following 171] 
2-Iodothiophene (10 mmol) was oxidised by sodium perborate according to the above mentioned 
procedure for 1b to 3b and 5b to 8b. 
Yield: 1.82 g (55 %). 
Melting point (decomp.): 143 °C. 
A suspension of 2-(diacetoxyiodo)thiophene (2 mmol) in 4 ml acetonitrile was added to a solution 
of p-toluenesulphonic acid monohydrate (4 mmol) in 4 ml acetonitrile under an argon atmosphere 
and stirred for 15 to 20 min at 0 °C. The reaction mixture was filtered quickly and the yellow solid 
product washed with ether. 2-[Hydroxy(tosyloxy)iodo]thiophene was dried for 5 min under 
vacuum and then stored under argon at -30 °C in the dark. 
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Yield: 1.56 g (98 %). 
Melting point (decomp.): 64.8 °C (mp (Lit.) 65-68 °C [222]). 
 
Sn-ADTQ 11 (1 mmol) and 2-[hydroxy(tosyloxy)iodo]thiophene (1 mmol) were suspended in 
15 ml dichloromethane. The mixture was stirred under argon at room temperature for 2 h. The 
solvent was removed under a constant argon flow and reduced pressure (~750 mbar). The 
residue was treated with ether to crystallise. The crude product was filtered off and washed with 
ether. 1’-[2-Acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-4’-phenyl(2-thienyl)Iodonium to-
sylate (10e) was dried under vacuum and stored in an exsiccator in the dark. 
Yield: 0.55 g (80 %). 
Melting point: 141.9 °C. 
1H-NMR (CDCl3): δ = 2.00 (s, 3H, CO-CH3), 2.19 (s, 3H, C1Ts-CH3), 2.53 (2H, H4), 3.31 (2H, H3), 
3.50 (s, 3H, C7-OCH3), 3.60 (s, 3H, C6-OCH3), 6.46 (s, 1H, H1), 6.68 (s, 1H, H5), 6.71 (s, 1H, 
H8), 7.04 (d, 2H, CH, H2Ts + H6Ts), 7.19 (1H, CH, H4Th), 7.37 (d, 2H, CH, H3Ts + H5Ts), 7.39 (d, 
2H, CH, H2’ + H6’), 7.56 (d, 2H, CH, H3’ + H5’), 8.04 (1H, CH, H3Th), 8.13 (1H, CH, H5Th). 
13C-NMR (CDCl3): δ = 21.1 (CH3, C1Ts-CH3), 21.9 (CH3, CO-CH3), 27.8 (CH2, C4), 41.4 (CH2, 
C3), 54.5 (CH, C1), 55.8 (C6, OCH3), 55.9 (C7, OCH3), 111.8 (CH, C8), 112.0 (CH, C5), 114.7 
(C, C2Th), 116.6 (C, C4’), 125.9 (2C, CH, C3Ts + C5Ts), 126.5 (C, C8a), 127.4 (C, C4a), 128.6 
(2C, CH, C2Ts + C6Ts), 131.1 (CH, C4Th), 132.2 (2C, CH, C2’ + C6’), 132.5 (CH, C3Th), 135.4 (2C, 
CH, C3’ + C5’), 135.6 (CH, C5Th), 138.5 (C, C1Ts), 145.3 (C, C4Ts), 147.5 (C, C1’), 147.7 (C, C7), 
148.4 (C, C6), 169.9 (CO). 
MS: m/e 520 [M+, 100] 
EA: C30H30INO6S2 calculated: C 52.1, H 4.37, N 2.03; found: C 51.6, H 4.46, N 1.21. 
 
1’-[2-Acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-4’-phenyl(phenyl)Iodonium tosylate 
(10g) [following 171] 
Sn-ADTQ 11 (1 mmol) and [hydroxy(tosyloxy)iodo]benzene (1 mmol) were suspended in 15 ml 
dichloromethane. The mixture was stirred under argon at room temperature for 2 h. The solvent 
was removed under a constant argon flow and reduced pressure (~750 mbar). The residue was 
treated with ether to crystallise. The crude product was filtered off and washed with ether. 10g 
was dried under vacuum and stored in an exsiccator in the dark. 
Yield: 0.34 g (50 %). 
Melting point: 141 °C. 
1H-NMR (CDCl3): δ = 1.88 (s, 3H, CO-CH3), 2.07 (s, 3H, C1Ts-CH3), 2.42 (d, 1H, H4 pseudo eq.), 
2.62 (d, 1H, H4 pseudo ax.), 3.18 (d, 1H, H3 pseudo ax.), 3.41 (s, 3H, C7-OCH3), 3.42 (d, 1H, H3 
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pseudo eq.), 3.49 (s, 3H, C6-OCH3), 6.32 (s, 1H, H1), 6.57 (s, 1H, H5), 6.59 (s, 1H, H8), 6.92 (d, 
2H, CH, H2Ts + H6Ts), 6.93 (1H, CH, H4Ph), 7.07 (d, 2H, CH, H2’ + H6’), 7.26 (d, 2H, CH, 
H3Ts + H5Ts), 7.71 (d, 2H, CH, H3Ph + H5Ph), 7.81 (d, 2H, CH, H2Ph + H6Ph), 7.91 (d, 2H, CH, 
H3’ + H5’). 
13C-NMR (CDCl3): δ = 21.1 (CH3, C1Ts-CH3), 21.9 (CH3, CO-CH3), 27.8 (CH2, C4), 41.4 (CH2, 
C3), 54.4 (CH, C1), 55.8 (C6, OCH3), 56.0 (C7, OCH3), 100.7 (C, C1Ph), 111.8 (CH, C8), 112.0 
(CH, C5), 117.5 (C, C4’), 125.8 (2C, CH, C3Ts + C5Ts), 126.5 (C, C8a), 127.4 (C, C4a), 128.6 
(2C, CH, C2Ts + C6Ts), 130.1 (CH, C4Ph), 131.0 (2C, CH, C2’ + C6’), 134.9 (2C, CH, C3’ + C5’), 
137.7 (2C, CH, C3Ph + C5Ph), 138.6 (C, C1Ts), 140.9 (2C, CH, C2Ph + C6Ph), 145.1 (C, C4Ts), 
147.5 (C, C1’), 147.7 (C, C7), 148.4 (C, C6), 169.9 (CO). 
MS: m/e 514 [M+, 100] 
EA: C32H32INO6S calculated: C 56.1, H 4.70, N 2.04; found: C 55.7, H 4.82, N 1.71. 
 
4.4 Radiosyntheses 
4.4.1 Production of n.c.a. [18F]fluoride 
The production of n.c.a. [18F]fluoride is routinely carried out at the JSW BC 1710 Cyclotron 
(Forschungszentrum Jülich). N.c.a. [18F]fluoride is obtained via bombardment of an isotopically 
enriched [18O]water target (1.3 ml) with a 17 MeV proton beam using the 18O(p,n)18F nuclear 
reaction. The n.c.a. [18F]fluoride is separated from the enriched [18O]water by an electrochemical 
cell [223]. By this method, up to 55 GBq n.c.a. [18F]fluoride can be produced within 1 h at a 
nominal beam current of 25 µA. 
 
4.4.2 Preparation of the n.c.a. [18F]fluoride-cryptate complex 
A 5 ml Wheaton© glass vial equipped with a triangle stirring bar and a silicone septum sealed lid, 
into which two needles are stuck, connecting the vacuum line and the argon gas line, is 
evacuated and flushed with argon three times. From the aqueous n.c.a. [18F]fluoride solution, 
30 to 50 MBq (10 - 50 µl) were given to Kryptofix© 2.2.2 (26 µmol) and 13 µl of a 1 M potassium 
carbonate solution. This mixture is taken with 0.8 ml anhydrous acetonitrile and given through the 
septum into the prepared vial by a 1 ml syringe. For an azeotropic distillation the vial is heated in 
an oil bath to 80 to 82 °C and a constant argon flow at 750 to 850 mbar is adjusted. When no 
acetonitrile/water mixture is left, again 1 ml acetonitrile is added to the vial. This step is repeated 
100  Experimental 
two times and subsequent by 5 min of full vacuum (~10 mbar) follow. After argon flushing and 
pressure balancing the resulting dry n.c.a. [18F]fluoride-cryptate complex is ready for nucleophilic 
18F-labelling reactions. 
 
4.4.3 Radiosyntheses of n.c.a. [18F]fluoroarenes 
The appropriate aryl(2-thienyl)iodonium salt (25 µmol) was dissolved in 1.0 ml anhydrous DMF. 
This solution was added by a syringe through the silicone septum to the vial containing the dry 
n.c.a. [18F]fluoride-cryptate complex and was stirred under 1100 mbar argon at 130 °C. The slight 
overpressure was necessary to avoid losses of volatile products, such as [18F]fluoroanisoles and 
[18F]fluorobenzene. At appropriate times aliquots of 10 µl were taken with a Hamilton© syringe via 
the septum and given to 50 µl cold acetonitrile. These samples were closed quickly and stored in 
liquid nitrogen until they were analysed by radio-HPLC and/or radio-TLC. 
 
4.4.4 Radiosynthesis of n.c.a. 4-[18F]fluorophenol 
4-Benzyloxyphenyl(2-thienyl)iodonium bromide (25 µmol) was used as precursor following the 
before mentioned procedure to give n.c.a. 4-benzyloxy-[18F]fluorobenzene. After 15 to 20 min the 
whole reaction mixture was given into 10 ml water by a 20 ml syringe. This mixture was passed 
though SepPak© C18 plus cartridge pre-washed with 3 ml ethanol and 5 ml water. The cartridge 
was washed with 3 ml water and dried by an argon flow for 5 min. Before elution, the cartridge 
was connected to a dry SepPak© ALOX cartridge. The product absorbed on the solid C18 phase 
was eluted with 3 ml of methanol and given through both cartridges into a new reaction vial. 4-
Benzyloxy-[18F]fluorobenzene was analysed by radio-TLC and radio-HPLC. 
Ammonium formate (~5 mmol) and palladium black (~0.15 mmol) were added to the solution. For 
debenzylation the mixture was stirred at 80 C for 15 -20 min. The whole reaction mixture was 
taken and filtered through a Merck LiChrolut© glass column (65 x 10 mm) containing only a PTFE 
frit (porosity 10 µm) which was washed with 0.5 ml methanol. The obtained n.c.a. 
4-[18F]fluorophenol was analysed by radio-TLC and radio-HPLC. 
 
4.4.5 Radiosynthesis of n.c.a. [18F]F-ADTQ 
The precursor 10c, 10e or 10g was dissolved in 1 ml anhydrous DMF and given to the activated 
[18F]fluoride-cryptate complex. This mixture was stirred at the appropriate temperature for the 
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desired reaction time. Aliquots of 10 µl were taken, added to 50 µl methanol and analysed by 
radio-TLC and/or radio-HPLC. 
 
4.4.6 Radiosynthesis of [131I]I-ADTQ 
For radioiodination the isotope iodine-131 was purchased from Amersham Buchler (Germany) 
and was obtained as sodium [131I]iodide solution (sodium hydroxide solution pH 7 to 11) with 
~1.48 GBq/ml specific volume activity. 
 
To 50 µl of a 11 solution in ethanol (c = 0.2 µmol/ml) and 5 µl of an aqueous chloramine T 
solution (1 M) 5 µl (~7.5 MBq) of [131I]iodine solution is added. After addition of 5 µl hydrochloric 
acid solution (1 M) the reaction vial was shaken for 2 min at room temperature. 
To stop the reaction about 100 µl of the HPLC eluent was added. [131I]10a was analysed and 
separated by radio-HPLC. 
 
4.5 Radioanalytical methods 
For identification and determination of the radiochemical yields (RCY) both radio high 
performance liquid chromatography (radio-HPLC) and radio thin layer chromatography (radio-
TLC) were used. All 18F-labelled compounds were identified by their non-radioactive reference 
compounds via comparison of the UV-signals with the radioactive signals. [18F]1 to [18F]3, [18F]5 
and [18F]6 are volatile products and not suitable for radio-TLC, thus these [18F]fluoroarenes were 
only analysed by radio-HPLC. 
 
4.5.1 Radio thin layer chromatography 
Analytical radio thin layer chromatography (radio-TLC) was carried out to determine the RCY and 
to verify that no further especially very polar radioactive species than those detected by radio-
HPLC were present. Radio-TLC was performed on Macherey-Nagel (Germany) precoated silica 
gel plates (PolyGram SIL G/UV254, 40 x 80 mm) with different solvent systems. In practice, 
~1.5 µl of the sample solution was given on the TLC plates and developed in the appropriate 
solvent mixtures. The developed radio-TL-chromatograms were measured on an Instant 
ImagerTM (Packard, USA) for radioactivity. Individual Rf-values of standards are listed in Table 
4.1 along with solvent systems (given as v:v ratios). 
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Table 4.1: Rf-Values and solvent systems (given in v:v ratios) of the relevant fluorine 
reference compounds for radio-TLC on silica gel plates 
Compound Solvent system (v:v) Rf 
4-benzyloxy-1-fluorobenzene (4) n-hexane/ether (2:1) 0.79 
 n-hexane/ethyl acetate (3:1) 0.91 
1-chloro-4-fluorobenzene (7) n-hexane 0.52 
1-bromo-4-fluorobenzene (8) n-hexane/ether (1:1) 0.85 
1-fluoro-4-iodobenzene (9) n-hexane/ether (1:1) 0.78 
F-ADTQ (10) petrol ether/acetone (2:1) 0.35 
4-fluorophenol n-hexane/ethyl acetate (3:1) 0.59 
 
4.5.2 Radio high performance liquid chromatography 
Analytical radio high performance chromatography (radio-HPLC) was performed on the same 
system as described in chapter 4.1 (General) for the non-radioactive HPLC. For measurement of 
radioactivity the outlet of the UV/Vis detector is connected to a NaI(Tl) well-type scintillation 
detector (EG&G ACE MateTM). The aliquots of the labelled compounds were analysed by 
reversed-phase radio-HPLC using a Phenomenex© Luna 5µ C18 column (3 x 250 mm) and as 
mobile phase acetonitrile/water or methanol/water systems in various concentration ratios. The 
flow rate was varied from 0.6 to 1.0 ml/min. All measurements were performed at room 
temperature. Individual k’-values of the reference compounds, mobile phase systems (given in 
v:v ratios) and the flow rate are given in Table 4.2. 
 
An analysis of the specific activity obtained after labelling was carried out for [18F]3 and [131I]10a 
via HPLC. The integral of the UV-signals obtained by the UV/Vis-detector is proportional to the 
applied amount of non-radioactive reference material. The measured peak-areas were fitted by 
linear regression as functions of the amount of reference compound and led to straight lines, 
which were used for calibration (cf. Figure 4.1 and Figure 4.2). 
In the determination of the specific activity of [18F]3 no UV-signal corresponding to 3 was 
detected, thus only a lower limit of the specific activity of > 58 TBq/mmol was estimated. 
From 131I-labelling reactions of 11 with starting activities of ~7.5 MBq an average specific activity 
of [131I]10a of 681 GBq/mmol (18.4 Ci/mmol) was determined. 
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Table 4.2: k’-values, solvent systems (in v:v ratios) and flow rates of the relevant fluorine 
reference compounds for radio-HPLC (Phenomenex© Luna 5µ C18 column) 
Compound Solvent system (v:v); flow [ml/min] k’ 
2-fluoroanisole (1) acetonitrile/water (40:60); 0.7 2.44 
3-fluoroanisole (2) acetonitrile/water (40:60); 0.7 3.82 
4-fluoroanisole (3) acetonitrile/water (40:60); 0.7 3.32 
4-benzyloxy-1-fluorobenzene (4) acetonitrile/water (60:40); 1.0 3.39 
4-methyl-1-fluorobenzene (5) acetonitrile/water (40:60); 0.7 4.81 
fluorobenzene (6) acetonitrile/water (40:60); 0.7 3.00 
1-chloro-4-fluorobenzene (7) acetonitrile/water (40:60); 0.7 5.30 
1-bromo-4-fluorobenzene (8) acetonitrile/water (40:60); 0.7 6.65 
4-iodo-1-fluorobenzene (9) acetonitrile/water (40:60); 0.7 8.84 
F-ADTQ (10) methanol/water (70:30); 0.6 1.23 
I-ADTQ (10a) methanol/water (70:30); 0.8 2.53 
 
 
Figure 4.1: Integral of the UV-peak as a function of the quantity of 3 
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Figure 4.2: Integral of the UV-peak as a function of the quantity of 10a 
 
 
4.6 Pharmacological evaluation of [131I]I-ADTQ 
Pharmacology evaluation studies were carried out by the Pharmacology Group of the Institute of 
Nuclear Chemistry (Forschungszentrum Jülich GmbH).  
4.6.1 Ex vivo study 
To investigate if [131I]I-ADTQ [131I]10a passes the blood-brain barrier, female NMRI mice 
weighing 25 ± 2 g received about 4 µCi [131I]10a by tail vein injection. The animals were 
sacrificed 10 min and 60 min after tracer injection, the brains removed, weighed and the 
radioactivity measured with a gamma-counter. For ex vivo autoradiography the brains were 
frozen, cut into 40 µm thick horizontal slices and exposed to a phosphor imaging plate (Fuji). 
After exposure for 90 min, a laser phosphor imager (BAS 5000, Fuji) controlled with software by 
the vendor (Version 3.14, Raytest, Germany) scanned the images. 
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4.6.2 In vitro autoradiography 
For autoradiography, frozen brains of Wistar rats were cut horizontal at -18 °C into 20 µm thick 
sections (Leica AG Microsystems, Germany), mounted onto gelatine-coated object glasses 
(LO-Laboroptik GmbH) and stored at -80 °C until use. 
For the assay, the brain sections were thawed and dried at room temperature. After preincuba-
tion for 15 min at 4 °C in 50 mM Tris-HCl containing 0.5 mM CaCl2, the cryosections were 
incubated with additionally 50 mM KSCN and about 0.5 nM or 7.5 nM of [131I]10a 
(AS = 21.45 Ci/mmol) in the buffer for 45 min at 4 °C. Adjacent sections were incubated in the 
presence of 15 µM unlabeled I-ADTQ 10a or the AMPA antagonist CNQX. After treatment the 
sections were washed twice for 15 sec in buffer without KSCN at 4 °C, dipped in deionised water, 
dried and exposed for 45 min to a phosphor imaging plate (Fuji). 
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 Summary 
Diaryliodonium salts have been proven as potent precursors for direct nucleophilic n.c.a. 
18F-labelling even of electron rich aromatic compounds. In addition, it is known that the 2-thienyl 
group represents a highly electron rich moiety and that it induces a high regioselectivity in 
reactions of aryl(2-thienyl)iodonium salts with nucleophiles. However, the 2-thienyl group has 
only been employed in non-radioactive studies thus far. 
In this work, the nucleophilic 18F-labelling methods using diaryliodonium salts were extended by 
the development of aryl(2-thienyl)iodonium salts as precursors for the nucleophilic 18F-intoduction 
into arenes, even of electron rich nature. In a systematic approach, a broad investigation of 
eighteen aryl(2-thienyl)iodonium salts was accomplished in order to study the suitability and 
applicability of this class of compounds for direct nucleophilic 18F-labelling chemistry. 
As first precursors the electron rich ortho-, meta- and para-methoxyphenyl(2-thienyl)iodonium 
salts were synthesised as their bromide, iodide, tosylate and triflate. Further, para-substituted 
(R = BnO, CH3, H, Cl, Br, I) aryl(2-thienyl)iodonium bromides were prepared as precursors with a 
systematically varying electron density. 
Three methods for the preparation of aryl(2-thienyl)iodonium salts were compared and tested in 
this work. One, an ipso-demetallation using boronic acids and the Koser’s reagent analogue of 
2-iodothiophene has the advantage of a regiospecific reaction, but led to many impurities and 
side-products, especially with electron rich molecules. The other approaches are based on an 
electrophilic aromatic substitution reaction, where a (diacetoxyiodo)arene reacts with a corres-
ponding aromatic component in presence of concentrated sulphuric acid as catalyst. Both differ 
by the location of diacetoxyiodo substituent which is either on the thiophene or homoarene 
component. In case 2-(diacetoxyiodo)thiophene was one reagent, the formed aryl(2-thienyl)-
iodonium salt was always obtained as an isomeric mixture of ortho- and para-derivatives. In the 
reversed order, using (diacetoxyiodo)arenes and thiophene, the highly activated 2-position of 
thiophene led regiospecifically to the desired 2-thienyl derivative. Therefore the appropriate 
iodoarenes were oxidised to their diacetoxyiodo analogue by a gentle procedure using sodium 
perborate. Only the 4-benzyloxyiodobenzene and 1,4-diiodobenzene required different treat-
ments and were oxidised via sodium periodate and peracetic acid, respectively. 
Using these, the corresponding iodonium bromides and iodides were directly formed in yields of 
18 to 67 % and 30 to 60%, respectively. The methoxyphenyl(2-thienyl)iodonium tosylates and 
triflates were prepared by an oxidative anion metathesis of the bromide salts using hydrogen 
peroxide. The tosylates were obtained in yields of 76 to 93 % and the triflates in yields of 
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37 to 98 %. All precursors were obtained as pure samples and only for a few re-crystallisation 
was necessary. Most of the aryl(2-thienyl)iodonium salts were here prepared for the first time. 
At first, the general reaction conditions of the n.c.a. 18F-labelling procedure were optimised. This 
was carried out with 2-methoxyphenyl(2-thienyl)iodonium bromide which led to n.c.a. 
2-[18F]fluoroanisole. The activation of n.c.a. [18F]fluoride was performed with the [K⊂2.2.2]2CO3-
system at an optimum concentration of 26 mmol/l. Varying the concentration of the precursor 
from 6 mmol/l to 75 mmol/l in DMF showed the best result with 25 mmol/l. In order to prove the 
n.c.a. scale an analysis of the high specific activity (AS) was carried out exemplarily with 4-
[18F]fluoroanisole via HPLC. Since no corresponding UV-signal was detected, only a lower limit of 
AS > 58 TBq/mmol could be determined. 
The 18F-introduction into diaryliodonium salts proceeds via a SNAr-mechanism where aprotic 
polar solvents being the best suitable medium. Therefore acetonitrile (ACN), dimethylacetamide 
(DMAA), dimethylformamide (DMF) and dimethyl sulphoxide (DMSO) were compared and their 
effects on the RCY of n.c.a. 2-[18F]fluoroanisole were examined. DMF led to best result with a 
RCY of 60 % at 130 °C. ACN (90 °C) and DMAA (130 °C) gave only 10 to 15 % RCY. In DMSO 
the 18F-labelling did not work and only a RCY of ~1 to 2 % was observed. Thus, strong influence 
of solvents on the n.c.a. 18F-substitution reactions on aryl(2-thienyl)iodonium salts was observed, 
whereby DMF represents the optimal reaction medium. 
In general, higher temperatures lead to an increase of RCY and reaction rates in n.c.a. 18F-for-
iodonium exchange procedures. Consequently, the reaction temperature was varied from 90 to 
150 °C. Expectedly, the reaction rate increased with higher temperature. Above 130 °C, 
however, the thermal decomposition of the precursor molecules enters into competition to the 
18F-introduction. The optimal temperature where the 18F-exchange still succeeded and the 
decomposition did not become the crucial factor was found at 130 + 3 °C. 
Different counter anions of iodonium salts strongly influence the 18F-labelling reaction but 
literature data differ in this factor. An advantage of inorganic counter anions is an effective ion 
pair separation of diaryliodonium salts in polar solvents. On one hand, dissociated diaryliodonium 
salts provide a “naked” diaryliodonium cation which is in favour for the attack of [18F]fluoride. On 
the other hand, counter anions with high nucleophilicity compete for the substitution. Organic 
counter anions can be ruled out for this problem, but due to a more covalent binding to iodine, 
they cause a steric and electronic hindrance. The effects of bromides, iodides, tosylates and 
triflates as counter anions were investigated and, based on the RCY, the following order was 
obtained: tosylate < iodide < triflate < bromide. However, in terms of kinetics a different order 
based on the initial reaction rates was observed: tosylate < bromide < iodide < triflate. To explain 
the disagreement in RCY and kinetics, effects of different dissociation grade and the decom-
position tendency of the precursor molecules are assumed. 
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Evidence for the grade of dissociation of diaryliodonium salts in various solvents can be received 
by NMR spectra. The proton shifts of 2-methoxyphenyl(2-thienyl)iodonium bromide in d6-DMF 
showed a fraction of 92 % in the non-dissociated versus 8 % in the dissociated form; for the 
iodide the fraction were 87 % and 13 %, respectively. Tosylates and triflates show no dissociation 
according to their NMR spectra. Thus, the proton shifts / NMR data as well as the RCY obtained 
favour the presence of non-fully dissociated aryl(2-thienyl)iodonium salts. 
Using ortho-, meta- and para-methoxyphenyl(2-thienyl)iodonium bromide in the 18F-exchange 
reaction gave information about the dependence of the 18F-labelling reaction on the substituent 
position. Nucleophilic 18F-labelling reactions with diaryliodonium salts are strongly affected by the 
substitution pattern. Furthermore, a so-called ortho-effect as result of the trigonal-bipyramidal 
intermediate during the 18F-substitution causes generally a preferred attack on ortho-substituted 
rings. Expectedly, the ortho-derivative gave a much higher RCY with 60 % of n.c.a. [18F]fluoro-
anisole than the para-derivative with a RCY of 25 to 30 % and the meta-derivative with a RCY of 
~20 %. With regard to kinetics, the meta-derivative showed a faster initial reaction rate than the 
ortho- and para-derivative with almost similar rates.  
In view of a systematic examination, the reaction rates k’ of the 18F-substitution on substituted 
aryl(2-thienyl)iodonium bromides were compared. Pseudo-first order kinetics were determined by 
linear regression as a function of the reaction time. The k’-values showed a distinct dependence 
on the electronic character of the substituents and the following order in decreasing reaction rate 
k’ was obtained: 4-Br > 4-I > 4-Cl > 3-OCH3 > H > 4-CH3 > 2-OCH3 > 4-OBn > 4-OCH3. As 
expected, the electron rich molecules 2- and 4-[18F]fluoroanisole and 4-benzyloxy-1-
[18F]fluorobenzene showed the slowest rates, where the ortho-effect of 2-methoxyphenyl(2-
thienyl)iodonium bromide caused a slightly faster rate. All precursors showed increasing rates 
along with stronger activation up to the fastest rates with the highly activated para-halides. 
The k’-values were correlated in a Hammett relationship with the appropriate Hammett constants 
of the substituents. It showed a good linear fit which confirmed the expected SNAr-mechanism of 
the 18F-substitution on aryl(2-thienyl)iodonium salts. Furthermore, the reaction parameter ρ was 
determined with ρ = + 1.16 + 0.2 and confirmed the nucleophilic mechanism and a consistent 
mechanism over the range of investigated substituents. A deviation of the para-methoxy 
derivative from the linear relation is accounted on a strong resonance effect of this electron 
donating group on the iodonium group. Also the para-bromo derivative showed also a larger 
deviation from the linear correlation which was not completely understood. 
In all 18F-substitution reactions on aryl(2-thienyl)iodonium salts the high electron density of the 
2-thienyl group induced a regiospecific 18F-introduction; i.e. [18F]fluorothiophene was not formed 
in any reaction. Thus, the one-step nucleophilic n.c.a. 18F-labelling procedure of electron rich 
molecules via aryl(2-thienyl)iodonium salts developed in this work has proven to be a very potent 
and fast access to 18F-labelled arenes. 
Summary  109 
In order to demonstrate the versatility and applicability of this method in practice, the 
radiosyntheses of two pharmacological relevant molecules were carried out. First, the well-known 
primary 18F-labelling synthon 4-[18F]fluorophenol was synthesised via 4-benzyloxyphenyl(2-
thienyl)iodonium bromide. Within 40 min the desired n.c.a. 4-[18F]fluorophenol was obtained with 
an overall RCY of 34 to 36 % by 18F-labelling under the optimised conditions, described above, 
and subsequent reductive debenzylation using ammonium formate and palladium. The new 
elaborated approach presents a more convenient and faster radiosynthesis for this versatile 18F-
labelling synthon. Moreover, 4-[18F]fluorophenol is obtained in anhydrous methanol which allows 
further radiosynthetic steps including compounds susceptible to moisture without time-consuming 
drying procedures. 
Second, the complex molecule 2-acetyl-6,7-dimethoxy-1-(4’-fluorophenyl)-1,2,3,4-tetrahydroiso-
quinoline (F-ADTQ), earlier characterised as non-competitive AMPA receptor antagonist, was 
18F-labelled via three different iodonium precursors. Ipso-demetallation of the trimethyltin 
derivative (Sn-ADTQ) was used to prepare two tosylate precursors containing the 2-thienyl group 
with good yields of 80 % and 50 %, respectively. However, the n.c.a. 18F-labelling of these three 
precursors only led to very low RCY of 1.2 to 3.6 %. The bromide precursor gave the best result, 
when relying on two 18F-labelling attempts. The tosylates showed a small increase in RCY from 
1.2 % (phenyl) to 2.9 % (2-thienyl). 
The reference F-ADTQ was synthesised via a Pictet-Spengler approach as described in the 
literature. Similarly, 2-acetyl-6,7-dimethoxy-1-(4’-iodophenyl)-1,2,3,4-tetrahydroisoquinoline 
(I-ADTQ) was prepared for the first time. As mentioned above, F-ADTQ is known as AMPA 
receptor antagonist whereas the iodine derivative was not described or pharmacologically 
characterised so far. Therefore I-ADTQ was labelled with iodine-131 via the trimethyltin precursor 
using [131I]iodide in ethanol and chloramine T as oxidant. After 2 min reaction time at room 
temperature, a very high RCY of 97 + 2 % of 2-acetyl-6,7-dimethoxy-1-(4’-[131I]iodophenyl)-
1,2,3,4-tetrahydroisoquinoline ([131I]I-ADTQ) was obtained without any radioactive side-product 
formed. The radio-HPL chromatogram showed a very good separation of [131I]I-ADTQ from the 
trimethyltin precursor Sn-ADTQ. The [131I]I-ADTQ was isolated with a specific activity of ca. 
680 GBq/mmol and could be used for preliminary pharmacological evaluation studies. [131I]I-
ADTQ passes the blood-brain-barrier with an excellent brain uptake, but no specific accumulation 
was observed, thus a too high non-specific binding can be assumed. 
For proof of identity and determination of radiochemical yields and specific activities radio-HPLC 
and radio-TLC methods and systems were developed for all radioactive compounds. Further-
more, compounds synthesised for the first time were characterised by NMR-spectroscopy, mass 
spectrometry and elemental analysis (CHN). 
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 Abbreviations 
ACN acetonitrile 
ADTQ 2-Acetyl-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline 
AMPA α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid 
As specific activity 
b.p. boiling point 
BBB blood-brain barrier 
Bn benzyl group (-CH2C6H5) 
Bq Becquerel 
c.a. carrier-added 
c.f. carrier-free 
CAT chloramine T 
cf. confer 
Ci Curie (1 Ci = 3.7 · 1010 Bq) 
CNS central nervous system 
CT computed tomography 
d days (half-life), duplet (NMR), deuterium (nuclear reactions) 
DCM dichloromethane 
DMAA dimethylacetamide 
DMF dimethylformamide 
DMSO dimethyl sulphoxide 
DNA deoxyribonucleic acid 
DOPA 3,4-dihydroxy-L-phenylalanine 
e.g. for example (lat. exempli gratia) 
EC electron capture 
eq. equivalent 
EtOH ethanol 
eV electronvolt 
F-ADTQ 2-acetyl-6,7-dimethoxy-1-(4‘-fluorophenyl)-1,2,3,4-tetrahydro-
isoquinoline 
FDG 2-fluoro-2-deoxy-D-glucose 
GABA γ-aminobutyric acid 
GC gas chromatography 
HPLC high performance liquid chromatography 
i.e. that is (lat. id est) 
I-ADTQ 2-acetyl-6,7-dimethoxy-1-(4‘-iodophenyl)-1,2,3,4-tetrahydro-
isoquinoline 
iGluR(s) ionotropic glutamate receptor(s) 
IR infrared 
k reaction rate constant 
 K reaction equilibrium constant 
KA kainic acid / kainate 
LET linear energy transfer 
LFER linear free energy relationship 
LSF least square fit 
m multiplet 
m.p. melting point 
MeOH methanol 
mGluR(s) metabotropic glutamate receptor(s) 
(f)MRI (functional) magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
MRT magnetic resonance tomography 
n.c.a. no-carrier-added 
NA Avogadro’s number 
NDMA N-methyl-D-aspartate 
NMR nuclear magnetic resonance 
NR(s) NDMA receptor(s) 
ns nanoseconds 
p proton 
PET positron emission tomography 
PLC phospholipase C 
ppm parts per million 
PTC phase transfer catalyst 
q quartet 
RCY radiochemical yield 
RIA radioimmunoassay 
s singlet 
Sn-ADTQ 2-Acetyl-6,7-dimethoxy-1-(4’-trimethylstannylphenyl)-1,2,3,4-
tetrahydroisoquinoline 
SNAr nucleophilic aromatic substitution 
spall. spallation 
SPE(C)T single photon emission (computed) tomography 
t triplet 
T½  half-life 
TLC thin layer chromatography 
UV ultraviolet 
VEGF vascular endothelial growth factor 
vs. versus 
ρ reaction parameter (Hammett equation) 
σ substituent constant (Hammett equation) 
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